Antibodies and scavengers for chelated radionuclides

Antibodies that stably bind to DOTAM and Pb chelates address the instability issues in PRIT, enhancing tumor radiation delivery and reducing toxicity, improving radioimmunotherapy and imaging efficacy.

JP7582867B2Active Publication Date: 2024-11-13ORANO MED MANUFACTURING SAS +1
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2020558420
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2018-04-16
Filing Date
2019-04-16
Publication Date
2024-11-13
Estimated Expiration
2039-04-16

AI Technical Summary

Technical Problem

Existing radionuclide chelating agents for pretargeted radioimmunotherapy (PRIT) do not stably bind to all radionuclides, leading to reduced radiation delivery to tumors and increased toxicity due to slow complex formation and instability, particularly with DOTA complexes.

Method used

Development of antibodies that specifically bind to DOTAM and lead (Pb) chelates with high affinity, including both stable and radioactive isotopes, capable of also binding bismuth (Bi) as a decay product, providing stable and effective targeting for radioimmunotherapy and radioimaging.

Benefits of technology

The antibodies achieve stable and high-affinity binding to Pb-DOTAM and Bi-DOTAM, enhancing radiation delivery to tumors while minimizing toxicity, thus improving the efficacy of radioimmunotherapy and radioimaging applications.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007582867000138
    Figure 0007582867000138
  • Figure 0007582867000139
    Figure 0007582867000139
  • Figure 0007582867000140
    Figure 0007582867000140
Patent Text Reader

Abstract

This application relates to antibodies, including bispecific antibodies, that specifically bind to chelated radionuclides. This application further relates to the use of such bispecific antibodies in applications such as radioimmunoimaging and radioimmunotherapy. This application further relates to clearing agents and compositions useful in such methods. [Selection diagram] Figure 51
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] This application relates to antibodies, including bispecific antibodies, that specifically bind to chelated radionuclides. This application further relates to the use of such bispecific antibodies in applications such as radioimmunoimaging and radioimmunotherapy. This application further relates to clearing agents and compositions useful in such methods. [Background technology]

[0002] Monoclonal antibodies have been developed to target drugs to cancer cells. By conjugating toxic drugs to antibodies that bind to tumor-associated antigens, it may be possible to kill tumors more specifically, while causing less damage to surrounding tissue.

[0003] Pretargeted radioimmunotherapy (PRIT) uses an antibody construct that has affinity for a tumor-associated antigen on one hand and for a radiolabeled compound on the other. In the first step, the antibody is administered and localized within the tumor. The radiolabeled compound is then administered. Because the radiolabeled compound is small, it can be rapidly delivered to the tumor and quickly cleared. This reduces radiation exposure outside the tumor (Goldenberg et al., Theranostics 2012, 2(5), pp. 523-540). In addition to its direct cell-killing effect, PRIT can also act as an inducer of cell death in immunogenic cells and a potential combination partner for cancer immunotherapy and endogenous vaccination approaches. Similar procedures can also be used for imaging. Pretargeting can use bispecific antibodies or avidin-biotin systems, but the latter has the disadvantage that avidin / streptavidin is immunogenic.

[0004] Radionuclides for use in PRIT are generally in the form of a chelate loaded with the radionuclide of interest.

[0005] Su et al. (Nucl Med Biol 2005, 32:741-747) evaluated an antibody pretargeting system containing mAb-streptavidin and DOTA-biotin. 212 Pb-DOTA-biotin is not stable, with over 30% release 212 Bi( 212 Pb decay products) 212 It was found that it was released from Pb-DOTA.

[0006] WO2010 / 099536 describes bispecific antibodies capable of binding to DOTA conjugates of yttrium, ruthenium, and gadolinium. However, DOTA does not stably bind to all radionuclides and may exhibit slow complexation rates (Yong and Brechbiel, Dalton Trans. 2001, June 21; 40(23), pp. 6068-6076). Chelators that do not stably bind to radionuclides pose the risk of reduced radiation delivery to tumors while increasing toxicity. Summary of the Invention

[0007] The present invention provides antibodies that bind to metal chelates comprising DOTAM and lead (Pb). DOTAM can chelate Pb in a stable manner to form a Pb[DOTAM] complex.

[0008] The antibodies of the invention bind to a chelate comprising DOTAM and Pb, where Pb can be a stable (non-radioactive) isotope or a radioactive isotope. Radioactive lead isotopes are useful in applications such as radioimaging and radioimmunotherapy.

[0009] Preferably, the antibodies of the present invention have very high affinity for the Pb-DOTAM chelate, in the pM to fM range.

[0010] The antibody further binds to bismuth (Bi) chelated by DOTAM. 212 Pb is 212is the parent radionuclide of Bi, 212 It can serve as an in vivo generator of Bi. The antibody's ability to bind chelated Bi as well as chelated Pb increases its usefulness in applications such as radioimmunotherapy, where Bi isotopes are produced as decay products from Pb isotopes. In some embodiments, the antibody can bind both Bi-DOTAM chelates and Pb-DOTAM with very high affinity in the pM to fM range.

[0011] Furthermore, the antibodies of the invention are optionally or preferably selective for Bi-DOTAM and Pb-DOTAM compared to other chelator-metal complexes, such as Cu-DOTAM chelate.

[0012] In one embodiment, the invention provides an antibody comprising an antigen-binding site specific for a Pb-DOTAM chelate, wherein said antigen-binding site comprises a heavy chain comprising at least one, two or three heavy chain CDR sequences: a) the heavy chain CDR1 comprises the amino acid sequence GFSLSTYSMS (SEQ ID NO: 1); b) the heavy chain CDR2 comprises the amino acid sequence FIGSRGDTYYASWAKG (SEQ ID NO: 2); c) the heavy chain CDR3 comprises the amino acid sequence ERDPYGGGAYPPHL (SEQ ID NO: 3); and / or the antigen-binding site comprises a light chain comprising at least one, two or three light chain CDR sequences: d) the light chain CDR1 comprises the amino acid sequence QSSHSVYSDNDLA (SEQ ID NO: 4); e) the light chain CDR2 comprises the amino acid sequence QASKLAS (SEQ ID NO: 5); f) An antibody is provided, wherein the light chain CDR3 comprises the amino acid sequence LGGYDDESDTYG (SEQ ID NO: 6).

[0013] In some embodiments, the antigen-binding site comprises both a light chain and a heavy chain as defined above.

[0014] In another embodiment, the present invention provides an antibody comprising an antigen-binding site specific for a Pb-DOTAM chelate, said antigen-binding site comprising at least: a) a heavy chain CDR2 comprising the amino acid sequence FIGSRGDTYYASWAKG (SEQ ID NO: 2), or a variant thereof having one, two, or up to three substitutions in SEQ ID NO: 2, wherein these substitutions do not include Phe50, Asp56, and / or Tyr58, and optionally also do not include Gly52 and / or Arg54; b) a heavy chain CDR3 comprising the amino acid sequence ERDPYGGGAYPPHL (SEQ ID NO: 3), or a variant thereof having one, two, or up to three substitutions in SEQ ID NO: 3, wherein the substitutions do not include Glu95, Arg96, Asp97, Pro98, and optionally do not include Ala100C, Tyr100D, and / or Pro100E, and / or optionally do not include Tyr99; c) a light chain CDR1 comprising the amino acid sequence QSSHSVYSDNDLA (SEQ ID NO: 4), or a variant thereof having one, two, or up to three substitutions in SEQ ID NO: 4, wherein the substitutions do not include Tyr28 and Asp32; d) a light chain CDR3 comprising the amino acid sequence LGGYDDESDTYG (SEQ ID NO: 6), or a variant thereof having one, two, or up to three substitutions in SEQ ID NO: 6, wherein these substitutions do not include Gly91, Tyr92, Asp93, Thr95c, and Tyr96. The present invention provides an antibody comprising:

[0015] Residue numbering is according to Kabat.

[0016] In some embodiments, the antibody optionally further comprises: i) a heavy chain CDR1 comprising the amino acid sequence GFSLSTYSMS (SEQ ID NO: 1) or a variant thereof having one, two, or up to three substitutions in SEQ ID NO: 1; ii) a light chain CDR2 comprising the amino acid sequence QASKLAS (SEQ ID NO: 5) or a variant thereof having at least one, two, or three substitutions in SEQ ID NO: 5, optionally excluding Gln50; and a light chain CDR2 which are:

[0017] In any embodiment of the invention relating to variants of the above CDR-containing sequences, the protein may be invariant at one or more of the residues listed above.

[0018] In some embodiments, antibodies according to the invention bind to the same epitope on the chelated radionuclide as, or an overlapping epitope on the chelated radionuclide as, bound by, the antibodies disclosed herein.

[0019] In some embodiments, the antibody binds to the same epitope as, or an overlapping epitope with, that of Fab PRIT-0213 or PRIT-0214. i) an antibody having a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 8; or i) an antibody having a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 9 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 10 It may bind to the same epitope as, or an overlapping epitope with,

[0020] In one embodiment, the antigen binding site comprises: a) a heavy chain CDR1 comprising the amino acid sequence GFSLSTYSMS (SEQ ID NO: 1); b) a heavy chain CDR2 comprising the amino acid sequence FIGSRGDTYYASWAKG (SEQ ID NO: 2); c) a heavy chain CDR3 comprising the amino acid sequence ERDPYGGGAYPPHL (SEQ ID NO: 3); d) a light chain CDR1 comprising the amino acid sequence QSSHSVYSDNDLA (SEQ ID NO: 4); e) a light chain CDR2 comprising the amino acid sequence QASKLAS (SEQ ID NO: 5); f) a light chain CDR3 comprising the amino acid sequence LGGYDDESDTYG (SEQ ID NO: 6) The amino acid sequence comprises at least 1, 2, 3, 4, 5, or 6 CDRs selected from:

[0021] Optionally, the antibody in any of the above embodiments is human, chimeric or humanized.

[0022] Optionally, the antigen-binding site may comprise a heavy chain variable domain comprising an amino acid sequence selected from the group consisting of SEQ ID NO:7 and SEQ ID NO:9, or a variant thereof comprising an amino acid sequence having at least 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to SEQ ID NO:7 or SEQ ID NO:9.

[0023] Optionally, the antigen-binding site may comprise a light chain variable domain comprising an amino acid sequence selected from the group consisting of SEQ ID NO:8 and SEQ ID NO:10, or a variant thereof comprising an amino acid sequence having at least 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to SEQ ID NO:8 or SEQ ID NO:10.

[0024] Optionally, an antigen-binding site specific for a Pb-DOTAM chelate may comprise a heavy chain variable domain comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 7 or SEQ ID NO: 9, or a variant thereof as defined above, and a light chain variable domain comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 8 or SEQ ID NO: 10, or a variant thereof as defined above. For example, an antigen-binding site specific for a Pb-DOTAM chelate may comprise a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 7, or a variant thereof, and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 8, or a variant thereof. In another embodiment, it may comprise a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 9, or a variant thereof, and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 10, or a variant thereof.

[0025] The antibody may be in any format, including whole antibodies and antibody fragments. The antibody may be monospecific. In this form, the antibody is useful, for example, in selection and purification schemes, for example, to facilitate the isolation of radiolabeled moieties.

[0026] In some embodiments, antibodies that specifically bind to Pb-DOTAM chelates are coupled to cell binding / targeting moieties to produce targeted agents, which are useful, for example, for pretargeted radioimmunotherapy or pretargeted radioimmunoimaging.

[0027] Coupling may preferably be by expression as a fusion polypeptide or protein. Fusion may be direct or via a linker. Fusion polypeptides or proteins can be produced recombinantly, avoiding the need for conjugation chemistry.

[0028] In some embodiments, the targeting moiety (comprising an antigen binding site for the target) is an antibody or fragment thereof, i.e., in some embodiments, the antibody may be in the form of a multispecific (e.g., bispecific) antibody, as discussed further below.

[0029] In another aspect, the present invention further relates to multispecific antibodies / antibody conjugates suitable for targeting Pb-DOTAM chelates to target cells.

[0030] Thus, in another aspect, the present invention relates to a bispecific or multispecific antibody that specifically binds both a Pb-DOTAM chelate and a target antigen, e.g., an antigen expressed on the surface of a target cell. The bispecific antibody comprises at least one antigen-binding site specific for DOTAM-chelated lead and at least one antigen-binding site for the target antigen.

[0031] In some embodiments, the antigen binding site specific for the Pb-DOTAM chelate may be according to any of the above embodiments.

[0032] The target antigen may be any antigen as further discussed herein, e.g., any tumor-specific antigen. In some embodiments, it may be a protein or polypeptide expressed by a pathogen such as a prokaryote or virus.

[0033] In some embodiments, the tumor-associated antigen may be CEA (carcinoembryonic antigen). That is, in some embodiments, the bispecific antibody may comprise at least one antigen-binding site specific for Pb-DOTAM chelate and at least one antigen-binding site specific for CEA. CEA is advantageous in the context of the present invention because it is internalized relatively slowly, and thus a high percentage of the bispecific antibody remains available on the surface of the cell after initial treatment for binding to the radionuclide. Other poorly internalized targets / tumor-associated antigens are also preferred and are described herein. Other examples of tumor-associated antigens that may be useful in the present invention include CD20 or HER2.

[0034] In some embodiments, when the target antigen is CEA, the antigen binding site specific for CEA is d) the heavy chain CDR1 comprises the amino acid sequence of SEQ ID NO: 11; e) the heavy chain CDR2 comprises the amino acid sequence of SEQ ID NO: 12; f) the heavy chain CDR3 comprises the amino acid sequence of SEQ ID NO: 13; may contain at least one, two, or three heavy chain CDRs; and / or an antigen-binding site specific for CEA, a) the light chain CDR1 comprises the amino acid sequence of SEQ ID NO: 14; b) the light chain CDR2 comprises the amino acid sequence of SEQ ID NO: 15; c) the light chain CDR3 comprises the amino acid sequence of SEQ ID NO: 16; It may include at least one, two, or three light chain CDRs.

[0035] In some embodiments, the antigen binding site for CEA is a) a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 11; b) a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 12; c) a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 13; d) a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 14; e) a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 15; f) a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 16 It may comprise at least one, two, three, four, five, or six (i.e., all) CDRs selected from:

[0036] In some embodiments, an antigen binding site for CEA may comprise a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 17, or a variant thereof comprising an amino acid sequence having at least 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to SEQ ID NO: 17.

[0037] Optionally, the antigen-binding site may comprise a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 18, or a variant thereof comprising an amino acid sequence having at least 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to SEQ ID NO: 18.

[0038] If desired, the antigen-binding site specific for CEA may comprise a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 17 or a variant thereof, and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 18 or a variant thereof.

[0039] A variety of possible formats for bispecific or multispecific antibodies are known in the art, including those further described herein. The antibodies of the present invention may adopt any of these formats. For example, in some embodiments, bispecific antibodies may be bivalent, trivalent, or tetravalent.

[0040] It may be preferred that the antibodies of the invention comprise an Fc region, the presence of which has benefits in the context of radioimmunotherapy and radioimaging, for example, extending the circulating half-life of the protein and / or resulting in higher tumor uptake than might be observed for smaller fragments.

[0041] In some embodiments, if an Fc region is present, it may be preferred that the Fc region be engineered to reduce effector function. This may include substitution of one or more of Fc region residues 234, 235, 238, 265, 269, 270, 297, 327, and / or 329, for example, one or more of 234, 235, and / or 329. In some embodiments, the Fc region may be engineered to include a Pro329 to Gly substitution, a Leu234 to Ala substitution, and / or a Leu235 to Ala substitution (EU index numbering).

[0042] Various formats of multispecific antibodies containing an Fc domain are known.

[0043] In one embodiment, the bispecific or multispecific antibody may comprise i) an Fc domain, ii) at least one Fab, cross-Fab, Fv, scFab, or scFv fragment or single domain antibody (VHH) comprising an antigen binding site specific for the Pb-DOTAM chelate, and iii) at least one Fab, cross-Fab, Fv, scFab, or scFv fragment or single domain antibody (VHH) comprising an antigen binding site specific for a target antigen.

[0044] In some embodiments, it may be preferable for the bispecific or multispecific antibody to be multivalent, e.g., bivalent, with respect to the target antigen (e.g., tumor-associated antigen), which has the advantage of increasing avidity.

[0045] In some embodiments, the bispecific or multispecific antibody is monovalent with respect to Pb-DOTAM, which reduces the risk of high molecular weight complex formation when clearing agents are used (see further discussion below).

[0046] Thus, in some embodiments, the antibody may be trivalent: bivalent for the target antigen and monovalent for Pb-DOTAM.

[0047] In one exemplary format, a bispecific or multispecific antibody may comprise a full-length antibody (e.g., an IgG) comprising a first and a second antibody heavy chain and a first and a second antibody light chain, where the first heavy chain and the first light chain assemble to form an antigen-binding site for a first antigen, and the second heavy chain and the second light chain assemble to form an antigen-binding site for a second antigen. If desired, additional antigen-binding moieties can be fused to the N- or C-terminus of the first and / or second heavy chain, e.g., via a polypeptide linker, to increase valency with respect to one or both antigens. For example, an additional antigen-binding moiety for the first antigen can be fused to the N-terminus of one or both heavy chain molecules.

[0048] In another exemplary format, the bispecific or multispecific antibody may comprise a full-length antibody (e.g., an IgG) comprising an antigen-binding site for a first antigen (e.g., which may be bivalent for the first antigen) and further comprises at least one antigen-binding portion specific for a second antigen. In various embodiments, the antigen-binding portion may be a Fab fragment, a crossover Fab molecule, an scFab, an Fv molecule, an scFv, or a single-domain antibody (VHH), or may be a portion of a second full-length antibody. For example, the antibody may comprise a full-length antibody comprising an antigen-binding site for the first antigen and further comprise at least a second heavy chain variable domain and a second light chain variable domain that together form an antigen-binding site for the second antigen. Either the first or second antigen is a Pb-DOTAM chelate, and the other antigen is the target antigen.

[0049] In some embodiments of the formats herein, the second antigen is a Pb-DOTAM chelate and the first antigen is a target, for example, a tumor-associated antigen (in some embodiments, CEA, CD20, or ERBB2).

[0050] In another exemplary format, a bispecific or multispecific antibody may comprise a full-length antibody comprising an antigen-binding site for a first antigen (which may be, for example, bivalent for the first antigen), wherein the N- or C-terminus of one of the heavy chains is linked to a first polypeptide via a polypeptide linker, and the first polypeptide associates with a second polypeptide to form a Fab or cross-Fab that comprises a binding site for the second antigen. For example, this format may be used in combination with a Fab or cross-Fab, such that the first and second polypeptides together form an antigen-binding site for the second antigen. i) a first polypeptide consisting of a VH domain and a CH1 domain associated with a second polypeptide consisting of a VL and a CL domain; or ii) a first polypeptide consisting of a VL domain and a CH1 domain associated with a second polypeptide consisting of a VH and a CL domain; or iii) a first polypeptide consisting of a VH domain and a CL domain associated with a second polypeptide consisting of a VL and a CH1 domain; may include:

[0051] In some embodiments, the fusion can be at the N-terminus of one of the heavy chains of a full-length antibody.

[0052] In another particular embodiment, the antibody a) a full-length antibody that specifically binds to a first antigen and consists of two antibody heavy chains and two antibody light chains; b) i) an antibody heavy chain variable domain (VH); or ii) an antibody heavy chain variable domain (VH) and an antibody heavy chain constant domain (CH1); or iii) antibody heavy chain variable domain (VH) and antibody light chain constant domain (CL) A polypeptide consisting of a polypeptide in which the N-terminus of a VH domain is fused to the C-terminus of one of the two heavy chains of the full-length antibody via a peptide linker; c) i) an antibody light chain variable domain (VL); or ii) an antibody light chain variable domain (VL) and an antibody light chain constant domain (CL); or iii) an antibody light chain variable domain (VL) and an antibody heavy chain constant domain (CH1) A polypeptide consisting of A polypeptide in which the N-terminus of the VL domain is fused to the C-terminus of the other of the two heavy chains of the full-length antibody via a peptide linker. Includes; It may also be a bispecific antibody, in which the antibody heavy chain variable domain of the peptide under (b) and the antibody light chain variable domain of the peptide under (c) together form an antigen-binding site for a second antigen.

[0053] In this format, either the first or second antigen may be a Pb-DOTAM chelate, and the other will be a target antigen, e.g., a tumor-associated antigen.

[0054] In some embodiments, the second antigen is a Pb-DOTAM chelate and the first antigen is a target, eg, a tumor-associated antigen (in some embodiments, CEA, CD20, or ERBB2).

[0055] The antibodies described above may be trivalent. In another possible embodiment, additional antigen-binding moieties may be fused to increase valency with respect to one or both antigens, as further discussed herein.

[0056] Optionally, the linker (and any linker discussed herein) may be a peptide of at least 5 amino acids, preferably between 25 and 50 amino acids. The linker may be a rigid linker or a flexible linker. In some embodiments, it is flexible, comprising or consisting of Thr, Ser, Gly, and / or Ala residues. For example, it may comprise or consist of Gly and Ser residues. In some embodiments, it may be (Gly-Gly-Gly-Gly-Ser). n

[0037] In some embodiments, the linker may have a repeating motif such as:

[0038] , where n is, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. In some embodiments, the linker may be or include the sequence GGGGSGGGGSGGGGSGGGGS (SEQ ID NO: 26). Other linkers may be used and can be identified by one of skill in the art.

[0057] Further details of this antibody format are provided in WO2010 / 115589A1 (Roche Glycart AG), which is incorporated herein by reference in its entirety.

[0058] as needed, i) in the constant domain CL of the first light chain of the full length antibody under a) the amino acid at position 124 is substituted independently (in one preferred embodiment independently by lysine (K), arginine (R) or histidine (H) (numbering according to Kabat) and in the constant domain CHI of the first heavy chain under a) the amino acid at position 147 or the amino acid at position 213 is substituted independently by glutamic acid (E) or aspartic acid (D) (numbering according to EU index of Kabat); or ii) in the constant domain CL of the second light chain under b) the amino acid at position 124 is independently substituted (in one preferred embodiment independently by lysine (K), arginine (R) or histidine (H) (numbering according to Kabat) and in the constant domain CH1 of the second heavy chain under b) the amino acid at position 147 or the amino acid at position 213 is independently substituted by glutamic acid (E) or aspartic acid (D) (numbering according to EU index of Kabat).

[0059] In one embodiment, the bispecific antibody of the invention may have a trivalent structure as described above, a) a full-length antibody that specifically binds to CEA and is composed of two antibody heavy chains and two antibody light chains, the heavy chain has at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identity to the heavy chain of amino acids 1-450 (inclusive, based on consecutive numbering) of SEQ ID NO: 22 or 23 (i.e., to the portion of the sequence before the linker); a full-length antibody whose light chain has at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identity to the light chain of SEQ ID NO: 21; and / or b) i) an antibody heavy chain variable domain (VH) having at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identity to the heavy chain variable domain of SEQ ID NO: 7; or ii) an antibody heavy chain variable domain (VH) and an antibody heavy chain constant domain (CH1) having at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identity to the heavy chain variable domain of SEQ ID NO: 7; or iii) an antibody heavy chain variable domain (VH) and an antibody light chain constant domain having at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identity to the heavy chain variable domain of SEQ ID NO: 7. A polypeptide consisting of a polypeptide in which the N-terminus of a VH domain is fused via a peptide linker to the C-terminus of one of the two heavy chains of said full-length antibody; and / or c) i) an antibody light chain variable domain (VL) having at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identity to the light chain variable domain of SEQ ID NO: 8; or ii) an antibody light chain variable domain (VL) and an antibody light chain constant domain (CL) having at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identity to the light chain variable domain of SEQ ID NO: 8; or iii) an antibody light chain variable domain (VL) and an antibody heavy chain constant domain (CH1) having at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identity to the light chain variable domain of SEQ ID NO: 8. A polypeptide consisting of It may comprise a polypeptide in which the N-terminus of the VL domain is fused to the C-terminus of the other of the two heavy chains of the full-length antibody via a peptide linker; The antibody heavy chain variable domain of the peptide below (b) and the antibody light chain variable domain of the peptide below (c) together form the antigen binding site for the Pb-DOTAM chelate.

[0060] In one example, one of the heavy chains of a full-length antibody contains a so-called "knob mutation" (T366W and optionally one of S354C or Y349C, preferably S354C) according to EU index numbering, and the other contains a so-called "hole mutation" (T366S, L368A and Y407V, optionally Y349C or S354C, preferably Y349C) (see, e.g., Carter, P. et al., Immunotechnol. 2 (1996) 73).

[0061] In some embodiments, the two antibody heavy chains under (a) comprise: i) a first antibody heavy chain having at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identity to the heavy chain of amino acids 1 to 450 (inclusive, based on consecutive numbering) of SEQ ID NO: 23 (i.e., to the portion of the sequence before the linker), and having a C at position 349, an S at position 366, an A at position 368, and a V at position 407 (EU numbering); and ii) a second antibody heavy chain having at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identity to the heavy chain of amino acids 1 to 450 (inclusive, based on consecutive numbering) of SEQ ID NO: 22, and having a C at position 354 and a W at position 366 (EU numbering).

[0062] The "fixed" residues described herein are "knob-into-hole" mutations in CH3 or other residues, such as disulfide bridge-forming residues, that pair with the corresponding residue on the CH3 of the other heavy chain to favor the formation of the desired molecule. Possible residues that may be present on the other heavy chain may be from the sequences in Table 2 (e.g., sequences 19 and 20 or 22 and 23). For example, in one embodiment, if the first antibody heavy chain has a C at position 349, the second antibody heavy chain has a C at position 354.

[0063] Optionally, the linker is as described above.

[0064] In another embodiment, the bispecific antibody of the invention may have a trivalent structure as described above, a) a full-length antibody that specifically binds to CEA and is composed of two antibody heavy chains and two antibody light chains, the heavy chain has at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identity to the heavy chain of amino acids 1-450 (inclusive, based on consecutive numbering; i.e., the sequence before the linker) of SEQ ID NO: 19 or 20; a full-length antibody, wherein the light chain has at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identity to the light chain of SEQ ID NO: 21; b) i) an antibody heavy chain variable domain (VH) having at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identity to the heavy chain variable domain of SEQ ID NO: 9; or ii) an antibody heavy chain variable domain (VH) and an antibody heavy chain constant domain (CH1) having at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identity to the heavy chain variable domain of SEQ ID NO: 9; or iii) an antibody heavy chain variable domain (VH) and an antibody light chain constant domain having at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identity to the heavy chain variable domain of SEQ ID NO: 9 A polypeptide consisting of a polypeptide in which the N-terminus of a VH domain is fused to the C-terminus of one of the two heavy chains of the full-length antibody via a peptide linker; c) i) an antibody light chain variable domain (VL) having at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identity to the light chain variable domain of SEQ ID NO: 10; or ii) an antibody light chain variable domain (VL) and an antibody light chain constant domain (CL) having at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identity to the light chain variable domain of SEQ ID NO: 10; or iii) an antibody light chain variable domain (VL) and an antibody heavy chain constant domain (CH1) having at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identity to the light chain variable domain of SEQ ID NO: 10. A polypeptide consisting of A polypeptide in which the N-terminus of the VL domain is fused to the C-terminus of the other of the two heavy chains of the full-length antibody via a peptide linker. may include; The antibody heavy chain variable domain of the peptide below (b) and the antibody light chain variable domain of the peptide below (c) together form the antigen binding site for the Pb-DOTAM chelate.

[0065] As described above, in any of the above embodiments, one of the heavy chains of the full-length antibody contains a so-called "knob mutation" (T366W and optionally one of S354C or Y349C, preferably S354C) according to EU index numbering, and the other contains a so-called "hole mutation" (T366S, L368A and Y407V, optionally Y349C or S354C, preferably Y349C) (see, e.g., Carter, P. et al., Immunotechnol. 2 (1996) 73).

[0066] In one embodiment, the two antibody heavy chains under (a) may comprise: i) a first antibody heavy chain having at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identity to the heavy chain of amino acids 1-450 of SEQ ID NO: 22, and having a C at position 354 and a W at position 366 (EU numbering); and ii) a second antibody heavy chain having at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identity to the heavy chain of amino acids 1-450 of SEQ ID NO: 23, and having a C at position 349, an S at position 366, an A at position 368, and a V at position 407 (EU numbering).

[0067] Optionally, the linker is as described above.

[0068] In another embodiment, the bispecific antibody comprises: i) a first heavy chain having an amino acid sequence having at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identity to the heavy chain of SEQ ID NO: 22; ii) a second heavy chain having at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identity to the heavy chain of SEQ ID NO: 23; iii) two antibody light chains having at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identity to the light chain of SEQ ID NO: 21 Includes:

[0069] In yet another embodiment, the bispecific antibody comprises: i) a first heavy chain having the amino acid sequence of SEQ ID NO: 22; ii) a second heavy chain having the amino acid sequence of SEQ ID NO: 23; and iii) two antibody light chains having the amino acid sequence of SEQ ID NO: 21 The molecule referred to herein as PRIT-0213 comprises:

[0070] In another embodiment, the bispecific antibody comprises: i) a first heavy chain having an amino acid sequence having at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identity to the heavy chain of SEQ ID NO: 19; ii) a second heavy chain having at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identity to the heavy chain of SEQ ID NO: 20; iii) two antibody light chains having at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identity to the light chain of SEQ ID NO: 21 Includes:

[0071] In yet another embodiment, the bispecific antibody comprises: i) a first heavy chain having the amino acid sequence of SEQ ID NO: 19; ii) a second heavy chain having the amino acid sequence of SEQ ID NO: 20; and iii) two antibody light chains having the amino acid sequence of SEQ ID NO: 21 The molecule referred to herein as PRIT-0214 comprises:

[0072] In one embodiment, the bispecific antibody of the invention may have a trivalent structure as described above, a) a full-length antibody that specifically binds to ERBB2 and is composed of two antibody heavy chains and two antibody light chains, the heavy chain has at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identity to the heavy chain of amino acids 1 to 449 (inclusive, based on consecutive numbering) of SEQ ID NO: 36 or 37 (i.e., to the portion of the sequence before the linker); a full-length antibody whose light chain has at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identity to the light chain of SEQ ID NO: 38; and / or b) i) an antibody heavy chain variable domain (VH) having at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identity to the heavy chain variable domain of SEQ ID NO:7 or SEQ ID NO:9 (in some embodiments, preferably SEQ ID NO:7); or ii) an antibody heavy chain variable domain (VH) and an antibody heavy chain constant domain (CH1) having at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identity to the heavy chain variable domain of SEQ ID NO:7 or SEQ ID NO:9 (in some embodiments, preferably SEQ ID NO:7); or iii) an antibody heavy chain variable domain (VH) and an antibody light chain constant domain (CL) having at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identity to the heavy chain variable domain of SEQ ID NO: 7 or SEQ ID NO: 9 (in some embodiments, preferably SEQ ID NO: 7). A polypeptide consisting of a polypeptide in which the N-terminus of a VH domain is fused via a peptide linker to the C-terminus of one of the two heavy chains of said full-length antibody; and / or c) i) an antibody light chain variable domain (VL) having at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identity to the light chain variable domain of SEQ ID NO:8 or SEQ ID NO:10 (in some embodiments, preferably SEQ ID NO:8); or ii) an antibody light chain variable domain (VL) and an antibody light chain constant domain (CL) having at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identity to the light chain variable domain of SEQ ID NO:8 or SEQ ID NO:10 (in some embodiments, preferably SEQ ID NO:8); or iii) an antibody light chain variable domain (VL) and an antibody heavy chain constant domain (CH1) having at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identity to the light chain variable domain of SEQ ID NO: 8 or SEQ ID NO: 10 (in some embodiments, preferably SEQ ID NO: 8). A polypeptide consisting of It may comprise a polypeptide in which the N-terminus of the VL domain is fused to the C-terminus of the other of the two heavy chains of the full-length antibody via a peptide linker; The antibody heavy chain variable domain of the peptide below (b) and the antibody light chain variable domain of the peptide below (c) together form the antigen binding site for the Pb-DOTAM chelate.

[0073] In one example, one of the heavy chains of a full-length antibody contains a so-called "knob mutation" (T366W and optionally one of S354C or Y349C, preferably S354C) according to EU index numbering, and the other contains a so-called "hole mutation" (T366S, L368A and Y407V, optionally S354C or Y349C, preferably Y349C) (see, e.g., Carter, P. et al., Immunotechnol. 2 (1996) 73).

[0074] In some embodiments, the two antibody heavy chains under (a) comprise: i) a first antibody heavy chain having at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identity to the heavy chain of amino acids 1 to 449 (inclusive, based on consecutive numbering) of SEQ ID NO: 37 (i.e., to the portion of the sequence before the linker), and having a C at position 349, an S at position 366, an A at position 368, and a V at position 407 (EU numbering); and ii) a second antibody heavy chain having at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identity to the heavy chain of amino acids 1 to 449 (inclusive, based on consecutive numbering) of SEQ ID NO: 36, and having a C at position 354 and a W at position 366 (EU numbering).

[0075] Optionally, the linker is as described above.

[0076] In another embodiment, the bispecific antibody comprises: i) a first heavy chain having an amino acid sequence having at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identity to the heavy chain of SEQ ID NO: 36; ii) a second heavy chain having at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identity to the heavy chain of SEQ ID NO: 37; iii) two antibody light chains having at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identity to the light chain of SEQ ID NO: 38 Includes:

[0077] In yet another embodiment, the bispecific antibody comprises: i) a first heavy chain having the amino acid sequence of SEQ ID NO: 36; ii) a second heavy chain having the amino acid sequence of SEQ ID NO: 37; and iii) two antibody light chains having the amino acid sequence of SEQ ID NO: 38 The molecule referred to herein as P1AD9827 comprises:

[0078] In another embodiment, the bispecific antibody of the invention may have a trivalent structure as described above, a) a full-length antibody that specifically binds to CD20 and consists of two antibody heavy chains and two antibody light chains, the heavy chain has at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identity to the heavy chain of amino acids 1 to 448 (inclusive, based on consecutive numbering) of SEQ ID NO: 47 or 48 (i.e., to the portion of the sequence before the linker); a full-length antibody whose light chain has at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identity to the light chain of SEQ ID NO: 49; and / or b) i) an antibody heavy chain variable domain (VH) having at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identity to the heavy chain variable domain of SEQ ID NO:7 or SEQ ID NO:9 (in some embodiments, preferably SEQ ID NO:7); or ii) an antibody heavy chain variable domain (VH) and an antibody heavy chain constant domain (CH1) having at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identity to the heavy chain variable domain of SEQ ID NO: 7 or SEQ ID NO: 9 (in some embodiments, preferably SEQ ID NO: 7); iii) an antibody heavy chain variable domain (VH) and an antibody light chain constant domain (CL) having at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identity to the heavy chain variable domain of SEQ ID NO: 7 or SEQ ID NO: 9 (in some embodiments, preferably SEQ ID NO: 7). A polypeptide consisting of a polypeptide in which the N-terminus of a VH domain is fused via a peptide linker to the C-terminus of one of the two heavy chains of said full-length antibody; and / or c) i) an antibody light chain variable domain (VL) having at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identity to the light chain variable domain of SEQ ID NO:8 or SEQ ID NO:10 (in some embodiments, preferably SEQ ID NO:8); or ii) an antibody light chain variable domain (VL) and an antibody light chain constant domain having at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identity to the light chain variable domain of SEQ ID NO:8 or SEQ ID NO:10 (in some embodiments, preferably SEQ ID NO:8); iii) an antibody light chain variable domain (VL) and an antibody heavy chain constant domain having at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identity to the light chain variable domain of SEQ ID NO: 8 or SEQ ID NO: 10 (in some embodiments, preferably SEQ ID NO: 8). A polypeptide consisting of A polypeptide in which the N-terminus of the VL domain is fused to the C-terminus of the other of the two heavy chains of the full-length antibody via a peptide linker. may include; The antibody heavy chain variable domain of the peptide below (b) and the antibody light chain variable domain of the peptide below (c) together form the antigen binding site for the Pb-DOTAM chelate.

[0079] In one example, one of the heavy chains of a full-length antibody contains a so-called "knob mutation" (T366W and optionally one of S354C or Y349C, preferably S354C) according to EU index numbering, and the other contains a so-called "hole mutation" (T366S, L368A and Y407V, optionally Y349C or S354C, preferably Y349C) (see, e.g., Carter, P. et al., Immunotechnol. 2 (1996) 73).

[0080] In some embodiments, the two antibody heavy chains under (a) comprise: i) a first antibody heavy chain having at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identity to the heavy chain of amino acids 1 to 448 (inclusive, based on consecutive numbering) of SEQ ID NO: 48 (i.e., the portion of the sequence before the linker), and having a C at position 349, an S at position 366, an A at position 368, and a V at position 407 (EU numbering); and ii) a second antibody heavy chain having at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identity to the heavy chain of amino acids 1 to 448 (inclusive, based on consecutive numbering) of SEQ ID NO: 47, and having a C at position 354 and a W at position 366 (EU numbering).

[0081] Optionally, the linker is as described above.

[0082] In another embodiment, the bispecific antibody comprises: i) a first heavy chain having an amino acid sequence having at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identity to the heavy chain of SEQ ID NO: 47; ii) a second heavy chain having at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identity to the heavy chain of SEQ ID NO: 48; iii) two antibody light chains having at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identity to the light chain of SEQ ID NO: 49 Includes:

[0083] In yet another embodiment, the bispecific antibody comprises: i) a first heavy chain having the amino acid sequence of SEQ ID NO: 47; ii) a second heavy chain having the amino acid sequence of SEQ ID NO: 48; and iii) two antibody light chains having the amino acid sequence of SEQ ID NO: 49 The molecule referred to herein as P1AD9826 comprises:

[0084] In a further aspect, the present invention relates to a polynucleotide or set of polynucleotides encoding any of the antibodies described herein. In a further embodiment, the present invention relates to a vector or set of expression vectors, optionally an expression vector, comprising said polynucleotide or polynucleotides. In a further object, the present invention relates to a prokaryotic or eukaryotic host cell comprising a vector of the present invention. Additionally, a method of producing an antibody is provided, comprising culturing the host cell so that the antibody is produced.

[0085] The bispecific or multispecific antibodies described herein may be useful in a variety of applications, including therapeutic and diagnostic applications, such as pretargeted radioimmunotherapy and pretargeted radioimmunoimaging.

[0086] Thus, in a further aspect, the present invention relates to any bispecific or multispecific antibody described herein for use in pretargeted radioimaging. In such embodiments, the chelated Pb is preferably 203 It is Pb.

[0087] Methods for targeting radioisotopes to tissues or organs for imaging include: i) administering to a subject a multispecific or bispecific antibody described herein, wherein the antibody binds to a target antigen and localizes to the surface of a cell expressing the target antigen; and ii) subsequently administering to the individual a Pb radionuclide chelated with DOTAM or a functional variant thereof, wherein the Pb radionuclide binds to the antibody localized on the surface of the target cell. may include:

[0088] Optionally, between steps (i) and (ii), a clearing agent is administered that binds to the antigen-binding site specific for the Pb-DOTAM chelate. The clearing agent blocks the antigen-binding site for Pb-DOTAM and prevents circulating antibodies from binding to the chelated Pb radionuclide. Alternatively, or in addition, the clearing agent can increase the rate of antibody clearance from the body. The "clearing agent" may alternatively be referred to as a "blocking agent"; these terms are interchangeable in the following discussion.

[0089] The scavenger may comprise a complex of a metal ion and DOTAM or its functional variant, said complex being recognized by the antigen binding site for Pb-DOTAM. Preferably, the metal ion is a stable isotope or an essentially stable isotope. "Stable isotope" means an isotope that does not undergo radioactive decay. "Inherently stable isotope" means an isotope that undergoes radioactive decay with a very long half-life, making it safe for use. Preferably, the metal ion is selected from ions of Pb, Ca, and Bi. For example, the scavenger may comprise Pb complexed with DOTAM or its functional variant, Ca complexed with DOTAM or its functional variant, or Bi complexed with DOTAM or its functional variant. 209 Bi(1.9x10 19 Pb may contain stable isotopes of Pb (essentially stable isotopes with half-lives of 10 years). 204 Pb, 206 Pb, 207 Pb and 208 It may also be naturally occurring lead, which is a mixture of Pb.

[0090] DOTAM or its functional variants are conjugated to a removal moiety. This moiety provides a removal agent with low tumor uptake, for example, due to its size and / or high hydrodynamic radius. Suitable removal moieties are further discussed below. In some embodiments, the removal agent may comprise DOTAM or its functional variants conjugated to dextran or its derivatives.

[0091] In another embodiment of the imaging method, the multispecific or bispecific antibody can be bound to a chelated Pb radionuclide at the time of administration.

[0092] Optionally, in any embodiment, the method further comprises: iii) Imaging tissues or organs where Pb radionuclides chelated with DOTAM or its functional variants are localized. It may further include:

[0093] In some embodiments, the target antigen may be a tumor-specific antigen and the imaging may be a method of imaging a tumor or multiple tumors.

[0094] In a further aspect, the present invention relates to the antibodies described herein for use in methods of pretargeted radioimmunotherapy. In such embodiments, the chelated Pb is preferably 212 It is Pb.

[0095] Methods for targeting radioisotopes to tissues or organs for therapy include: i) administering to a subject a multispecific or bispecific antibody described herein, wherein the antibody binds to a target antigen and localizes to the surface of a cell expressing the target antigen; and ii) subsequently administering a Pb radionuclide chelated with DOTAM or a functional variant thereof, wherein the Pb radionuclide is bound to the antibody localized on the surface of the cell. may include:

[0096] If desired, between steps (i) and (ii) a removal agent is administered as described above.

[0097] In some embodiments, the target antigen is a tumor-associated antigen and the method is a method of treating cancer. In other embodiments, the target antigen may be an antigen associated with infection, for example, a protein expressed by a prokaryote or a virus-infected cell.

[0098] In some embodiments, the antibodies described herein can be administered as part of a combination therapy. For example, they can be administered in combination with one or more radiosensitizers and / or chemotherapeutic agents: the radiosensitizer or chemotherapeutic agent and the antibody can be administered simultaneously or sequentially in either order.

[0099] The radioimaging and radioimmunotherapy methods described herein can be optionally performed using, for example, antibodies and 203 Pb-DOTAM and 212 Both Pb-DOTAM can be combined, for example, by administration as a mixture.

[0100] The present invention further relates to a pharmaceutical composition comprising an antibody of the present invention and a pharmaceutically acceptable excipient.

[0101] In a further embodiment, the present invention provides a method for treating a cancer cell line comprising administering to a patient a cancer cell line comprising administering to the ... i) pharmaceutically acceptable excipients; ii) Pb radionuclides chelated by DOTAM or its functional variants; iii) a remover as described herein; iv) one or more additional chemotherapeutic agents; and / or v) one or more radiosensitizers The present invention relates to a kit including one, two, three, four or all of the above.

[0102] In a further aspect of the present invention, the inventors have developed novel clearing agents, which can be used in any of the diagnostic, imaging or therapeutic methods as described herein.

[0103] In one aspect, the present invention relates to a remover comprising dextran or a derivative thereof conjugated to a chelator selected from DOTAM and functional variants of DOTAM, wherein the chelator forms a complex with Pb, Zn, Ca, or Bi. The remover typically contains a chelated metal ion, such as a Pb, Zn, Ca, or Bi ion.

[0104] The clearing agent may comprise an aminodextran coupled to DOTAM or a functional variant of DOTAM, for example, DOTAM coupled to an aminodextran using isothiocyanate coupling (e.g., a compound obtained by reacting aminodextran with p-SCN-Bn-TCMC).

[0105] One potential difficulty with the use of ablation agents is the possibility that they may enter the tumor and negatively affect subsequent binding of the radioligand.

[0106] The inventors have further found that when using dextran-based clearing agents that i) have a high average molecular weight and ii) are subject to a molecular weight cutoff such that fragments below a certain size are removed, good clearance from the blood can be achieved along with low clearing agent penetration into the tumor.

[0107] Thus, preferred clearing agents are those in which i) the average molecular weight of the dextran or derivative thereof in the clearing agent is between 200 and 800 kDa, optionally greater than 300, 350, 400 or 450 kDa, optionally less than 700, 650, 600 or 550 kDa, and optionally about 500 kDa; and ii) dextran, dextran derivative or clearing agent below a particular molecular weight cutoff is removed, the molecular weight cutoff being 50 kDa or more, 100 kDa or more, or 200 kDa or more, optionally in the range of 50 kDa to 250 kDa or 50 kDa to 200 kDa, optionally 100 kDa to 200 kDa, and optionally about 100 kDa, 150 kDa or 200 kDa.

[0108] In a further aspect, the invention relates to a method for preparing the clearing agent and to the use of the clearing agent in a method of radioimmunotherapy or radioimmunoimaging.

[0109] These and other aspects of the invention are discussed further below. [Brief explanation of the drawings]

[0110] [Figure 1] Figure 1 shows a schematic diagram of a possible bispecific antibody format, which contains two antigen-binding sites for one target (A) and one antigen-binding site for a second target (B) (2:1 format). [Figure 2] Figure 2 shows the structure of PRIT-0213 complexed with Pb-DOTAM. [Figure 3] FIG. 3 shows a representation of the interaction sites of PRIT-0213 complexed with Pb-DOTAM, numbered according to Kabat. [Figure 4]Figure 4 shows the distribution of 212Pb 24 hours after injection of radiolabeled DOTAM (%ID / g ± SD, n=3). PRIT-0206, -0207, -0208, and -0165 target T84.66, while PRIT-0186, -0187, and -0156 target CH1A1A. PRIT-0175 is a non-CEA binding control. [Figure 5] Figure 5 shows the distribution of 203Pb, expressed as counts per minute (CPM), 96 hours after injection of PRIT antibody pre-conjugated with radiolabeled DOTAM (CPM ± SD, n = 3). PRIT-0205, -0206, -0207, -0208, and -0209 are fully humanized constructs, while PRIT-0165 and -0175 are positive and negative controls, respectively. [Figure 6] Figure 6 shows the accumulation / clearance of 203Pb-DOTAM-bsAb in BxPC3 tumors and blood, expressed as CPM ± SD (n = 3), at various time points after injection of PRIT antibody pre-conjugated with radiolabeled DOTAM. PRIT-0206 is a fully humanized version of PRIT-0165; PRIT-0175 is a non-CEA-binding control. [Figure 7] FIG. 7 shows the distribution of radioactivity in selected tissues 2 hours after injection of 212Pb-labeled clearing agent in MKN45 tumor-bearing mice (% ID / g±SD, n=3). [Figure 8] FIG. 8 shows the distribution of radioactivity in selected tissues and urine 24 hours after injection of 212Pb-labeled clearing agent in MKN45 tumor-bearing mice (% ID / g±SD, n=3). [Figure 9] FIG. 9 shows the organ-wise distribution of radioactivity in selected tissues and urine 24 hours after injection of 212Pb-labeled clearing agent in MKN45 tumor-bearing mice (% ID±SD, n=3). [Figure 10]FIG. 10 shows the distribution of radioactivity in selected tissues one week after injection of 203Pb-labeled clearing agent in tumor-free mice (% ID / g±SD, n=3). [Figure 11] FIG. 11 shows the organ-specific radioactivity distribution in selected tissues one week after injection of 203Pb-labeled clearing agent in tumor-free mice (% ID±SD, n=3). [Figure 12] Figure 12 shows the radioactivity content in blood 4 hours after injection of Pb-DOTAM (%ID / g ± SD, n = 3). The striped bar represents the no-CA control (no clearing agent) to which all candidate reagents were compared. Asterisks mark the level of statistical significance, from low (*) to high (***). [Figure 13] Figure 13 shows the mean radioactivity content in blood 24 hours after injection of 212Pb-DOTAM (%ID / g±SD, n=3). The striped bar represents the no-CA control (no clearing agent) to which all candidate reagents were compared. [Figure 14] FIG. 14 shows the radioactivity content in blood and tumor 24 hours after injection of 212Pb-DOTAM (%ID / g±SD, n=3). [Figure 15] Figure 15 shows the distribution of 212Pb (%ID / g ± SD, n=3) 24 hours after injection of radiolabeled DOTAM using 30 or 100 μg of bispecific antibody and 10-100 μg of clearing agent with a 100 or 30 kDa filtration cutoff, or no clearing agent at all (PBS). [Figure 16] Figure 16 shows the effect of increasing amounts of clearing agent (0-100 μg) on ​​Pb activity concentrations in blood and tumors. Tumors were pretargeted using 100 μg of PRIT-0165 followed by Dex500 diafiltration at a 100 kDa cutoff or PBS 4 days later. Pb-DOTAM was administered 2 hours after clearing agent. Symbols represent %ID / g 24 hours after radioactivity injection, and the line represents a linear regression of the tumor data. [Figure 17]Figure 17 shows the distribution of radioactivity in selected tissues 24 hours after injection of Pb-DOTAM (%ID / g ± SD, n = 3). The dark gray and black bars represent the no-CA positive control (no clearing agent) to which the candidate reagents were compared. [Figure 18] Figure 18 shows the Pb content (% ID / g ± SD, n = 3) in blood and tumors 24 hours after injection of Pb-DOTAM, as well as the corresponding tumor-to-blood ratios. The dark gray and black bars represent the no-CA positive control (no clearing agent) to which the candidate reagents were compared. [Figure 19] Figure 19 shows the tumor-to-blood ratio 24 hours after injection of 212Pb-DOTAM as a function of clearing agent (CA) dose (PJRD08-46) and TCMC saturation (9 to 1, 20 to 1, 39 to 1, or 84 to 1). The dashed lines represent the linear regression (R2 = 0.82) and nonlinear curve fit (R2 = 0.74) of the data, respectively. [Figure 20] Figure 20 shows the distribution of 212Pb 24 hours after injection of radiolabeled DOTAM (% ID / g ± SD, n = 3). Bars with white and gray backgrounds represent targeting of T84.66 and CH1A1A, respectively; black bars represent the non-CEA binding control. [Figure 21] FIG. 21 shows the distribution of radioactivity in selected tissues 24 hours after injection of 212Pb-DOTAM for treatment cycles 1 and 2 in the BxPC3 model (%ID / g±SEM, n=3). [Figure 22] Figure 22 shows the mean body weight in groups A-G (n=8) after CEA-PRIT in the BxPC3 model. Curves were truncated at the first death in each group. Vertical dotted lines indicate Pb-DOTAM administration for some or all groups according to the study design. [Figure 23] Figure 23 shows the mean body weight change in groups A-G (n=8) after CEA-PRIT in the BxPC3 model, expressed as a percentage of initial body weight. Curves were truncated at the first death in each group. Vertical dotted lines indicate Pb-DOTAM administration for some or all groups according to the study design. [Figure 24] Figure 24 shows the tumor growth mean and standard error for groups A-G in the BxPC3 model (n=8). Curves were truncated at the first death in each group. Vertical dotted lines indicate Pb-DOTAM administration for some or all groups according to the study design. [Figure 25] Figure 25 shows individual tumor growth curves for groups A through G in the BxPC3 model. The vertical dotted lines indicate administration of 212Pb-DOTAM. [Figure 26] Figure 26 shows Kaplan-Meier curves showing survival in groups A to G in the BxPC3 model (n = 8). The vertical dotted lines indicate administration of 212Pb-DOTAM. [Figure 27] FIG. 27 shows the distribution of radioactivity in selected tissues 24 hours after injection of 212Pb-DOTAM for treatment cycles 1 and 2 in the LS174T model (%ID / g±SD, n=3). [Figure 28] Figure 28 shows the mean body weight in groups A-G (n=8) after CEA-PRIT in the LS174T model. Curves were censored at the first death in each group. Vertical dotted lines indicate Pb-DOTAM administration for some or all groups according to the study design. [Figure 29] Figure 29 shows the mean body weight change in groups A-G (n=8) after CEA-PRIT in the LS174T model, expressed as a percentage of initial body weight. Curves were truncated at the first death in each group. Vertical dotted lines indicate Pb-DOTAM administration for some or all groups according to the study design. [Figure 30] Figure 30 shows the tumor growth mean and standard error for groups A-G in the LS174T model (n=8). Curves were truncated at the first death in each group. Vertical dotted lines indicate Pb-DOTAM administration for some or all groups according to the study design. [Figure 31] Figure 31 shows individual tumor growth curves for groups A through G in the LS174T model. The vertical dotted lines indicate administration of 212Pb-DOTAM. [Figure 32]Figure 32 shows Kaplan-Meier curves showing survival in groups A to G in the LS174T model (n=8). The vertical dotted lines indicate administration of 212Pb-DOTAM. [Figure 33] Figure 33 shows the distribution of radioactivity in selected tissues 24 hours after injection of Pb-DOTAM (%ID / g ± SD, n = 3). Gray bars represent tissue accumulation after injection of various amounts of Dex500-(50%) clearing agent (CA); black bars represent the no-CA control (no clearing agent). [Figure 34] Figure 34 shows the Pb content in blood and tumors 24 hours after injection of Pb-DOTAM, as well as the corresponding tumor-to-blood ratio (% ID / g ± SD, n = 3). Gray bars represent tissue accumulation after injection of various amounts of Dex500-(50%) clearing agent (CA); black bars represent the no-CA control (no clearing agent). [Figure 35] FIG. 35 shows the radioactivity content in the blood 4 hours after injection of 212Pb-DOTAM (%ID / g±SD, n=3). [Figure 36] Figure 36 shows the binding of one antibody (PRIT-0165) to MKN-45 cells, which is detected using either secondary detection (right panel, Alexa 488) or DOTAM FITC (left panel, FITC-A). [Figure 37] Figure 37 shows a possible format for a bispecific antibody, using CEA as an exemplary target antigen. Other target antigens can also be used. [Figure 38] FIG. 38 shows binding of P1AD8927 to KPL-4 cells to demonstrate Her2 binding ability: detection of the antibody using a human IgG-specific secondary antibody. [Figure 39] FIG. 39 shows binding of P1AD8927 to KPL-4 cells to demonstrate DOTAM binding capacity: isotype-corrected detection using Pb-DOTAM-FITC. [Figure 40] FIG. 40 shows binding of P1AD8926 to Raji cells to demonstrate CD20 binding capacity: detection of the antibody using a human IgG-specific secondary antibody. [Figure 41] FIG. 41 shows binding of P1AD8926 to Raji cells to demonstrate DOTAM binding capacity: isotype-corrected detection using Pb-DOTAM-FITC. [Figure 42] FIG. 42 shows a study summary of protocol 103 evaluating CEA-PRIT of scBxPC3 tumors in SCID mice (h=hours, d=days, w=weeks). [Figure 43] Figure 43: Panel A shows the mean accumulation of 212Pb in collected tissues after both treatment cycles, expressed as %ID / g ± SD (n=3). Panel B shows the individual tumor uptake of 212Pb per mouse, along with the corresponding tumor volume (mm3) at the time of euthanasia. [Figure 44] Figure 44 shows the mean tumor growth curves and standard errors for groups A-G in the BxPC3 model (n=10). Curves were censored at n<5. The vertical dotted line indicates Pb-DOTAM administration (30 or 10 μCi) for some or all groups, depending on the study design. [Figure 45] Figure 45 shows individual tumor growth curves for groups A to G in the BxPC3 model (n=10). Vertical dotted lines indicate administration of 212Pb-DOTAM (30 or 10 μCi). [Figure 46] Figure 46 shows Kaplan-Meier curves showing survival in groups A to G in the BxPC3 model (n = 10). The vertical dotted lines indicate administration of 212Pb-DOTAM (30 or 10 μCi). [Figure 47] Figure 47 shows the mean weight loss in groups A-G after CEA PRIT in the BxPC3 model (n=10). Curves were censored at n<5. Vertical dotted lines indicate Pb-DOTAM administration for some or all groups according to study design. [Figure 48]Figure 48 shows the distribution of Pb-BsAb (20 μCi, 100 μg) in SCID mice bearing scBxPC3 tumors. Mice were injected with 20 μCi of pre-bound Pb-DOTAM-CEA-DOTAM or Pb-DOTAM-DIG-DOTAM (negative control), followed by organ harvest at 1, 4, 7, or 10 days post-injection to assess accumulated radioactivity in the collected tissues (%ID / g ± SD, n=5). [Figure 49] Figure 49 shows the accumulation of 203Pb-BsAb in scBxPC3 tumors 1-10 days after injection of 20 μCi / 100 μg of pre-bound 203Pb-DOTAM-CEA-DOTAM or 203Pb-DOTAM-DIG-DOTAM (negative control) (%ID / g±SD, n=5). [Figure 50] Figure 50 shows the distribution of Pb in SCID mice bearing scBxPC3 tumors. Five minutes to 48 hours after radioactivity injection, mice were injected with CEA-DOTAM BsAb and CA before Pb-DOTAM administration (%ID / g ± SD, n=5). *Cumulative Pb content in urine and feces over time, i.e., at each time point including previous values. Estimated %ID / g in urine was based on 1 / 5 (10 mL) of pooled urine / lavage fluid (50 mL) from five mice. [Figure 51] Figure 51 shows a study outline for protocol 131 evaluating the in vivo distribution of 212Pb after PRIT using CEA-DOTAM BsAb, Pb-DOTAM-dextran-500 CA, and 212Pb-DOTAM quenched with one of five different metals (Zn, Gd, Cu, Ca, or Pb) in SCID mice bearing scBxPC3 tumors (d = days, h = hours). [Figure 52] FIG. 52 shows the distribution of 212Pb in tumor-bearing SCID mice 2 hours after injection of CEA-DOTAM-pretargeted 212Pb-DOTAM (%ID / g±SD, n=4). [Figure 53]FIG. 53 shows the distribution of 212Pb in selected normal tissues of tumor-bearing SCID mice 2 hours after injection of 212Pb-DOTAM quenched with different metals (% ID / g). [Figure 54] FIG. 54 shows the distribution of 212Pb in tumor-bearing SCID mice 24 hours after injection of 212Pb-DOTAM pretargeted by CD20-DOTAM BsAb or negative control DIG-DOTAM (% ID / g±SD, n=3). [Figure 55] Figure 55 shows the distribution of 212Pb in tumor-bearing SCID mice 24 hours after injection of 212Pb-DOTAM pretargeted by HER2-DOTAM BsAb or negative control DIG-DOTAM (% ID / g±SD, n=3). [Figure 56] FIG. 56 shows a study outline for protocol 154 evaluating the biodistribution of 212Pb-DOTAM after CEA-PRIT using various BsAb constructs in SCID mice bearing scHPAF-II tumors (h=hours, d=days). [Figure 57] Figure 57 shows the distribution of 212Pb in tumor-bearing SCID mice 6 hours after injection of 212Pb-DOTAM pretargeted with either negative control DIG-DOTAM, standard CEA-DOTAM BsAb, or one of the alternative BsAb constructs (%ID / g±SD, n=3). [Figure 58] Figure 58 shows the blood content and tumor accumulation of 212Pb 6 hours after injection of 212Pb-DOTAM pretargeted with either negative control DIG-DOTAM, standard CEA-DOTAM BsAb, or one of the alternative BsAb constructs (%ID / g±SD, n=3). [Figure 59]Figure 59 shows the experimental schedule for protocol 162. CD20-PRIT was performed in SCID mice bearing scWSU-DLCL2 tumors using CD20-DOTAM BsAb, Ca-DOTAM-dextran-500 CA, and 212Pb-DOTAM; one-stage RIT was performed in SCID mice bearing scWSU-DLCL2 tumors using CD20-DOTAM BsAb pre-conjugated with 212Pb-DOTAM (212Pb-DOTAM-CD20-DOTAM). [Figure 60] Figure 60 shows the distribution of Pb in tumor-bearing SCID mice 24 hours after injection of CD20-DOTAM-pretargeted Pb-DOTAM or pre-bound Pb-DOTAM-CD20-DOTAM. Radioactivity content in organs and tissues is expressed as mean %ID / g and standard deviation (SD; n=3). [Figure 61] FIG. 61 shows the mean WSU-DLCL2 sc tumor growth for groups AG, expressed in mm3 ± SEM (n=10). [Figure 62] Figure 62 shows the mean change in mouse body weight after various treatments, expressed as % of initial body weight ± SEM. Dotted lines indicate 212Pb or antibody injection depending on the treatment scheme. DETAILED DESCRIPTION OF THE INVENTION

[0111] definition For purposes herein, an "acceptor human framework" is a framework comprising the amino acid sequence of a light chain variable domain (VL) framework or a heavy chain variable domain (VH) framework derived from a human immunoglobulin framework or a human consensus framework, as defined below. An acceptor human framework "derived from" a human immunoglobulin framework or a human consensus framework may comprise the same amino acid sequence thereto, or it may contain amino acid sequence changes. In some embodiments, the number of amino acid changes is 10 or less, 9 or less, 8 or less, 7 or less, 6 or less, 5 or less, 4 or less, 3 or less, or 2 or less. In some embodiments, the VL acceptor human framework is identical in sequence to the VL human immunoglobulin framework sequence or the human consensus framework sequence.

[0112] "Affinity" refers to the strength of the sum of non-covalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). Unless otherwise indicated, "binding affinity" as used herein refers to the intrinsic binding affinity that reflects a 1:1 interaction between members of a binding pair (e.g., an antibody and an antigen). The affinity of a molecule X for its partner Y can generally be represented by the dissociation constant (Kd). Affinity can be measured by common methods known in the art, including those described herein. Specific demonstrative and exemplary embodiments for measuring binding affinity are described below.

[0113] An "affinity matured" antibody refers to an antibody with one or more alterations in one or more hypervariable regions (HVRs) compared to a parent antibody that does not possess such alterations, which alterations result in an improvement in the affinity of the antibody for antigen.

[0114] The terms "anti-Pb-DOTAM antibody," "antibody that binds Pb-DOTAM," "antibody that binds Pb-DOTAM chelate," and equivalent terms refer to an antibody that can bind Pb-DOTAM chelate with sufficient affinity such that it is useful in sorting and / or purification schemes to isolate Pb-DOTAM-labeled moieties and / or such that it can localize Pb-DOTAM to the site of the antibody, e.g., for targeting Pb-DOTAM to cells. The terms "anti-target antibody" and "antibody that binds to a target" refer to an antibody that can bind to a target with sufficient affinity such that it is useful in therapeutic and / or diagnostic applications involving localization of the antibody to the target, e.g., when expressed on the surface of a cell. In one embodiment, the extent of binding of the antibody to an unrelated moiety and / or unrelated target protein is less than about 10% of the binding of the antibody to Pb-DOTAM or the target, as measured, e.g., by radioimmunoassay (RIA). In certain embodiments, the antibody has a cytotoxicity of ≦1 μM, ≦100 nM, ≦10 nM, ≦1 nM, ≦0.1 nM, ≦0.01 nM, or ≦0.001 nM (e.g., 10 -8 M or less, e.g., 10 -8 M~10 -13 M, e.g., 10 -9 M~10 -13 M) for Pb-DOTAM and / or the target.

[0115] The term "antibody" as used herein is used in the broadest sense and encompasses a variety of antibody structures, including, but not limited to, monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments, so long as they exhibit the desired antigen-binding activity.

[0116] "Antibody fragment" refers to a molecule other than an intact antibody that contains a portion of the intact antibody that binds to the antigen to which the intact antibody binds. Examples of antibody fragments include, but are not limited to, Fv, Fab, Fab', Fab'-SH, F(ab')2; diabodies; linear antibodies; single-chain antibody molecules (e.g., scFv); and multispecific antibodies formed from antibody fragments.

[0117] An "antibody that binds to the same epitope" as a reference antibody can refer to an antibody that blocks the binding of the reference antibody to its antigen by 50% or more in a competition assay, or conversely, a reference antibody that blocks the binding of an antibody to its antigen by 50% or more in a competition assay. Exemplary competition assays are provided herein.

[0118] The term "chimeric" antibody refers to an antibody in which a portion of the heavy and / or light chain is derived from a particular source or species, while the remainder of the heavy and / or light chain is derived from a different source or species.

[0119] The "class" of an antibody refers to the type of constant domain or constant region possessed by its heavy chain. There are five major classes of antibodies: IgA, IgD, IgE, IgG, and IgM, some of which can be further divided into subclasses (isotypes), e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2. The heavy chain constant domains corresponding to the different classes of immunoglobulins are called α, δ, ε, γ, and μ, respectively.

[0120] As used herein, the term "cytotoxic agent" refers to a substance that inhibits or prevents cellular function and / or causes cell death or destruction. Cytotoxic agents include, but are not limited to, radioisotopes (e.g., 225 Ac, 211 At, 131 I, 125 I, 90 Y, 186 Re, 188 Re, 153 Sm, 212 Bi,213 Bi, 32 P, 212 radioactive isotopes of Pb and Lu); chemotherapeutic agents or drugs (e.g., methotrexate, adriamycin, vinca alkaloids (vincristine, vinblastine, etoposide), doxorubicin, melphalan, mitomycin C, chlorambucil, daunorubicin or other intercalating agents); growth inhibitors; enzymes and fragments thereof, such as diffusion-degrading enzymes; antibiotics; toxins, such as small molecule toxins or enzymatically active toxins of bacterial, fungal, plant or animal origin (including fragments and / or variants thereof); and various anti-tumor or anti-cancer agents disclosed below.

[0121] "Effector function" refers to the biological activity attributable to the Fc region of an antibody, which varies with antibody isotype. Examples of antibody effector functions include C1q binding and complement-dependent cytotoxicity (CDC); Fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; down-regulation of cell surface receptors (e.g., B cell receptors); and B cell activation.

[0122] An "effective amount" of an agent, eg, a pharmaceutical formulation, refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic or prophylactic result.

[0123] The term "Fc region" as used herein defines the C-terminal region of an immunoglobulin heavy chain containing at least a portion of the constant region. This term includes native sequence Fc regions and Fc region variants. In one embodiment, a human IgG heavy chain Fc region extends from Cys226 or Pro230 toward the carboxyl terminus of the heavy chain. However, the C-terminal lysine of the Fc region (Lys447) may or may not be present. Unless otherwise specified herein, the numbering of amino acid residues in the Fc region or constant region is according to the EU numbering system, also referred to as the EU index, as described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, MD, 1991.

[0124] "Framework" or "FR" refers to variable domain residues other than hypervariable region (HVR) residues. The FR of a variable domain generally consists of four FR domains: FR1, FR2, FR3, and FR4. Thus, the HVR and FR sequences generally appear in VH (or VL) in the following order: FR1-H1(L1)-FR2-H2(L2)-FR3-H3(L3)-FR4.

[0125] The terms "full-length antibody," "intact antibody," and "whole antibody" are used interchangeably herein and refer to an antibody having a heavy chain that has a structure substantially similar to a native antibody structure or that contains an Fc region as defined herein. A full-length antibody may be, for example, an IgG.

[0126] The terms "host cell," "host cell line," and "host cell culture" are used interchangeably and refer to cells into which exogenous nucleic acid has been introduced, including the progeny of such cells. Host cells include "transformants" and "transformed cells," including the primary transformed cell and progeny derived therefrom, regardless of the number of transfers. The progeny may not be completely identical in nucleic acid content to the parent cell and may contain mutations. Mutant progeny that have the same function or biological activity as screened or selected for in the originally transformed cell are also included herein.

[0127] A "human antibody" is one having an amino acid sequence corresponding to that of an antibody produced by a human or human cell, or derived from a non-human source that utilizes the human antibody repertoire or other human antibody coding sequences. This definition of human antibody specifically excludes humanized antibodies that comprise non-human antigen-binding residues.

[0128] A "human consensus framework" is a framework that represents the amino acid residues most commonly occurring in a selected human immunoglobulin VL or VH framework sequence. Typically, the selected human immunoglobulin VL or VH sequence is derived from a subgroup of variable domain sequences. Typically, the subgroup of sequences is a subgroup as described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th ed., NIH Publication 91-3242, Bethesda, MD (1991), vols. 1-3. In one embodiment, for the VL, the subgroup is subgroup kappa I as described in Kabat et al., supra. In one embodiment, for the VH, the subgroup is subgroup III as described in Kabat et al., supra.

[0129] A "humanized" antibody refers to a chimeric antibody comprising amino acid residues derived from non-human HVRs and human FRs. In certain embodiments, a humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the HVRs (e.g., CDRs) correspond to those of a non-human antibody and all or substantially all of the FRs correspond to those of a human antibody. A humanized antibody may optionally comprise at least a portion of an antibody constant region derived from a human antibody. A "humanized" form of an antibody, e.g., a non-human antibody, refers to an antibody that has undergone humanization.

[0130] As used herein, the term "hypervariable region" or "HVR" refers to each region of an antibody variable domain that is hypervariable in sequence ("complementarity determining region" or "CDR"), and / or forms structurally defined loops ("hypervariable loops"), and / or contains antigen contact residues ("antigen contacts"). Generally, antibodies contain six HVRs: three in VH (H1, H2, H3) and three in VL (L1, L2, L3). Exemplary HVRs are: (a) hypervariable loops located at amino acid residues 26-32 (L1), 50-52 (L2), 91-96 (L3), 26-32 (H1), 53-55 (H2), and 96-101 (H3) (Chothia and Lesk, J. Mol. Biol. 196:901-917 (1987)); (b) CDRs present at amino acid residues 24–34 (L1), 50–56 (L2), 89–97 (L3), 31–35b (H1), 50–65 (H2), and 95–102 (H3) (Kabat et al., Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda MD (1991)); (c) antigenic contacts present at amino acid residues 27c-36 (L1), 46-55 (L2), 89-96 (L3), 30-35b (H1), 47-58 (H2), and 93-101 (H3) (MacCallum et al., J. Mol. Biol. 262:732-745 (1996)); and (d) HVR amino acid residues 46–56 (L2), 47–56 (L2), 48–56 (L2), 49–56 (L2), 26–35 (H1), 26–35b (H1), 49–65 (H2), 93–102 (H3), and 94–102 (H3). including combinations of (a), (b), and / or (c).

[0131] Alternatively, the sequence of CDR-H1 described herein may extend from Kabat 26 to Kabat 35.

[0132] In one embodiment, the HVR or CDR residues include those identified in Table 2 or elsewhere herein.

[0133] Unless otherwise indicated, HVR / CDR residues and other residues in the variable domain (e.g., FR residues) are numbered herein according to Kabat et al., supra.

[0134] An "immunoconjugate" is an antibody conjugated to one or more heterologous molecules, including but not limited to, cytotoxic agents.

[0135] An "individual" or "subject" is a mammal. Mammals include, but are not limited to, domestic animals (e.g., cows, sheep, cats, dogs, and horses), primates (e.g., humans and non-human primates such as monkeys), rabbits, and rodents (e.g., mice and rats). In certain embodiments, the individual or subject is human.

[0136] The molecules described herein may be "isolated." An "isolated" antibody is one that has been separated from components of its natural environment. In some embodiments, the antibody is purified to greater than 95% or 99% purity, as determined, for example, by electrophoresis (e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis) or chromatography (e.g., ion exchange or reverse-phase HPLC). For a review of methods for assessing antibody purity, see, e.g., Flatman et al., J. Chromatogr. B 848:79-87 (2007).

[0137] The terms "nucleic acid molecule" or "polynucleotide" include any compound and / or substance comprising a polymer of nucleotides. Each nucleotide is composed of a base, specifically a purine or pyrimidine base (i.e., cytosine (C), guanine (G), adenine (A), thymine (T), or uracil (U)), a sugar (i.e., deoxyribose or ribose), and a phosphate group. Nucleic acid molecules are often described by the sequence of bases, which represents the primary (linear) structure of the nucleic acid molecule. The sequence of bases is typically represented from 5' to 3'. As used herein, the term nucleic acid molecule encompasses deoxyribonucleic acid (DNA), including, for example, complementary DNA (cDNA) and genomic DNA, ribonucleic acid (RNA), particularly messenger RNA (mRNA), synthetic forms of DNA or RNA, and mixed polymers comprising two or more of these molecules. Nucleic acid molecules may be linear or circular. Furthermore, the term nucleic acid molecule includes both sense and antisense strands, as well as both single- and double-stranded forms. Furthermore, the nucleic acid molecules described herein may contain natural or non-natural nucleotides. Examples of non-natural nucleotides include modified nucleotide bases with derivatized sugar or phosphate backbone linkages or chemically modified residues. Nucleic acid molecules also encompass DNA and RNA molecules suitable as vectors for direct expression of the antibodies of the present invention in vitro and / or in vivo, for example, in a host or patient. Such DNA (e.g., cDNA) or RNA (e.g., mRNA) vectors may be unmodified or modified. For example, mRNA can be chemically modified to enhance the stability of the RNA vector and / or the expression of the encoded molecule, and the mRNA can be injected into a subject to generate antibodies in vivo (see, e.g., Stadler et al., Nature Medicine 2017, published online June 12, 2017, doi:10.1038 / nm.4356 or EP2101823B1).

[0138] An "isolated" nucleic acid refers to a nucleic acid molecule that has been separated from a component of its natural environment. Isolated nucleic acid includes a nucleic acid molecule that is contained in cells that ordinarily contain the nucleic acid molecule, but where the nucleic acid molecule is present extrachromosomally or at a chromosomal location that is different from its natural chromosomal location.

[0139] An "isolated nucleic acid encoding an antibody" refers to one or more nucleic acid molecules encoding antibody heavy and light chains (or fragments thereof), comprising such nucleic acid molecules in a single vector or in separate vectors, and wherein such nucleic acid molecules are present in one or more locations in a host cell.

[0140] As used herein, the term "monoclonal antibody" refers to an antibody obtained from a population of substantially homogeneous antibodies; i.e., the individual antibodies comprising the population are identical and / or bind to the same epitope, except for possible antibody variants, e.g., containing naturally occurring mutations or arising during production of the monoclonal antibody preparation, which are generally present in minor amounts. In contrast to polyclonal antibody preparations, which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody of a monoclonal antibody preparation is directed against a single determinant on an antigen. Thus, the modifier "monoclonal" indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies and should not be construed as requiring production of the antibody by any particular method. For example, monoclonal antibodies used in accordance with the present invention can be produced by a variety of techniques, including, but not limited to, hybridoma methods, recombinant DNA methods, phage display methods, and methods utilizing transgenic animals containing all or part of the human immunoglobulin loci; such methods, as well as other exemplary methods for producing monoclonal antibodies, are described herein.

[0141] A "naked antibody" refers to an antibody that is not conjugated to a heterologous moiety (e.g., a cytotoxic moiety) or radiolabel. The naked antibody may be present in a pharmaceutical formulation.

[0142] "Native antibodies" refer to naturally occurring immunoglobulin molecules with various structures. For example, native IgG antibodies are heterotetrameric glycoproteins of approximately 150,000 daltons, composed of two identical disulfide-bonded light chains and two identical heavy chains. From the N-terminus to the C-terminus, each heavy chain has a variable region (VH), also called a variable heavy chain domain or a heavy chain variable domain, followed by three constant domains (CH1, CH2, and CH3). Similarly, from the N-terminus to the C-terminus, each heavy chain has a variable region (VL), also called a variable light chain domain or a light chain variable domain, followed by a constant light chain (CL) domain. Based on the amino acid sequence of its constant domain, the light chain of an antibody can be assigned to one of two types, called kappa (κ) and lambda (λ).

[0143] The term "package insert" is used to refer to instructions customarily included in commercially available packages of such therapeutic agents containing information regarding the indications, uses, dosage, administration, concomitant therapy, contraindications and / or warnings concerning the use of such therapeutic agents.

[0144] "Amino acid sequence identity percentage (%)" with respect to a reference polypeptide sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical to the amino acid residues in the reference polypeptide sequence, after aligning the sequences and, if necessary, introducing gaps to achieve the maximum sequence identity percentage, without considering any conservative substitutions as part of the sequence identity.Alignment for determining amino acid sequence identity percentage can be achieved in various ways within the skill of the art, for example, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software.Those skilled in the art can determine the appropriate parameters for aligning sequences, including any algorithm required to achieve maximum alignment across the entire length of the sequences being compared.However, for the purposes herein, amino acid sequence identity percentage values ​​are generated using the sequence comparison computer program ALIGN-2. The ALIGN-2 sequence comparison computer program was written by Genentech, Inc., and its source code has been filed with user documentation at the U.S. Copyright Office, Washington, DC 20559, and is registered under U.S. Copyright Office Registration Number TXU510087. The ALIGN-2 program is publicly available from Genentech, Inc., South San Francisco, California, or can be compiled from the source code. The ALIGN-2 program should be compiled for use on UNIX operating systems, including Digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and do not vary.

[0145] In situations where ALIGN-2 is used for amino acid sequence comparison, the % amino acid sequence identity of a given amino acid sequence A with, compared to, or to a given amino acid sequence B (alternatively, it can be expressed as a given amino acid sequence A having or containing a certain % amino acid sequence identity with, compared to, or to a given amino acid sequence B) is calculated as follows: 100x fraction X / Y where X is the number of amino acid residues in an alignment of A and B by the sequence alignment program ALIGN-2 that are scored as identical matches by the program, and Y is the total number of amino acid residues in B. It will be understood that if the length of amino acid sequence A is not equal to the length of amino acid sequence B, the % amino acid sequence identity of A to B will not be equal to the % amino acid sequence identity of B to A. Unless specifically stated otherwise, all % amino acid sequence identity values ​​used herein are obtained as described in the immediately preceding paragraph using the ALIGN-2 computer program.

[0146] The term "pharmaceutical formulation" refers to a preparation that is in a form that allows the biological activity of the active ingredients contained therein to be effective and that does not contain additional ingredients that are unacceptably toxic to the subject to which the formulation is administered.

[0147] A "pharmaceutically acceptable carrier" refers to an ingredient in a pharmaceutical formulation, other than an active ingredient, that is non-toxic to a subject. Pharmaceutically acceptable carriers include, but are not limited to, buffers, additives, stabilizers, or preservatives.

[0148] As used herein, "treatment" (and grammatical variations thereof, such as "treat" or "treating") refers to clinical intervention in an attempt to alter the natural course of the individual being treated and can be performed for prophylaxis or during the course of clinical pathology. Desirable effects of treatment include, but are not limited to, preventing the appearance or recurrence of disease, alleviating symptoms, diminishing any direct or indirect pathological consequences of disease, preventing metastasis, slowing the rate of disease progression, ameliorating or alleviating the disease state, and achieving remission or improving prognosis. In some embodiments, the antibodies of the invention are used to delay the onset of disease or slow the progression of disease.

[0149] The term "variable region" or "variable domain" refers to the domain of an antibody heavy or light chain that is involved in binding the antibody to an antigen. The variable domains of the heavy and light chains of natural antibodies (VH and VL, respectively) generally have similar structures, with each domain containing four conserved framework regions (FR) and three hypervariable regions (HVR) (see, for example, Kindt et al., Kuby Immunology, 6th ed., W.H. Freeman and Co., p. 91 (2007)). A single VH or VL domain may be sufficient to confer antigen-binding specificity. Furthermore, antibodies that bind to a specific antigen can be isolated using a VH or VL domain derived from an antibody that binds to that antigen, and a library of complementary VL or VH domains, respectively, can be screened. See, e.g., Portolano et al., J. Immunol. 150:880-887 (1993); Clarkson et al., Nature 352:624-628 (1991).

[0150] As used herein, the term "vector" refers to a nucleic acid molecule capable of propagating another nucleic acid to which it is linked. The term includes vectors as self-replicating nucleic acid structures as well as vectors that integrate into the genome of a host cell into which they are introduced. Certain vectors are capable of directing the expression of nucleic acids to which they are operatively linked. Such vectors are referred to herein as "expression vectors."

[0151] As used herein, the term "Pb" or "lead" includes its ions, e.g., Pb(II). Thus, the knowledgeable reader will understand that, e.g., lead, Pb, 212 Pb or 203 It will be understood that the term Pb is intended to encompass ionic forms of the element, particularly Pb(II). In various embodiments of the invention, Pb may be a radioactive isotope (e.g., when used in methods of radioimmunotherapy or radioimmunoimaging) or may be a stable, non-radioactive isotope (e.g., as may be preferred in the context of a scavenger).

[0152] "DOTAM" has the chemical name: 1,4,7,10-tetrakis(carbamoylmethyl)-1,4,7,10-tetraazacyclododecane, The following formula: The compound is TIFF0007582867000001.tif63170.

[0153] 212 Pb-DOTAM has the following structure: It has TIFF0007582867000002.tif56170.

[0154] In certain aspects and embodiments, the present invention also uses functional variants or derivatives of DOTAM that contain metal ions.Suitable variants / derivatives of DOTAM differ from the structure of DOTAM to a certain limited extent and retain their functional ability (i.e., retain sufficient activity to be used for one or more purposes described herein).In such aspects and embodiments, DOTAM and functional variants / derivatives of DOTAM may be one of the active variants disclosed in WO2010 / 099536.

[0155] Suitable functional variants / derivatives have the following formula: A compound of TIFF0007582867000003.tif65170, or a pharmaceutically acceptable salt thereof [In the formula, R N is H, C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Cycloalkyl, C 3~7 Cycloalkyl-C 1~4 Alkyl, C 2~7 Heterocycloalkyl, C 2~7 Heterocycloalkyl-C 1~4 Alkyl, phenyl, phenyl-C 1~4 -Alkyl, C 1~7 Heteroaryl, and C 1~7 Heteroaryl-C 1~4 - alkyl; C 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenyl, and C 2~6 Alkynyl is one, two, three, or four independently selected R W each of which may be substituted with a group; 3~7 Cycloalkyl, C 3~7 Cycloalkyl-C 1~4 Alkyl, C 2~7 Heterocycloalkyl, C 2~7 Heterocycloalkyl-C 1~4Alkyl, phenyl, phenyl-C 1~4 -Alkyl, C 1~7 Heteroaryl, and C 1~7 Heteroaryl-C 1~4 -alkyl is one, two, three, or four independently selected R X each optionally substituted with a group; L 1 independently C 1~6 Alkylene, C 1~6 Alkenylene, or C 1~6 alkynylene, each of which is one, two, or three independently selected R 1 optionally substituted with a group; L 2 is C 2~4 linear alkylene, and independently selected R 1 may be substituted with a C 1~4 Alkyl and / or C 1~4 optionally substituted with 1, 2, 3, or 4 groups independently selected from haloalkyl; R 1 is D 1 -D 2 -D 3 , halogen, cyano, nitro, hydroxyl, C 1~6 Alkoxy, C 1~6 Haloalkoxy, C 1~6 Alkylthio, C 1~6 Alkylsulfinyl, C 1~6 Alkyl sulfonyl, amino, C 1~6 Alkylamino, Di-C 1~6 Alkylamino, C 1~4 Alkylcarbonyl, carboxy, C 1~6 Alkoxycarbonyl, C 1~6 Alkylcarbonylamino, di-C 1~6 Alkylcarbonylamino, C 1~6 Alkoxycarbonylamino, C 1~6 Alkoxycarbonyl-(C 1~6 Alkyl)amino, carbamyl, C 1~6 Alkylcarbamyl, and di-C 1~6 independently selected from alkylcarbamyl; D 1 are respectively, C 6~10 Aryl-C 1~4 Alkyl, C 1~9 Heteroaryl-C 1~4 Alkyl, C 3~10 Cycloalkyl-C 1~4 Alkyl, C 2~9 Heterocycloalkyl-C 1~4 Alkyl, C 1~8 Alkylene, C 1~8 Alkenylene, and C 1~8 alkynylene; 1~8 Alkylene, C 1~8 Alkenylene, and C 1~8 Alkynylene is defined as one, two, three, or four independently selected R 4 may be substituted with a group; 6~10 Aryl-C 1~4 Alkyl, C 1~9 Heteroaryl-C 1~4 Alkyl, C 3~10 Cycloalkyl-C 1~4 Alkyl, C 2~9 Heterocycloalkyl-C 1~4 Alkyl is one, two, three, or four independently selected R 5 each optionally substituted with a group; D 2 are each independently absent or C 1~20 is a straight chain alkylene, 1~20 The 1 to 6 non-adjacent methylene groups of the linear alkylene are independently selected from -D 4 - moiety, provided that the C 1~20 At least one methylene unit in the linear alkylene chain may optionally be -D 4 provided that the C is not replaced by a - part; 1~20 Straight chain alkylenes can be substituted with halogen, cyano, nitro, hydroxyl, C 1~4 Alkyl, C 1~4 Haloalkyl, C 1~4 Alkoxy, C 1~4 Haloalkoxy, Amino, C 1~4 Alkylamino, Di-C1~4 Alkylamino, C 1~4 Alkylcarbonyl, carboxy, C 1~4 Alkoxycarbonyl, C 1~4 Alkylcarbonylamino, di-C 1~4 Alkylcarbonylamino, C 1~4 Alkoxycarbonylamino, C 1~4 Alkoxycarbonyl-(C 1~4 Alkyl)amino, carbamyl, C 1~4 Alkylcarbamyl, and di-C 1~4 optionally substituted with one or more groups independently selected from alkylcarbamyl; D 3 are H, halogen, cyano, nitro, hydroxyl, and C, respectively. 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~14 Cycloalkyl, C 3~14 Cycloalkyl-C 1~4 Alkyl, C 2~14 Heterocycloalkyl, C 2~14 Heterocycloalkyl-C 1~4 Alkyl, C 6~14 Aryl, C 6~14 Aryl-C 1~4 Alkyl, C 1~13 Heteroaryl, C 1~13 Heteroaryl-C 1~4 alkyl; 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenyl, C 2~6 Alkynyl is one, two, three, or four independently selected R 6 each of which may be substituted with a group; 3~14 Cycloalkyl, C 3~14 Cycloalkyl-C 1~4 Alkyl, C 2~14 Heterocycloalkyl, C 2~14 Heterocycloalkyl-C 1~4 Alkyl, C 6~14 Aryl, C 6~14Aryl-C 1~4 Alkyl, C 1~13 Heteroaryl, C 1~13 Heteroaryl-C 1~4 Alkyl is one, two, three, or four independently selected R 7 each optionally substituted with a group; D 4 are -O-, -S-, and -NR, respectively. a C(=O)-, -NR a C(=S)-, -NR b C(=O)NR c --NR b C(=S)NR c -, -S(=O)-, -S(=O)2-, -S(=O)NR a -, -C(=O)-, -C(=S)-, -C(=O)O-, -OC(=O)NR a -, -OC(=S)NR a -, -NR a -, -NR b S(=O)NR c -, and NR b S(=O)NR O - independently selected from; R 4 and R 6 are halogen, cyano, nitro, hydroxyl, and C 1~4 Alkoxy, C 1~4 Haloalkoxy, C 1~4 Alkylthio, C 1~4 Alkylsulfinyl, C 1~4 Alkyl sulfonyl, amino, C 1~4 Alkylamino, Di-C 1~4 Alkylamino, C 1~4 Alkylcarbonyl, carboxy, C 1~4 Alkoxycarbonyl, C 1~4 Alkylcarbonylamino, di-C 1~4 Alkylcarbonylamino, C 1~4 Alkoxycarbonylamino, C 1~4 Alkoxycarbonyl-(C 1~4 Alkyl)amino, carbamyl, C 1~4 Alkylcarbamyl, and di-C 1~4independently selected from alkylcarbamyl; R 5 are halogen, cyano, cyanate, isothiocyanate, nitro, hydroxyl, and C 1~4 Alkyl, C 2~4 Alkenyl, C 2~4 Alkynyl, C 1~4 Alkoxy, C 1~4 Haloalkoxy, C 1~4 Alkylthio, C 1~4 Alkylsulfinyl, C 1~4 Alkyl sulfonyl, amino, C 1~4 Alkylamino, Di-C 1~4 Alkylamino, C 1~4 Alkylcarbonyl, carboxy, C 1~4 Alkoxycarbonyl, C 1~4 Alkylcarbonylamino, di-C 1~4 Alkylcarbonylamino, C 1~4 Alkoxycarbonylamino, C 1~4 Alkoxycarbonyl-(C 1~4 Alkyl)amino, carbamyl, C 1~4 Alkylcarbamyl, and di-C 1~4 independently selected from alkylcarbamyl; R 7 are halogen, cyano, nitro, hydroxyl, and C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Cycloalkyl, C 3~7 Cycloalkyl-C 1~4 Alkyl, C 2~7 Heterocycloalkyl, C 2~7 Heterocycloalkyl-C 1~4 Alkyl, phenyl, phenyl-C 1~4 Alkyl, C 1~7 Heteroaryl, C 1~7 Heteroaryl-C 1~4 Alkyl, -OR O , -SR O , -S(=O)R P , -S(=O)2R P , -S(=O)NR sR t , -C(=O)R P , -C(=O)OR P , -C(=O)NR s R t , -OC(=O)R P , -OC(=O)NR s R t , -NR s R t , -NR q C(=O)R r , -NR q C(=O)OR r , -NR q C(=O)NR r , -NR q S(=O)2R r , and N.R. P S(=O)NR s R t wherein C is independently selected from 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 The alkynyl may each be optionally substituted with 1, 2, 3, or 4 independently selected R' groups; 3~7 Cycloalkyl, C 3~7 Cycloalkyl-C 1~4 Alkyl, C 2~7 Heterocycloalkyl, C 2~7 Heterocycloalkyl-C 1~4 Alkyl, phenyl, phenyl-C 1~4 Alkyl, C 1~7 Heteroaryl, C 1~7 Heteroaryl-C 1~4 The alkyl may each be optionally substituted with 1, 2, 3, or 4 independently selected R″ groups; R a , R b , and R c are H and C, respectively. 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Cycloalkyl, C 3~7 Cycloalkyl-C 1~4 Alkyl, C 2~7Heterocycloalkyl, C 2~7 Heterocycloalkyl-C 1~4 Alkyl, phenyl, phenyl-C 1~4 Alkyl, C 1~7 Heteroaryl, C 1~7 Heteroaryl-C 1~4 alkyl; 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenyl, C 2~6 Alkynyl is one, two, three, or four independently selected R W each of which may be substituted with a group; 3~7 Cycloalkyl, C 3~7 Cycloalkyl-C 1~4 Alkyl, C 2~7 Heterocycloalkyl, C 2~7 Heterocycloalkyl-C 1~4 Alkyl, phenyl, phenyl-C 1~4 Alkyl, C 1~7 Heteroaryl, C 1~7 Heteroaryl-C 1~4 Alkyl is one, two, three, or four independently selected R X each optionally substituted with a group; R O , R p , R q , R r , R s and R t are H and C, respectively. 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Cycloalkyl, C 3~7 Cycloalkyl-C 1~4 Alkyl, C 2~7 Heterocycloalkyl, C 2~7 Heterocycloalkyl-C 1~4 Alkyl, phenyl, phenyl-C 1~4 Alkyl, C 1~7 Heteroaryl, C 1~7 Heteroaryl-C 1~4 alkyl;1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenyl, C 2~6 Alkynyl is one, two, three, or four independently selected R y each of which may be substituted with a group; 3~7 Cycloalkyl, C 3~7 Cycloalkyl-C 1~4 Alkyl, C 2~7 Heterocycloalkyl, C 2~7 Heterocycloalkyl-C 1~4 Alkyl, phenyl, phenyl-C 1~4 Alkyl, C 1~7 Heteroaryl, C 1~7 Heteroaryl-C 1~4 Alkyl is one, two, three, or four independently selected R z each optionally substituted with a group; R', R w and R y are hydroxyl, cyano, nitro, and C 1~4 Alkoxy, C 1~4 Haloalkoxy, Amino, C 1~4 Alkylamino, and di-C 1~4 independently selected from alkylamino; R'', R x , and R z are hydroxyl, halogen, cyano, nitro, and C 1~4 Alkyl, C 1~4 Haloalkyl, C 1~4 Alkoxy, C 1~4 Haloalkoxy, Amino, C 1~4 Alkylamino, and di-C 1~4 independently selected from alkylamino; provided that the valence does not exceed the valence of each atom of the optionally substituted moiety. may be.

[0156] Suitably, functional variants / derivatives of the above formula have an affinity for an antibody of the invention that is equal to or greater than that of DOTAM, and have a binding strength for Pb that is equal to or greater than that of DOTAM ("affinity" as measured by the dissociation constant, as described above). For example, the dissociation constant of a functional variant / derivative with an antibody or / Pb of the invention may be 1.1-fold or less, 1.2-fold or less, 1.3-fold or less, 1.4-fold or less, 1.5-fold or less, or 2-fold or less than the dissociation constant of DOTAM with the same antibody / Pb.

[0157] R N are H and C, respectively. 1~6 Alkyl, or C 1~6 Haloalkyl; preferably H, C 1~4 Alkyl, or C 1~4 Most preferably, R N are H respectively.

[0158] For DOTAM variants, 1, 2, 3 or most preferably, each L 2 is a C2 alkylene. Advantageously, the C2 alkylene variant of DOTAM may have a particularly high affinity for Pb. 2 Optional substituents for R 1 , C 1~4 Alkyl, or C 1~4 It may be haloalkyl. Preferably, L 2 Optional substituents for C 1~4 Alkyl or C 1~4 It may also be haloalkyl.

[0159] If necessary, L 2 may each be an unsubstituted C2 alkylene -CH2CH2-.

[0160] L 1 are each preferably C 1~4 It is alkylene, more preferably C1 alkylene such as -CH2-.

[0161] Functional variants / derivatives may also include DOTAM or the above-mentioned compounds conjugated to one or more additional moieties, such as small molecules, polypeptides, or carbohydrates. This attachment may occur through one carbon in the macrocycle backbone. The small molecule may be, for example, a dye (Alexa 647 or Alexa 488), biotin, or a biotin moiety. The polypeptide may be, for example, an oligopeptide, such as a therapeutic peptide or polypeptide, such as an antibody. Exemplary carbohydrates include dextran, linear or branched polymers or copolymers (e.g., polyalkylenes, poly(ethylene-lysine), polymethacrylates, polyamino acids, polysaccharides or oligosaccharides, dendrimers).

[0162] Functional variants / derivatives of DOTAM have the following formula: TIFF0007582867000004.tif64170 [wherein each Z independently represents R as defined above. 1 p, q, r, and s are 0, 1, or 2; and p+q+r+s is 1 or greater. Preferably, p, q, r, and s are 0 or 1, and / or p+q+r+s is 1. For example, the compound may have p+q+r+s=1, and Z is a p-SCN-benzyl moiety; such compounds are commercially available from Macrocyclics, Inc. (Plano, Texas).

[0163] Detailed Description Compositions and Methods antibody In one aspect, the present invention is based, in part, on the provision of antibodies that specifically bind to Pb-DOTAM (i.e., a chelate comprising DOTAM complexed with Pb, also referred to herein as a "Pb-DOTAM chelate").

[0164] In certain embodiments, an antibody that specifically binds to Pb-DOTAM may have one or more of the following properties: ·Specific binding to Pb-DOTAM and Bi-DOTAM; · Selective for Pb-DOTAM compared to other chelated metals such as Cu-DOTAM; ·Binds to Pb-DOTAM with very high affinity; binds to the same epitope on Pb-DOTAM as an antibody described herein, e.g., PRIT-0213 or PRIT-0214, and / or has the same contact residues as said antibody.

[0165] Radioisotopes of Pb are useful in methods of diagnosis and therapy. Specific radioisotopes of lead that may be useful in the present invention include: 212 Pb and 203 Pb. Stable isotopes of lead, such as 204 Pb, 206 Pb, 207 Pb or 208 Pb can also be used in the scavenger. Pb is a stable (non-radioactive) isotope. 204 Pb, 206 Pb, 207 Pb and 208 It may also be naturally occurring lead, which is a mixture of Pb.

[0166] Radionuclides that are alpha particle emitters have the potential for more specific tumor cell killing with less damage to surrounding tissue than beta emitters due to a combination of short path lengths and high linear energy deposition. 212 Bi is an alpha particle emitter, but its short half-life precludes its direct use. 212 Pb is 212 is the parent radionuclide of Bi, 212 It acts as an in vivo generator of Bi, thereby 212 The short half-life of Bi can be effectively overcome (Yong and Brechbiel, Dalton Trans. 2001 June 21;40(23) pp. 6068-6076).

[0167] 203 Pb is a useful imaging isotope.203 Antibodies conjugated to Pb-DOTAM may be useful in radioimmunoimaging (RII).

[0168] Generally, radiometals are used in chelated form. In an embodiment of the present invention, DOTAM is used as a chelating agent. DOTAM is a stable chelating agent for Pb(II) (Yong and Brechbiel, Dalton Trans. 2001, June 21; 40(23) pp. 6068-6076; Chappell et al., Nuclear Medicine and Biology, Vol. 27, pp. 93-100, 2000). Thus, DOTAM is 212 Pb and 203 It is particularly useful in conjugation with the isotopes of lead discussed above, such as Pb.

[0169] As discussed above, antibodies according to the present invention bind to Pb-DOTAM. In some embodiments, the antibodies preferably bind to Pb-DOTAM with a K value of binding affinity of 100 pM, 50 pM, 20 pM, 10 pM, 5 pM, 1 pM or less, e.g., 0.9 pM or less, 0.8 pM or less, 0.7 pM or less, 0.6 pM or less, or 0.5 pM or less.

[0170] The antibody further binds to Bi chelated with DOTAM. In some embodiments, the antibody preferably binds to Bi-DOTAM (i.e., a chelate comprising DOTAM complexed to bismuth, also referred to herein as a "Bi-DOTAM chelate") with a binding affinity Kd value of 1 nM, 500 pM, 200 pM, 100 pM, 50 pM, 10 pM or less, e.g., 9 pM, 8 pM, 7 pM, 6 pM, 5 pM or less.

[0171] In some embodiments, the antibody may bind to Bi-DOTAM and Pb-DOTAM with similar affinity, e.g., the affinity ratio, e.g., the ratio of Kd values, for Bi-DOTAM / Pb-DOTAM is preferably in the range of 0.1 to 10, e.g., 1 to 10.

[0172] Sample affinity values ​​for an exemplary antibody according to the invention (PRIT-0213) are provided below: TIFF0007582867000005.tif54170

[0173] Affinity was determined by KinExA equilibrium measurements.

[0174] Furthermore, the antibodies of the present invention are preferably selective for Bi-DOTAM and / or Pb-DOTAM compared to other chelated metals, such as Cu-DOTAM. For example, the affinity ratio, e.g., the ratio of Kd values, for Pb-DOTAM / Cu-DOTAM may be at least 100,000.

[0175] In some embodiments, the antibody i) a first heavy chain having the amino acid sequence of SEQ ID NO: 22; ii) a second heavy chain having the amino acid sequence of SEQ ID NO: 23; and iii) two antibody light chains having the amino acid sequence of SEQ ID NO: 21 Preferably, the antibody binds to Pb-DOTAM and / or Bi-DOTAM with an affinity (e.g., affinity Kd value) equal to or greater than that of a bispecific antibody (referred to herein as PRIT-0213) having the following structure:

[0176] In some embodiments, the antibody i) a first heavy chain having the amino acid sequence of SEQ ID NO: 19; ii) a second heavy chain having the amino acid sequence of SEQ ID NO: 20; and iii) two antibody light chains having the amino acid sequence of SEQ ID NO: 21 Preferably, the antibody binds to DOTAM-chelated Pb and / or DOTAM-chelated Bi with an affinity (e.g., affinity KD value) equal to or greater than that of a bispecific antibody (referred to herein as PRIT-0214) having the following affinity:

[0177] In some embodiments, antibodies according to the invention bind to the same or overlapping epitope of the chelated radionuclide as the antibodies disclosed herein.

[0178] In some embodiments, the antibody i) a first heavy chain having the amino acid sequence of SEQ ID NO: 22; ii) a second heavy chain having the amino acid sequence of SEQ ID NO: 23; and iii) two antibody light chains having the amino acid sequence of SEQ ID NO: 21 Fab PRIT-0213, which binds to the same or overlapping epitope of the Pb-DOTAM chelate (Pb-DOTAM) as Fab PRIT-0213,

[0179] The epitope of the chelated radionuclide (e.g., Pb-DOTAM) to which a given antibody binds can be determined and compared to the epitope of the chelated radionuclide to which an antibody disclosed herein (e.g., Fab PRIT-0213) binds.

[0180] The present disclosure describes in Example 14 the characterization of the binding interaction between Fab PRIT-0213 and Pb-DOTAM based on the determination of the crystal structure of Fab PRIT-0213 complexed with Pb-DOTAM at 1.40 Å resolution and analysis of this structure using the Protein Interface Surface and Assembly (PISA) program (Krissinel and Henrick, J Mol Biol (2007) 372(3):774-97).

[0181] In some embodiments, an antibody according to the invention may exhibit interactions with one or more of the following sites with respect to Pb-DOTAM: edge-to-face with the azacyclododecane ring region below the azacyclododecane ring (e.g., the tetracyclododecane ring), N6, N7, N8, N5, and / or C12, as determined, for example, by PISA analysis of the structure of the antibody complexed with Pb-DOTAM. In some embodiments, the antibody may exhibit interactions with one or more of the following sites with respect to Pb-DOTAM: N7, N8, edge-to-face with the azacyclododecane ring, the tetracyclododecane ring, and / or N6.

[0182] In some embodiments, the antibody may exhibit one or more of the following interactions with Pb-DOTAM, e.g., as determined by PISA analysis of the structure of the antibody complexed with Pb-DOTAM: an edge-to-face nonpolar interaction with the azacyclododecane ring, a polar interaction with N8, a hydrogen bond with N7, a hydrogen bond with N8, a polar interaction with N5, a nonpolar interaction with C12, a polar interaction with N7, a polar (hydrogen) bond with N6, and / or a nonpolar interaction with the tetracyclododecane ring.

[0183] In some embodiments, the antibody may exhibit one or more of the following interactions with Pb-DOTAM, as determined, for example, by PISA analysis of the structure of the antibody complexed with Pb-DOTAM: hydrogen bonds between one or more residues of the antibody heavy chain CDR3 and N7, hydrogen bonds between one or more residues of the antibody heavy chain CDR3 and N8, a nonpolar interaction between one or more residues of the antibody heavy chain CDR2 edge-to-face to the azacyclododecane ring, a nonpolar interaction between the antibody light chain CDR3 and the tetracyclododecane ring, and / or a nonpolar interaction between the antibody light chain CDR1 and N6.

[0184] In other embodiments, the antibodies may share the same contact residues as described herein; for example, these residues may be invariant. These residues include the following: a) in the heavy chain CDR2: Phe50, Asp56 and / or Tyr58, optionally also Gly52 and / or Arg54; b) in the heavy chain CDR3: Glu95, Arg96, Asp97, Pro98, Tyr99, Ala100C and / or Tyr100D, optionally also Pro100E; c) in the light chain CDR1: Tyr28 and / or Asp32; d) in the light chain CDR3: Gly91, Tyr92, Asp93, Thr95c and / or Tyr96; e) in the light chain CDR2: optionally, Gln50 may include:

[0185] Certain aspects and embodiments of antibodies according to the invention are discussed above. Further preferred aspects and embodiments according to the invention are discussed below. In all embodiments, the antibodies retain the ability to bind to Pb-DOTAM, and preferably also to Bi-DOTAM, and even more preferably retain the ability to bind with the affinity and / or selectivity discussed above.

[0186] In one embodiment, the present invention provides an anti-Pb-DOTAM antibody comprising at least one, two, three, four, five, or six CDRs selected from (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.

[0187] In one embodiment, the invention provides an antibody comprising at least one, at least two, or all three VH CDR sequences selected from: (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3. In one embodiment, the antibody comprises a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3. In another embodiment, the antibody comprises a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3 and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6. In a further embodiment, the antibody comprises a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3, a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6, and a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2. In a further embodiment, the antibody comprises a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3, a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2, and a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4. In a further embodiment, the antibody comprises (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3.

[0188] In another aspect, the invention provides an antibody comprising at least one, at least two, or all three VL CDR sequences selected from: (a) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; (b) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and (c) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6. In one embodiment, the antibody comprises: (a) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; (b) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and (c) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.

[0189] In another embodiment, an antibody of the invention comprises: (a) a VH domain comprising at least one, at least two, or all three VH CDR sequences selected from (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2, and (iii) a CDR-H3 comprising an amino acid sequence selected from SEQ ID NO: 3; and (b) a VL domain comprising at least one, at least two, or all three VL CDRs selected from (i) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4, and (ii) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5, and (c) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.

[0190] In another aspect, the present invention provides an antibody comprising: (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; (e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.

[0191] In some embodiments, the antibody may comprise one or more of CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and / or CDR-L3, each having substitutions, e.g., 1, 2, or 3 substitutions, compared to the amino acid sequences of SEQ ID NOs: 1 to 6. Preferably, these substitutions are not at invariant positions as described above.

[0192] For example, in some embodiments, CDR-H2 may comprise the amino acid sequence FIGSRGDTYYASWAKG (SEQ ID NO:2), or a variant thereof having one, two, or up to three substitutions in SEQ ID NO:2, which substitutions do not include Phe50, Asp56, and / or Tyr58, and optionally do not include Gly52 and / or Arg54 (all numbered according to Kabat).

[0193] In some embodiments, CDR-H2 may be substituted at one or more positions as shown below. Here, and in the substitution table below, substitutions are based on germline residues (underlined) or with amino acids that theoretically sterically fit and are present in the crystallized repertoire at that position. In some embodiments, the above residues are fixed, and other residues may be substituted according to the table below: In other embodiments, substitution of any residue may be made according to the table below. TIFF0007582867000006.tif122170

[0194] Optionally, CDR-H3 may comprise the amino acid sequence ERDPYGGGAYPPHL (SEQ ID NO: 3), or a variant thereof having one, two, or up to three substitutions in SEQ ID NO: 3, wherein the substitutions do not include Glu95, Arg96, Asp97, Pro98, and optionally also do not include Ala100C, Tyr100D, and / or Pro100E, and / or optionally also do not include Tyr99. For example, in some embodiments, the substitutions do not include Glu95, Arg96, Asp97, Pro98, Tyr99, Ala100C, and Tyr100D.

[0195] In certain embodiments, CDR-H3 may be substituted at one or more positions as shown below: In some embodiments, the above residues may be fixed, and other residues may be substituted according to the table below: In other embodiments, substitution of any residue may be made according to the table below. TIFF0007582867000007.tif109170

[0196] Optionally, CDR-L1 may comprise the amino acid sequence QSSHSVYSDNDLA (SEQ ID NO: 4), or a variant thereof having one, two, or up to three substitutions in SEQ ID NO: 4, which substitutions do not include Tyr28 and Asp32 (Kabat numbering).

[0197] In certain embodiments, CDR-L1 may be substituted at one or more positions as shown below: Again, in some embodiments, the above residues may be fixed, and other residues may be substituted according to the table below: In other embodiments, substitution of any residue may be made according to the table below. TIFF0007582867000008.tif102170

[0198] Optionally, CDR-L3 may comprise the amino acid sequence LGGYDDESDTYG (SEQ ID NO: 6), or a variant thereof having one, two, or up to three substitutions in SEQ ID NO: 6, which substitutions do not include Gly91, Tyr92, Asp93, Thr95c, and / or Tyr96 (Kabat).

[0199] In certain embodiments, CDR-L3 may be substituted at the following positions as shown below (many substitutions are envisioned as many residues are solvent exposed and do not have antigen contacts): Again, in some embodiments, the above residues may be fixed and other residues may be substituted according to the table below: In other embodiments, substitution of any residue may be made according to the table below. TIFF0007582867000009.tif142170

[0200] The antibody may further optionally comprise a CDR-H1 and a CDR-L2 having the sequences of SEQ ID NO: 1 or SEQ ID NO: 5, respectively, or a variant thereof having at least 1, 2, or 3 substitutions compared thereto, optionally conservative substitutions.

[0201] In any of the above embodiments, the anti-Pb-DOTAM antibody may be humanized. In one embodiment, the anti-Pb-DOTAM antibody comprises the CDRs as in any of the above embodiments and further comprises an acceptor human framework, e.g., a human immunoglobulin framework or a human consensus framework. In another embodiment, the anti-Pb-DOTAM antibody comprises the CDRs as in any of the above embodiments and further comprises framework regions derived from vk139 and / or vh226. For vk139, in some embodiments, there may be no backmutation. For vh226, the germline Ala49 residue may not be backmutated to Gly49.

[0202] Optionally, the antigen-binding site may comprise a heavy chain variable domain comprising an amino acid sequence selected from the group consisting of SEQ ID NO:7 and SEQ ID NO:9, or a variant thereof comprising an amino acid sequence having at least 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to SEQ ID NO:7 or SEQ ID NO:9. In certain embodiments, a VH sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions compared to the reference sequence, although antibodies comprising the sequence preferably retain the ability to bind Pb-DOTAM with affinity as described herein. The VH sequence may retain invariant residues as described above. In certain embodiments, a total of 1 to 10 amino acids are substituted, inserted, and / or deleted in SEQ ID NO:7 or SEQ ID NO:9. In certain embodiments, the substitutions, insertions, or deletions occur in regions outside the CDRs (i.e., FRs). Optionally, the antibody comprises a VH sequence in SEQ ID NO: 7 or SEQ ID NO: 9, including post-translational modifications of that sequence. In certain embodiments, the VH comprises one, two, or three CDRs selected from: (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3.

[0203] In another aspect, an anti-Pb-DOTAM antibody is provided, wherein the antibody comprises a light chain variable domain (VL) having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:8 or SEQ ID NO:10. In certain embodiments, a VL sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions compared to the reference sequence, but the anti-Pb-DOTAM antibody comprising that sequence preferably retains the ability to bind Pb-DOTAM with affinity as described herein. The VL sequence may retain invariant residues as described above. In certain embodiments, a total of 1 to 10 amino acids are substituted, inserted, and / or deleted in SEQ ID NO:8 or SEQ ID NO:10. In certain embodiments, the substitutions, insertions, or deletions are in regions outside the CDRs (i.e., FRs). Optionally, the anti-Pb-DOTAM antibody comprises a VL sequence in SEQ ID NO: 8 or SEQ ID NO: 10, including post-translational modifications of that sequence. In certain embodiments, the VL comprises one, two, or three CDRs selected from (a) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; (b) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and (c) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.

[0204] In another aspect, an anti-Pb-DOTAM antibody is provided, wherein the antibody comprises a VH as described in any of the embodiments provided above and a VL as described in any of the embodiments provided above. In one embodiment, the antibody comprises the VH and VL sequences of SEQ ID NO:7 and SEQ ID NO:8, respectively, including post-translational modifications of those sequences. In another embodiment, the antibody comprises the VH and VL sequences of SEQ ID NO:9 and SEQ ID NO:10, respectively, including post-translational modifications of those sequences.

[0205] In a further aspect of the invention, the antibody of any of the above embodiments is a monoclonal antibody, including a chimeric, humanized, or human antibody. In one embodiment, the antibody is an antibody fragment, such as an Fv, Fab, Fab', scFab, scFv, diabody, or F(ab')2 fragment. Antibody fragments include, but are not limited to, Fab, Fab', Fab'-SH, F(ab')2, Fv, and scFv fragments, as well as other fragments described below. For a review of certain antibody fragments, see Hudson et al., Nat. Med. 9:129-134 (2003). For a review of scFv fragments, see, e.g., Pluckthun, The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and Moore (eds.), (Springer-Verlag, New York), pp. 269-315 (1994); see also WO 93 / 16185; and U.S. Patent Nos. 5,571,894 and 5,587,458. For a discussion of Fab and F(ab')2 fragments that contain salvage receptor-binding epitope residues and have increased in vivo half-lives, see U.S. Patent No. 5,869,046.

[0206] Diabodies are antibody fragments with two antigen-binding sites, which may be bivalent or bispecific. See, for example, EP 404,097; WO 1993 / 01161; Hudson et al., Nat. Med. 9:129-134 (2003); and Hollinger et al., Proc. Natl. Acad. Sci. USA 90:6444-6448 (1993). Triabodies and tetrabodies are also described in Hudson et al., Nat. Med. 9:129-134 (2003).

[0207] Single-domain antibodies are antibody fragments that contain all or part of the heavy chain variable domain or all or part of the light chain variable domain of an antibody. In certain embodiments, single-domain antibodies are human single-domain antibodies (Domantis, Inc., Waltham, MA; see, e.g., U.S. Patent No. 6,248,516 B1).

[0208] Antibody fragments can be produced by a variety of techniques, including, but not limited to, proteolytic digestion of intact antibodies and production by recombinant host cells (e.g., E. coli or phage), as described herein.

[0209] In another embodiment, the antibody is a full-length antibody, eg, an intact IgG antibody or other antibody class or isotype, as defined herein.

[0210] Targeted Agents In some aspects, the antibody that specifically binds to DOTAM-chelated Pb is coupled to a cell binding agent / targeting moiety to produce a targeted agent. Optionally, the antibody that specifically binds to DOTAM-chelated Pb can be an antibody described in any of the above embodiments.

[0211] Coupling may be preferably via expression as a fusion polypeptide or protein. Fusion may be direct or via a linker. Fusion polypeptides or proteins can be produced recombinantly, avoiding the need for conjugation chemistry. Optionally, the linker may be a peptide of at least 5 amino acids, preferably between 25 and 30 amino acids. The linker may be rigid or flexible. In some embodiments, it is flexible, comprising or consisting of Thr, Ser, Gly, and / or Ala residues. For example, it may comprise or consist of Gly and Ser residues. In some embodiments, it may be (Gly-Gly-Gly-Gly-Ser).n

[0037] In some embodiments, the linker may have a repeating motif such as:

[0038] , where n is, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. In some embodiments, the linker may be or include the sequence GGGGSGGGGSGGGGSGGGGS (SEQ ID NO: 26). Other linkers may be used and can be identified by one of skill in the art.

[0212] Thus, a multispecific (e.g., bispecific) antibody conjugate is provided that specifically binds both a Pb-DOTAM chelate and another target antigen, e.g., an antigen present on the surface of a target cell.

[0213] Insofar as the present invention relates to a method of treatment and a product for use in the method of treatment, it is applicable to any condition treatable by cytotoxic activity targeted to diseased cells in a patient. The treatment is preferably for tumors or cancers (e.g., pancreatic, breast, or prostate cancer). However, the applicability of the present invention is not limited to tumors and cancers. For example, the treatment may also be for viral infections. Immunotoxins against viral antigens expressed on the surface of infected cells have been investigated for various viral infections, such as HIV, rabies, and EBV. Cai and Berger 2011 Antiviral Research 90(3):143-50 used an immunotoxin containing PE38 for targeted killing of cells infected with Kaposi's sarcoma-associated herpesvirus. Furthermore, Resimmune® (A-dmDT390-bisFv(UCHT1)) selectively kills human malignant T cells and transiently depletes normal T cells, and is believed to have potential for the treatment of T cell-driven autoimmune diseases such as multiple sclerosis and graft-versus-host disease, as well as T cell hematological cancers undergoing clinical trials.

[0214] Thus, suitable target antigens may include cancer cell antigens, particularly human cancer cell antigens, viral antigens or microbial antigens.

[0215] The target antigen described herein is designed to bind to diseased cells, such as tumor cells, via its cell surface antigen. The antigen is a normal cell surface antigen that is usually overexpressed or expressed at an abnormal time. Ideally, the target antigen is only expressed on diseased cells (such as tumor cells), but this is rarely observed in practice. As a result, the target antigen is usually selected based on its differential expression between diseased tissue and healthy tissue.

[0216] Thus, the targeting antibody can specifically bind to any suitable cell surface marker. The selection of a particular targeting moiety and / or cell surface marker can be selected depending on the particular cell population to be targeted. Cell surface markers are known in the art (see, e.g., Mufson et al., Front. Biosci., 11:337-43 (2006); Frankel et al., Clin. Cancer Res., 6:326-334 (2000); and Kreitman et al., AAPS Journal, 8(3):E532-E551 (2006)), and may be, for example, a protein or a carbohydrate. In an embodiment of the present invention, the targeting moiety (cell binding agent) is a ligand that specifically binds to a receptor on the cell surface. Exemplary ligands include, but are not limited to, vascular endothelial growth factor (VEGF), Fas, TNF-related apoptosis-inducing ligand (TRAIL), cytokines (e.g., IL-2, IL-15, IL-4, IL-13), lymphokines, hormones, and growth factors (e.g., transforming growth factor (TGFα), nerve growth factor, epidermal growth factor).

[0217] The cell surface marker may be, for example, a tumor-associated antigen.

[0218] As used herein, the term "tumor-associated antigen" or "tumor-specific antigen" refers to any molecule (e.g., protein, peptide, lipid, carbohydrate, etc.) that is exclusively or predominantly expressed or overexpressed by tumor cells and / or cancer cells, such that the antigen is associated with tumors and / or cancer. Tumor-associated antigens may also be expressed by normal, non-tumor, or non-cancerous cells. However, in such cases, expression of tumor-associated antigens by normal, non-tumor, or non-cancerous cells is not as robust as expression by tumor or cancer cells. In this regard, tumor or cancer cells may overexpress the antigen or express the antigen at a significantly higher level than expression by normal, non-tumor, or non-cancerous cells. Tumor-associated antigens may also be expressed by cells at different stages of development or maturation. For example, tumor-associated antigens may also be expressed by cells at embryonic or fetal stages that are not normally found in adult hosts. Alternatively, tumor-associated antigens may also be expressed by stem or progenitor cells that are not normally found in adult hosts.

[0219] A tumor-associated antigen may be an antigen expressed by any cell of any cancer or tumor, including the cancers and tumors described herein. A tumor-associated antigen may be a tumor-associated antigen of only one type of cancer or tumor, such that the tumor-associated antigen is associated with or characteristic of only one type of cancer or tumor. Alternatively, a tumor-associated antigen may be a tumor-associated antigen of (e.g., characteristic of) more than one type of cancer or tumor. For example, a tumor-associated antigen may be expressed by both breast cancer cells and prostate cancer cells, but not at all by normal, non-tumor, or non-cancer cells.

[0220] Exemplary tumor-associated antigens to which the cell-binding agents can specifically bind include, but are not limited to, mucin 1 (MUC1; tumor-associated epithelial mucin), preferentially expressed melanoma antigen (PRAME), carcinoembryonic antigen (CEA), prostate-specific membrane antigen (PSMA), PSCA, EpCAM, Trop2, granulocyte-macrophage colony-stimulating factor receptor (GM-CSFR), CD56, human epidermal growth factor receptor 2 (HER2 / neu) (also known as erbB-2), CDS, CD7, tyrosinase-related protein (TRP) I, and TRP2. In a preferred embodiment, the cell surface marker to which the targeting moiety (cell binding agent) specifically binds is cluster of differentiation (CD) 19, CD20, CD21, CD22, CD25, CD30, CD33 (sialic acid-binding Ig-like lectin 3, myeloid cell surface antigen), CD79b, CD123 (interleukin-3 receptor alpha), transferrin receptor, EGF receptor, mesothelin, cadherin, Lewis Y, glypican-3, FAP (fibroblast activation protein alpha), PSMA (prostate-specific membrane antigen), CA9 = CAIX (carbonic anhydrase IX), L1 The mesothelin is selected from the group consisting of CAM (neural cell adhesion molecule L1), endosialin, HER3 (epidermal growth factor receptor family member 3 activated conformation), Alk1 / BMP9 complex (anaplastic lymphoma kinase 1 / bone morphogenetic protein 9), TPBG=5T4 (trophoblast glycoprotein), ROR1 (receptor tyrosine kinase-like surface antigen), HER1 (epidermal growth factor receptor activated conformation), and CLL1 (C-type lectin domain family 12, member A). Mesothelin is expressed in, for example, ovarian cancer, mesothelioma, non-small cell lung cancer, lung adenocarcinoma, fallopian tube cancer, head and neck cancer, cervical cancer, and pancreatic cancer. CD22 is expressed in, for example, hairy cell leukemia, chronic lymphocytic leukemia (CLL), prolymphocytic leukemia (PLL), non-Hodgkin's lymphoma, small lymphocytic lymphoma (SLL), and acute lymphocytic leukemia (ALL).CD25 is expressed in, for example, leukemia and lymphoma, including hairy cell leukemia and Hodgkin's lymphoma.Lewis Y antigen is expressed in, for example, bladder cancer, breast cancer, ovarian cancer, colorectal cancer, esophageal cancer, gastric cancer, lung cancer, and pancreatic cancer. CD33 is expressed in, for example, acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CML), and myeloproliferative disorders.

[0221] In embodiments of the invention, the targeting moiety is an antibody (including an antibody fragment) that specifically binds to a target, e.g., a tumor-associated antigen. In such embodiments, the agent may be referred to as a bispecific or multispecific antibody.

[0222] Exemplary antibodies that specifically bind to tumor-associated antigens include, but are not limited to, antibodies against the transferrin receptor (e.g., HB21 and its variants), antibodies against CD22 (e.g., RFB4 and its variants), antibodies against CD25 (e.g., anti-Tac and its variants), antibodies against mesothelin (e.g., SS1, MORAb-009, SS, HN1, HN2, MN, MB, and its variants), and antibodies against the Lewis Y antigen (e.g., B3 and its variants). In this regard, the targeting moiety (cell binding agent) may be an antibody selected from the group consisting of ofB3, RFB4, SS, SS1, MN, MB, HN1, HN2, HB21, and MORAb-009, and antigen-binding portions thereof. Further exemplary targeting moieties suitable for use in the chimeric molecules of the present invention are described, for example, in U.S. Pat. Nos. 5,242,824 (anti-transferrin receptor); 5,846,535 (anti-CD25 antibodies); 5,889,157 (anti-Lewis Y antibodies); 5,981,726 (anti-Lewis Y antibodies); 5,990,296 (anti-Lewis Y antibodies); Y antibody); 7,081,518 (anti-mesothelin antibody); 7,355,012 (anti-CD22 and anti-CD25 antibodies); 7,368,110 (anti-mesothelin antibody); 7,470,775 (anti-CD30 antibody); 7,521,054 (anti-CD25 antibody); and 7,541,034 (anti-CD22 antibody); U.S. Patent Application Publication No. 2007 / 0189962 (anti-CD22 antibody); Frankel et al., Clin. Cancer Res., 6:326-334 (2000), and Kreitman et al., AAPS Journal, 8(3):E532-E551 (2006), each of which is incorporated herein by reference.

[0223] Antibodies have been generated to target specific tumor-associated antigens such as Cripto, CD30, CD19, CD33, glycoprotein NMB, CanAg, Her2 (ErbB2 / Neu), CD56 (NCAM), CD22 (Siglec2), CD33 (Siglec3), CD79, CD138, PSCA, PSMA (prostate-specific membrane antigen), BCMA, CD20, CD70, E-selectin, EphB2, melanotransferrin, Muc16, and TMEEF2.

[0224] In some embodiments of the present invention, the tumor-associated antigen may preferably be carcinoembryonic antigen (CEA). CEA may have the amino acid sequence of human CEA, in particular carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5), as set forth in UniProt (www.uniprot.org) accession number P06731 (version 119) or NCBI (www.ncbi.nlm.nih.gov / ) RefSeq NP_004354.2. Antibodies that have been raised against CEA include T84.66 and its humanized and chimeric versions, such as T84.66-LCHA, CH1A1a, described in WO2016 / 075278A1 and / or WO2017 / 055389, the anti-CEA antibody described in WO2011 / 034660, and CEA hMN-14 (see also U.S. Pat. Nos. 6,676,924 and 5,874,540) described in Table 2 below.

[0225] CEA is advantageous in the context of the present invention because it is internalized relatively slowly, thus leaving a high percentage of antibody available on the cell surface for binding to the radionuclide after initial treatment. Other poorly internalized targets / tumor-associated antigens are also preferred. For example, in some embodiments, the tumor-associated antigen may be CD20 or HER2. GenBank Accession Nos. NP_001005862, NP_004439, XP_005257196, and XP_005257197 disclose the Her2 protein sequence, provided by GenBank on October 4, 2013, and SwissProt database accession number P11836 discloses the CD20 sequence. In further embodiments, the target may be EGP-1 (epithelial glycoprotein-1, also known as trophoblast-2), colon-specific antigen-p (CSAp), or pancreatic mucin MUC1. See, e.g., Goldenberg et al., 2012 (Theranostics 2(5)), which is incorporated herein by reference. This reference also describes antibodies such as Mu-9, which binds to CSAp (see also Sharkey et al., Cancer Res. 2003;63:354-63), hPAM4, which binds to MUC1 (see also Gold et al., Cancer Res. 2008;68:4819-26), valtuzumab, which binds to CD20 (see also Sharkey et al., Cancer Res. 2008;68:5282-90), and hRS7, which binds to EGP-1 (see also Cubas et al., Biochim Biophys Acta 2009;1796:309-14). Any of these antibodies, or antigen-binding portions thereof, may be useful in the present invention, i.e., can be incorporated into the antibodies described herein.

[0226] multispecific antibodies As discussed above, in certain embodiments, the antibodies provided herein are multispecific antibodies, e.g., bispecific antibodies. Multispecific antibodies are monoclonal antibodies that have binding specificities for at least two different sites. Bispecific antibodies can be prepared as full-length antibodies or antibody fragments.

[0227] In recent years, various recombinant antibody formats have been developed, such as IgG antibody formats and tetravalent bispecific antibodies formed by fusion of single-chain domains (see, for example, Coloma, MJ et al., Nature Biotech 15 (1997) pp. 159-163; WO2001 / 077342; and Morrison, SL, Nature Biotech 25 (2007) pp. 1233-1234).

[0228] Other new formats have also been developed that no longer retain the antibody core structure (IgA, IgD, IgE, IgG or IgM), such as diabodies, triabodies or tetrabodies, minibodies and some single-chain formats (scFv, bis-scFv) that can bind to two or more antigens (Holliger, P. et al., Nature Biotech 23 (2005) pp. 1126-1136; Fischer, N., Leger, O., Pathobiology 74 (2007) pp. 3-14; Shen, J. et al., Journal of Immunological Methods 318 (2007) pp. 65-74; Wu, C. et al., Nature Biotech. 25 (2007) pp. 1290-1297).

[0229] All such formats use a linker that fuses the antibody core (IgA, IgD, IgE, IgG, or IgM) to an additional binding protein (e.g., scFv), or fuses, for example, two Fab fragments or scFvs (Fischer, N., Leger, O., Pathobiology 74 (2007) pp. 3-14). It should be noted that by maintaining a high degree of similarity to naturally occurring antibodies, one may wish to retain effector functions mediated by Fc receptor binding, such as, for example, complement-dependent cytotoxicity (CDC) or antibody-dependent cellular cytotoxicity (ADCC).

[0230] WO2007 / 024715 reports dual variable domain immunoglobulins as engineered multivalent and multispecific binding proteins. U.S. Patent No. 6,897,044 reports a process for preparing biologically active antibody dimers. U.S. Patent No. 7,129,330 reports a multivalent Fv antibody construct having at least four variable domains linked to each other via peptide linkers. U.S. Patent No. 7,129,330 reports dimeric and multimeric antigen-binding structures. U.S. Patent No. 6,511,663 reports a trivalent or tetravalent monospecific antigen-binding protein comprising three or four Fab fragments covalently linked to each other by a connecting structure that is not a natural immunoglobulin. WO2006 / 020258 reports a tetravalent bispecific antibody that can be efficiently expressed in prokaryotic and eukaryotic cells and is useful in therapeutic and diagnostic methods. A method for isolating or preferentially synthesizing dimers linked by at least one interchain disulfide bond from dimers not linked by at least one interchain disulfide bond from a mixture containing two types of polypeptide dimers is reported in US2005 / 0163782. A bispecific tetravalent receptor is reported in U.S. Patent No. 5,959,083. An engineered antibody with three or more functional antigen-binding sites is reported in WO2001 / 077342.

[0231] Multispecific and multivalent antigen-binding polypeptides are reported in WO 1997 / 001580. WO 1992 / 004053 reports homoconjugates typically prepared from IgG class monoclonal antibodies that bind to the same antigenic determinant and are covalently linked by a synthetic cross-linking agent. WO 1991 / 06305 reports oligomeric monoclonal antibodies with high avidity for antigens, typically resulting in the secretion of IgG class oligomers having two or more immunoglobulin monomers that bind together to form tetravalent or hexavalent IgG molecules. Ovine-derived antibodies and engineered antibody constructs are reported in U.S. Patent No. 6,350,860, and can be used to treat diseases in which interferon gamma activity is pathogenic. US2005 / 0100543 reports a targetable construct that is a multivalent carrier of bispecific antibodies, i.e., each molecule of the targetable construct can serve as a carrier for two or more bispecific antibodies. WO1995 / 009917 reports a genetically engineered bispecific tetravalent antibody. WO2007 / 109254 reports a stabilized binding molecule consisting of or comprising a stabilized scFv.

[0232] Multispecific antibodies can also be provided in an asymmetric format with domain crossovers in one or more binding arms of the same antigen specificity, i.e., by exchanging VH / VL domains (see, e.g., WO2009 / 080252 and WO2015 / 150447), CH1 / CL domains (see, e.g., WO2009 / 080253), or complete Fab arms (see, e.g., WO2009 / 080251, WO2016 / 016299; see also Schaefer et al., PNAS, 108 (2011) pp. 1187-1191, and Klein et al., MAbs 8 (2016) pp. 1010-20). In one embodiment, the multispecific antibody comprises crossover Fab fragments. The term "crossover Fab fragment" or "xFab fragment" or "crossover Fab fragment" refers to a Fab fragment in which either the variable or constant regions of the heavy and light chains are exchanged. A crossover Fab fragment contains a polypeptide chain composed of a light chain variable region (VL) and a heavy chain constant region 1 (CH1), and a polypeptide chain composed of a heavy chain variable region (VH) and a light chain constant region (CL). Asymmetric Fab arms can also be engineered by introducing charged or uncharged amino acid mutations at the domain interface to direct correct Fab pairing. See, for example, WO2016 / 172485.

[0233] Any of the above formats can be used for the multispecific antibodies according to the invention.

[0234] In one exemplary format, the bispecific antibody is a "trimerizer," as described, for example, in WO 214 / 180754. This refers to a trimeric antigen-binding molecule comprising three fusion polypeptides, each comprising at least one antigen-binding moiety fused to a trimerization domain derived from human cartilage matrix protein (CMP), where the trimerization domain can mediate stable binding of the trimeric antigen-binding molecule. The antigen-binding moieties may be, for example, Fab molecules, crossover Fab molecules, scFab, Fv molecules, scFv, or single-domain antibodies (VHHs). In some embodiments, each fusion protein comprises two (first and second) antigen-binding moieties, for example, where the first antigen-binding moiety is fused to the N-terminal amino acid of the trimerization domain and the second antigen-binding moiety is fused to the C-terminal amino acid of the trimerization domain, both optionally via a peptide linker. In this format, either the first or second antigen-binding moiety can bind to a Pb-DOTAM chelate. The other will bind to a target antigen, for example, a tumor-associated antigen. Each of the three antigen-binding molecules fused to the C-terminus may be specific for the same antigen; each of the three antigen-binding molecules fused to the N-terminus may be specific for a different antigen.

[0235] CMP trimerization domains useful herein are derived from the human cartilage proteins shown below, and in one embodiment comprise a sequence having at least 95% identity, and most preferably at least 98% identity, to the sequence of the trimerization domain shown below: In one embodiment, the trimerization domain comprises the sequence of the trimerization domain shown above.

[0236] TIFF0007582867000010.tif75170

[0237] In another exemplary format, the bispecific or multispecific antibody comprises a full-length antibody (e.g., an IgG) comprising a first and a second antibody heavy chain and a first and a second antibody light chain, wherein the first heavy chain and the first light chain assemble to form an antigen-binding site for a first antigen, and the second heavy chain and the second light chain assemble to form an antigen-binding site for a second antigen.

[0238] Correct assembly of the heavy heterodimer chains can be aided by the use of, for example, knob-into-hole mutations and / or other modifications discussed further below.

[0239] The correct assembly of light chains with their corresponding heavy chains can be aided by cross-mab technology. In this approach, a first heavy chain and a first light chain, or a second heavy chain and a second light chain, can assemble to form a cross-Fab fragment (while the other assembles to form a conventional Fab). Thus, in one embodiment, the first heavy chain may contain a VL domain instead of a VH domain (e.g., VL-CH1-hinge-CH2-CH3), the first light chain may contain a VH domain swapped for a VL domain (e.g., VH-CL), or the first heavy chain may contain a CL domain instead of an HC1 domain (e.g., VH-CL-hinge-CH2-CH3), and the first light chain may contain a CH1 domain instead of a CL domain (e.g., VL-CH1). In this embodiment, the second heavy chain and the second light chain have conventional domain structures (e.g., VH-CH1-hinge-CH2-CH3 and VL-CL, respectively). In alternative embodiments, the second heavy chain may comprise a VL domain instead of a VH domain (e.g., VL-CH1-hinge-CH2-CH3), the second light chain may comprise a VH domain swapped for a VL domain (e.g., VH-CL), or the second heavy chain may comprise a CL domain instead of an HC1 domain (e.g., VH-CL-hinge-CH2-CH3), and the second light chain may comprise a CH1 domain instead of a CL domain (e.g., VL-CH1). In this embodiment, the first heavy chain and the first light chain have conventional domain structures.

[0240] In some embodiments, the correct assembly of light chains with their corresponding heavy chains can additionally or alternatively be aided by the use of charge modifications as discussed below.

[0241] One such antibody is shown in Figure 37 as P1AE1768, where the second heavy chain comprises a CL domain in place of the HC1 domain (e.g., VH-CL-hinge-CH2-CH3) and the second light chain comprises a CH1 domain in place of the CL domain (e.g., VL-CH1); the first heavy chain and first light chain have conventional domain structures. The Fab with conventional structure contains charge modifications. Thus, in one embodiment, an antibody of the invention comprises first and second heavy chains of SEQ ID NOs: 59 and 58, respectively, and first and second light chains of SEQ ID NOs: 57 and 60, respectively.

[0242] In some embodiments of the above formats, the formats may be bivalent. In another possible embodiment, an additional antigen-binding moiety can be fused, for example, to the first and / or second heavy chain to increase the valency of one or both antigens. For example, an additional antigen-binding moiety for the first antigen can be fused to the N-terminus of one or both heavy chain molecules. The antibody may be multivalent, for example, bivalent, with respect to the first antigen (e.g., a tumor-associated antigen) and monovalent with respect to the second antigen (e.g., DOTAM-chelated Pb).

[0243] The additional antigen-binding portion may be, for example, an scFab, which contains an antigen-binding site for a first antigen (e.g., a tumor-associated antigen). An scFab contains a VH and a CH1 domain connected by a polypeptide linker to replace the VL and CL domains so that it can be expressed as a single chain. In other words, an scFab contains a polypeptide linker between the Fd and the light chain.

[0244] In another embodiment, the additional antigen-binding moiety is a Fab or cross-Fab. For example, the N- or C-terminus of one heavy chain can be linked by a polypeptide linker to a first polypeptide consisting of a VH domain and a CH1 domain that associates with a second polypeptide consisting of a VL domain and a CL domain to form a Fab. In another embodiment, the N- or C-terminus of one heavy chain can be linked by a polypeptide linker to a first polypeptide consisting of a VL domain and a CH1 domain that associates with a second polypeptide consisting of a VH domain and a CL domain. In another embodiment, the N- or C-terminus of one heavy chain can be linked by a polypeptide linker to a first polypeptide consisting of a VH domain and a CL domain that associates with a second polypeptide consisting of a VL domain and a CH1 domain.

[0245] In this format, it may be preferable that binding arms of the same antigen specificity are formed by binding to the same light chain. Thus, the antigen-binding moiety / arm for the first antigen may be a crossed Fab, and the antigen-binding moiety / arm for the second antigen may be a conventional Fab. Alternatively, the antigen-binding moiety / arm for the first antigen may be a conventional Fab, and the antigen-binding moiety / arm for the second antigen may be a crossed Fab.

[0246] This format may also include charge modifications, as discussed further below.

[0247] In one embodiment of this type: a full-length antibody comprising a first and a second antibody heavy chain and a first and a second antibody light chain, wherein the first heavy chain and the first light chain assemble to form a Fab comprising an antigen-binding site for a first antigen (e.g., a tumor-specific antigen, e.g., CEA), and the second heavy chain and the second light chain assemble to form a cross-Fab (e.g., the second heavy chain has a VL domain in place of the VH domain and the second light chain has a VH domain in place of the VL domain) comprising an antigen-binding site for a second antigen (e.g., DOTAM-chelated Pb); a full-length antibody in which either a first or a second antibody heavy chain is fused via a linker to a polypeptide comprising a CH1 and a VH domain, and the first polypeptide assembles with a second polypeptide comprising a CL and a VL, such that the first and second polypeptides assemble to form an Fab comprising an antigen-binding site for a first antigen. A multivalent antibody comprising:

[0248] The fusion may be to the N-terminus of one of the heavy chains of a full-length antibody, and optionally to the N-terminus of a second heavy chain.

[0249] Charge modifications can also be used if desired, for example, a Fab comprising an antigen binding site for a first antigen may include charge-modifying substitutions, as discussed below.

[0250] An example of such a format is P1AE1769, shown in Figure 37. Thus, in one embodiment, an antibody of the invention comprises first and second heavy chains of SEQ ID NO:64 and SEQ ID NO:63, respectively, and first and second light chains of SEQ ID NO:62 and SEQ ID NO:61, respectively.

[0251] Another exemplary format includes a full-length antibody, such as an IgG, that contains an antigen-binding site for a first antigen (which may be, e.g., bivalent for the first antigen) linked to an antigen-binding portion for a second antigen.

[0252] For example, the antigen-binding portion for the second antigen may be an scFab containing an antigen-binding site for the second antigen (e.g., a Pb-DOTAL chelate). In some embodiments, the scFab can be fused to the C-terminus of one of the two heavy chains of a full-length antibody, e.g., the C-terminus of its CH3 domain. Correct assembly of the heterodimeric heavy chain may be aided by, for example, the use of knob-into-hole mutations and / or other modifications discussed further below. One such antibody is exemplified in Figure 37 as P1AE1770. Thus, in one embodiment, an antibody of the invention comprises heavy chains of SEQ ID NOs: 66 and 67 and a light chain of SEQ ID NO: 65.

[0253] Another exemplary format includes a full-length antibody comprising an antigen-binding site for a first antigen (which may be, for example, bivalent for the first antigen), wherein the N- or C-terminus of one of the heavy chains is linked to a first polypeptide via a polypeptide linker, and the first polypeptide associates with a second polypeptide to form a Fab or cross-Fab that comprises a binding site for the second antigen. For example, this format can be used in combination with a second polypeptide, such that the first and second polypeptides together form an antigen-binding site for the second antigen. i) a first polypeptide consisting of a VH domain and a CH1 domain associated with a second polypeptide consisting of a VL and a CL domain; or ii) a first polypeptide consisting of a VL domain and a CH1 domain associated with a second polypeptide consisting of a VH and a CL domain; or iii) a first polypeptide consisting of a VH domain and a CL domain associated with a second polypeptide consisting of a VL and a CH1 domain; may include:

[0254] Correct assembly of the heavy chain heterodimers may be aided by, for example, the use of knob-into-hole mutations and / or other modifications discussed further below. For example, the Fab domain of a full-length antibody may contain charge modifications.

[0255] In one embodiment, the first polypeptide is linked to the C-terminus of one of the heavy chains, e.g., the C-terminus of its CH3 domain, via a polypeptide linker. The first polypeptide may comprise an N-terminal VL domain and a C-terminal CH1 domain. Thus, the heavy chain bearing the fusion may comprise, from N- to C-terminus, VH-CH1-hinge-CH2-CH3-linker-VL-CH1. The light chain may comprise VH-CL. The Fab of the full-length antibody may contain charge-modifying substitutions. One such antibody is shown in Figure 37 as P1AE1767. Thus, in one embodiment, an antibody of the invention comprises heavy chains of SEQ ID NOs: 63 and 64 and light chains of SEQ ID NOs: 61 and 62.

[0256] In another embodiment, the first polypeptide is linked to the N-terminus of the heavy chain VH domain via a polypeptide linker. The first polypeptide may comprise an N-terminal VL domain and a C-terminal CH1 domain. Thus, the heavy chain bearing the fusion may comprise, from N- to C-terminus, VL-CH1-linker-VH-CH1-hinge-CH2-CH3. The light chain may comprise VH-CL.

[0257] In another exemplary format, the antibody may comprise a full-length antibody that specifically binds to a first antigen and consists of two antibody heavy chains and two antibody light chains, with the C-terminus of each heavy chain fused to an antigen-binding moiety that specifically binds to a second antigen.

[0258] In one embodiment, the first antigen is a target, eg, a tumor-specific antigen, and the second antigen is a Pb-DOTAM chelate, although the reverse may also be true.

[0259] In another exemplary format, the antibody is a) a full-length antibody that specifically binds to a first antigen and consists of two antibody heavy chains and two antibody light chains; b) i) an antibody heavy chain variable domain (VH); or ii) an antibody heavy chain variable domain (VH) and an antibody heavy chain constant domain (CH1); or iii) antibody heavy chain variable domain (VH) and antibody light chain constant domain (CL) A polypeptide consisting of a polypeptide in which the N-terminus of a VH domain is fused to the C-terminus of one of the two heavy chains of the full-length antibody via a peptide linker; c) i) an antibody light chain variable domain (VL); or ii) an antibody light chain variable domain (VL) and an antibody light chain constant domain (CL); or iii) an antibody light chain variable domain (VL) and an antibody heavy chain constant domain (CH1) A polypeptide consisting of A polypeptide in which the N-terminus of the VL domain is fused to the C-terminus of the other of the two heavy chains of the full-length antibody via a peptide linker. Includes; It may also be a bispecific antibody, in which the antibody heavy chain variable domain of the peptide under (b) and the antibody light chain variable domain of the peptide under (c) together form an antigen-binding site for a second antigen.

[0260] In this format, if the first polypeptide is according to b(i), the second polypeptide is according to c(i); if the first polypeptide is according to b(ii), the second polypeptide is according to c(ii); and if the first polypeptide is according to b(iii), the second polypeptide is according to c(iii). Charge-modifying substitutions can also be used, for example, in the Fab of a full-length antibody.

[0261] In this format, the first or second antigen may be DOTAM-chelated Pb. The other may be a target, such as a tumor-associated antigen, for example, CEA, CD20, or ERBB2. In some embodiments, the second antigen is DOTAM-chelated Pb, and the first antigen is a target.

[0262] The above-described antibody may be trivalent. In another possible embodiment, an additional antigen-binding moiety can be fused to increase the valency for one or both antigens. For example, an additional antigen-binding moiety for a first antigen can be fused to the carboxy terminus of either or both heavy chains of a full-length antibody (e.g., a tumor-associated antigen) so that the antibody has a valency of 4 for the first antigen (when fused to the carboxy termini of both heavy chains) and a valency of 1 for the second antigen.

[0263] Examples of the above format in which the antibody (b) consists of a VH domain and the antibody (c) consists of a VL domain are PRIT-213 and PRIT214. An example of the above format in which the antibody (b) consists of a VH domain and a CL domain and the antibody (c) consists of a VL domain and a CH1 domain is P1AE1766 as shown in Figure 37. Thus, in one embodiment, an antibody of the invention comprises first and second heavy chains of SEQ ID NO:51 and SEQ ID NO:52, respectively, and a light chain of SEQ ID NO:50.

[0264] If desired, the format used for the multispecific antibodies of the invention may be a trivalent format as described in WO2010 / 115589A1 (Roche Glycart AG), which is incorporated herein by reference in its entirety.

[0265] WO2010 / 115589 describes an optional stabilization of the structure, whereby an antibody heavy chain variable region (VH) of the polypeptide under (b) and an antibody light chain variable domain (VL) of the polypeptide under (c) are linked by an interchain disulfide bridge, for example at the following positions: i) position 44 of the heavy chain variable domain to position 100 of the light chain variable domain; ii) position 105 of the heavy chain variable domain to position 43 of the light chain variable domain, or iii) position 101 of the heavy chain variable domain to position 100 of the light chain variable domain (always numbered according to the EU index of Kabat) It is stabilized by the introduction of a disulfide bond between

[0266] WO2010 / 115589 also discloses that the CH3 domain of said full-length antibodies according to the invention may be modified by the "knob-into-hole" technique, which is described in detail with some examples in, for example, WO96 / 027011, Ridgway, JB et al., Protein Eng 9 (1996) pp. 617-621; and Merchan, AM et al., Nat Biotechnol 16 (1998) pp. 677-681.

[0267] Thus, in some embodiments, the trivalent bispecific antibody is further characterized in that the CH3 domain of one heavy chain of a full-length antibody and the CH3 domain of the other heavy chain of a full-length antibody each meet at an interface that comprises the original interface between the antibody CH3 domains, and that the interface has been modified to promote the formation of the trivalent bispecific antibody, the modification comprising: a) the CH3 domain of one heavy chain is modified in such a way that, within the original interface of the CH3 domain of one heavy chain facing the original interface of the CH3 domain of the other heavy chain in the trivalent bispecific antibody, amino acid residues are replaced with amino acid residues having a larger side chain volume, thereby generating a protrusion within the interface of the CH3 domain of one heavy chain that can be positioned in a cavity within the interface of the CH3 domain of the other heavy chain; and b) In the original interface of the second CH3 domain facing the original interface of the first CH3 domain in the trivalent bispecific antibody, amino acid residues are replaced with amino acid residues having smaller side chain volumes, thereby creating a cavity in the interface of the second CH3 domain into which a protrusion in the interface of the first CH3 domain can be positioned. It is characterized by:

[0268] The amino acid residue having a larger side chain volume can optionally be selected from the group consisting of arginine (R), phenylalanine (F), tyrosine (Y), and tryptophan (W). The amino acid residue having a smaller side chain volume can optionally be selected from the group consisting of alanine (A), serine (S), threonine (T), and valine (V).

[0269] Optionally, in some embodiments, both CH3 domains are further modified by introducing a cysteine ​​(C) as an amino acid at the corresponding position in each CH3 domain to allow the formation of a disulfide bridge between both CH3 domains.

[0270] These and other details of the bispecific trivalent antibody format described in WO2010 / 115589A1 can be utilized in the present invention.

[0271] As used herein, the term "full-length antibody" refers to an antibody consisting of two "full-length antibody heavy chains" and two "full-length antibody light chains." A "full-length antibody heavy chain" may be a polypeptide consisting of, from the N-terminus to the C-terminus of the antibody heavy chain variable domain (VH), antibody constant heavy chain domain 1 (CH1), antibody hinge region (HR), antibody heavy chain constant domain 2 (CH2), and antibody heavy chain constant domain 3 (CH3), abbreviated as VH-CH1-HR-CH2-CH3; and, optionally, in the case of antibodies of the subclass IgE, antibody heavy chain constant domain 4 (CH4). Preferably, a "full-length antibody heavy chain" is a polypeptide consisting, from the N-terminus to the C-terminus, of VH, CH1, HR, CH2, and CH3. The possibility of cross-mAb formation is not intended to be excluded by reference to "full length." Thus, the heavy chain may have the VH domain swapped for a VL domain or the CH1 domain swapped for a CL domain. A "full-length antibody light chain" may be a polypeptide consisting of, from N- to C-terminus, an antibody light chain variable domain (VL) and an antibody light chain constant domain (CL), abbreviated as VL-CL. Alternatively, in the case of cross-mAbs, the VL domain can be swapped for a VH domain, or the CL domain can be swapped for a CH1 domain. The antibody light chain constant domain (CL) may be kappa (κ) or lambda (λ). Two full-length antibody chains are linked together via inter-polypeptide disulfide bonds between the CL and CH1 domains and between the hinge regions of the full-length antibody heavy chain. Typical examples of full-length antibodies are natural antibodies such as IgG (e.g., IgG1 and IgG2), IgM, IgA, IgD, and IgE). Full-length antibodies according to the present invention may be derived from a single species, e.g., human, or they may be chimerized or humanized. Each full-length antibody described herein comprises two antigen-binding sites formed by a pair of VH and VL. The C-terminus of the heavy or light chain of said full-length antibody refers to the last amino acid at the C-terminus of said heavy or light chain.

[0272] The N-terminus of the antibody heavy chain variable domain (VH) of the polypeptide under b) and the antibody light chain variable domain (VL) of the polypeptide under c) refers to the last amino acid at the N-terminus of the VH or VL domain.

[0273] In any of the above formats, the first antigen may be a tumor-associated antigen and the second antigen may be Pb-DOTAM (although these may be reversed in some embodiments).

[0274] In any of the above formats, the correct assembly of heavy chain heterodimers can be aided by modifications to the heavy chain sequences. In one embodiment, the knobs-into-holes technique is used. The interaction surfaces of the two CH3 domains can be altered to increase heterodimerization of both heavy chains containing these two CH3 domains. Each of the two CH3 domains (of the two heavy chains) can be a "knob," while the other is a "hole." For example, one contains a so-called "knob mutation" according to EU index numbering (T366W and optionally one of S354C or Y349C, preferably S354C), while the other contains a so-called "hole mutation" (T366S, L368A, and Y407V, optionally Y349C or S354C, preferably Y349C) (see, e.g., Carter, P. et al., Immunotechnol. 2 (1996) 73).

[0275] Additionally or alternatively, the introduction of disulfide bridges can be used to stabilize heterodimers (Merchant, AM et al., Nature Biotech 16 (1998) pp. 677-681; Atwell, S. et al., J. Mol. Biol. 270 (1997) pp. 26-35) and increase yields. Examples include the following positions: i) position 44 of the heavy chain variable domain to position 100 of the light chain variable domain; ii) position 105 of the heavy chain variable domain to position 43 of the light chain variable domain, or iii) position 101 of the heavy chain variable domain to position 100 of the light chain variable domain (always numbered according to the EU index of Kabat) Examples include the introduction of a disulfide bond between

[0276] charge modification The multispecific antibodies of the present invention may comprise amino acid substitutions in the Fab molecules comprised therein that are particularly efficient in reducing mispairing of light chains with non-matching heavy chains (Bence-Jones by-products) that can occur in the production of Fab-based bi / multispecific antigen-binding molecules having a VH / VL exchange in one (or more, in the case of molecules comprising more than two antigen-binding Fab molecules) of their binding arms (see also PCT Publication No. WO2015 / 150447, in particular the Examples therein, which is incorporated herein by reference in its entirety). The ratio of the desired multispecific antibody compared to undesired by-products, in particular Bence-Jones by-products that occur in one of its binding arms, can be improved by the introduction of oppositely charged amino acids at specific amino acid positions in the CH1 and CL domains of the Fab molecules (sometimes referred to herein as "charge modifications").

[0277] Thus, in some embodiments, antibodies of the invention comprising Fab molecules comprise at least one Fab having a heavy chain constant domain CH1 domain comprising a charge modification as described herein and a light chain constant CL domain comprising a charge modification as described herein.

[0278] Charge modifications are made in either a conventional Fab molecule (such as those shown in Figure 37: P1AE1766, P1AE1767, P1AE1768, P1AE1769) comprised in an antibody of the invention, or in a crossover Fab molecule (but not both) comprised in an antibody of the invention. In certain embodiments, charge modifications are made in a conventional Fab molecule (which, in certain embodiments, specifically binds to a target cell antigen) comprised in an antibody of the invention.

[0279] Thus, in some embodiments, an antibody of the invention comprises a) a first antigen-binding portion that binds a first antigen (e.g., a tumor-associated antigen) and b) a second antigen-binding portion that binds a second antigen (e.g., Dotam-Pb), wherein both the first and second antigen-binding portions of the bispecific antigen-binding molecule are Fab molecules, and one of the antigen-binding portions (in some embodiments, particularly the second antigen-binding portion) is a cross-linked Fab fragment, one of the Fab molecules comprising a CH1 domain comprising a charge modification as described herein, and a CL domain comprising a charge modification as described herein. The Fab comprising the charge modification may preferably be a conventional (non-cross-linked) Fab, e.g., the antigen-binding portion that binds the first antigen, in some embodiments.

[0280] The antibody according to the present invention may further comprise a third Fab molecule that specifically binds to the first antigen. In certain embodiments, the third Fab molecule is identical to the first Fab molecule under a). In these embodiments, amino acid substitutions (charge modifications) according to the following embodiments may be made in the constant domains CL and CH1 of the first and third Fab molecules, respectively. Alternatively, amino acid substitutions according to the following embodiments may be made in the constant domains CL and CH1 of the second Fab molecule under b), rather than in the constant domains CL and CH1 of the first and third Fab molecules.

[0281] In some embodiments, in a Fab molecule comprising a light chain constant domain CL comprising a charge modification and a heavy chain constant domain CH1 comprising a charge modification, the charge modification in the light chain constant domain CL is at position 124, and optionally 123 (Kabat numbering), and the charge modification in the heavy chain constant domain CH1 is at position 147 and / or 213 (Kabat numbering).

[0282] In some embodiments, in the light chain constant domain CL, the amino acid at position 124 is independently substituted by lysine (K), arginine (R), or histidine (H) (numbering according to Kabat) (in one preferred embodiment, independently by lysine (K)), and in the heavy chain constant domain CH1, the amino acid at position 147 and / or the amino acid at position 213 are independently substituted by glutamic acid (E) or aspartic acid (D) (numbering according to the EU index of Kabat).

[0283] In another embodiment, in the light chain constant domain CL, the amino acid at position 124 is independently substituted by lysine (K), arginine (R), or histidine (H) (numbering according to Kabat) (in one preferred embodiment, independently by lysine (K) or arginine (R)), and in the heavy chain constant domain CH1, the amino acid at position 147 or the amino acid at position 213 is independently substituted by glutamic acid (E) or aspartic acid (D) (numbering according to the EU index of Kabat).

[0284] In a further embodiment, in the light chain constant domain CL, the amino acid at position 124 is independently substituted by lysine (K) or arginine (R) (numbering according to Kabat) (in one preferred embodiment, independently by lysine (K) or arginine (R)), and in the heavy chain constant domain CH1, the amino acid at position 213 is independently substituted by glutamic acid (E) or aspartic acid (D) (numbering according to the EU index of Kabat).

[0285] In a further embodiment, in the light chain constant domain CL, the amino acid at position 124 is substituted independently by lysine (K), arginine (R), or histidine (H) (in one preferred embodiment, independently by lysine (K) or arginine (R)) (Kabat numbering), and in the heavy chain constant domain CH1, the amino acid at position 147 is substituted independently by glutamic acid (E) or aspartic acid (D) (Kabat numbering).

[0286] In a further embodiment, in the light chain constant domain, the amino acid at position 124 is independently substituted by lysine (K), arginine (R), or histidine (H) (Kabat numbering) (in one preferred embodiment, independently by lysine (K) or arginine (R)), the amino acid at position 123 is independently substituted by lysine (K), arginine (R), or histidine (H) (Kabat numbering) (in one preferred embodiment, independently by lysine (K) or arginine (R)), and in the heavy chain constant domain, CH1, the amino acid at position 147 is independently substituted by glutamic acid (E) or aspartic acid (D) (Kabat numbering), and the amino acid at position 213 is independently substituted by glutamic acid (E) or aspartic acid (D) (Kabat numbering).

[0287] In a further embodiment, in the light chain constant domain CL the amino acid at position 124 is substituted by a lysine (K) (Kabat numbering), the amino acid at position 123 is substituted by an arginine (R) (Kabat numbering), and in the heavy chain constant domain CHI the amino acid at position 147 is substituted by a glutamic acid (E) (Kabat EU index numbering), and the amino acid at position 213 is substituted by a glutamic acid (E) (Kabat EU index numbering).

[0288] In a further embodiment, in the light chain constant domain CL the amino acid at position 124 is substituted by lysine (K) (Kabat numbering), the amino acid at position 123 is substituted by lysine (K) (Kabat numbering), and in the heavy chain constant domain CHI the amino acid at position 147 is substituted by glutamic acid (E) (Kabat EU index numbering), and the amino acid at position 213 is substituted by glutamic acid (E) (Kabat EU index numbering).

[0289] In a further embodiment, in the light chain constant domain CL the amino acid at position 124 is substituted by a lysine (K) (Kabat numbering), the amino acid at position 123 is substituted by an arginine (R) (Kabat numbering), and in the heavy chain constant domain CH1 the amino acid at position 147 is substituted by a glutamic acid (E) (Kabat EU index numbering), and the amino acid at position 213 is substituted by an aspartic acid (D) (Kabat EU index numbering).

[0290] In a further embodiment, in the light chain constant domain the amino acid at position 124 is substituted by lysine (K) (Kabat numbering) and the amino acid at position 123 is substituted by lysine (K) (Kabat numbering), and in the heavy chain constant domain CH1 the amino acid at position 147 is substituted by glutamic acid (E) (Kabat EU index numbering) and the amino acid at position 213 is substituted by aspartic acid (D) (Kabat EU index numbering).

[0291] In one embodiment, the antibody comprises a first heavy chain and a first light chain that specifically binds to a first antigen, and a second heavy chain and a second light chain that specifically binds to a second antigen; a) the constant domain CL of the first light chain and the constant domain CH1 of the first heavy chain comprise a charge mutation substitution as described herein; b) The light chain constant domain CL and the heavy chain constant domain CH1 of the second light chain and the second heavy chain are replaced with each other (thus forming a cross-Fab). An example of such a configuration is shown for P1AE1768.

[0292] In another embodiment, the antibody a full-length antibody that specifically binds to a first antigen and consists of two heavy chains and two light chains, wherein the two heavy chain constant domains CH1 and the two light chain constant domains CL of the full-length antibody comprise a charge modification as described herein; and and an scFab comprising a VH and CH1 domain linked to a VL and CL domain via a polypeptide linker (VH-CH1-linker-VL-CL), wherein the scFab is fused to the N-terminus of one of the heavy chains, and the scFab forms an antigen-binding site for a second antigen. An example of such a configuration is P1AE1770.

[0293] In another embodiment, the multispecific antibody is a full-length antibody (which may, for example, be bivalent with respect to the first antigen) comprising an antigen-binding site for a first antigen, wherein the two heavy chain constant domains CH1 and the two light chain constant domains CL of the full-length antibody comprise a charge modification as described herein; It comprises a full-length antibody in which the C-terminus of one of the heavy chains (e.g., the C-terminus of its CH3 domain) is linked to a first polypeptide via a polypeptide linker, and the first polypeptide associates with a second polypeptide to form a cross-Fab that includes a binding site for a second antigen.

[0294] The first polypeptide may comprise an N-terminal VL domain and a C-terminal CH1 domain. Thus, the heavy chain bearing the fusion may comprise, from N- to C-terminus, VH-CH1-hinge-CH2-CH3-linker-VL-CH1. The light chain may comprise VH-CL. An example of such a configuration is P1AE1767.

[0295] In a further embodiment, the antibody a) a full-length antibody that specifically binds to a first antigen and consists of two antibody heavy chains and two antibody light chains, wherein the CH1 domain of the heavy chain and the CL domain of the light chain comprise a charge modification as described herein; b) i) an antibody heavy chain variable domain (VH); or ii) an antibody heavy chain variable domain (VH) and an antibody heavy chain constant domain (CH1); or iii) antibody heavy chain variable domain (VH) and antibody light chain constant domain (CL) A polypeptide consisting of a polypeptide in which the N-terminus of a VH domain is fused to the C-terminus of one of the two heavy chains of the full-length antibody via a peptide linker; c) i) an antibody light chain variable domain (VL); or ii) an antibody light chain variable domain (VL) and an antibody light chain constant domain (CL); or iii) an antibody light chain variable domain (VL) and an antibody heavy chain constant domain (CH1) A polypeptide consisting of A polypeptide in which the N-terminus of the VL domain is fused to the C-terminus of the other of the two heavy chains of the full-length antibody via a peptide linker. Includes; It may also be a bispecific antibody, in which the antibody heavy chain variable domain of the peptide under (b) and the antibody light chain variable domain of the peptide under (c) together form an antigen-binding site for a second antigen. Examples of such a configuration are PRIT-213 and p1AE1766.

[0296] In some embodiments, an antibody of the invention comprises a) a first antigen-binding portion that binds a first antigen, b) a second antigen-binding portion that binds a second antigen, and c) a third antigen-binding portion that binds the first antigen, wherein the first, second, and third antigen-binding portions of the antibody are all Fab molecules, and in one of the antigen-binding portions (particularly the second antigen-binding portion), the variable domains VL and VH of the Fab light chain and Fab heavy chain, respectively, are replaced by each other; i) the amino acid substitutions according to the above embodiment are made in the constant domains CL and CH1 of the first and third Fab molecules, respectively, but not in the constant domains CL and CH1 of the second Fab molecule under b); or ii) The amino acid substitutions according to the above embodiments are made in the constant domains CL and CH1 of the second Fab molecule under b), but not in the constant domains CL and CH1 of the first and third Fab molecules. In some embodiments, the charge modifications are present in a conventional (non-swapped) Fab: thus, for example, when the second antigen-binding moiety is a cross-Fab, option (i) is preferred.

[0297] In one particular embodiment, the multivalent antibody of the invention comprises: a full-length antibody comprising a first and a second antibody heavy chain and a first and a second antibody light chain, wherein the first heavy chain and the first light chain assemble to form a Fab comprising an antigen-binding site for a first antigen (e.g., a tumor-specific antigen, e.g., CEA), and the second heavy chain and the second light chain assemble to form a cross-Fab (e.g., the second heavy chain has a VL domain in place of the VH domain and the second light chain has a VH domain in place of the VL domain) comprising an antigen-binding site for a second antigen (e.g., DOTAM-chelated Pb); either a first or a second antibody heavy chain is fused via a linker to a polypeptide comprising a CH1 and a VH domain, and said first polypeptide assembles with a second polypeptide comprising a CL and a VL, such that the first and second polypeptides assemble to form an Fab comprising an antigen-binding site for a first antigen; Including full-length antibodies in which the CH1 domain of the first heavy chain and the CL domain of the first light chain comprise a charge modification as described herein.

[0298] Additionally, the CH1 domain of the first polypeptide and the CL domain of the second polypeptide may comprise a charge modification as described herein.

[0299] The fusion can also be to the N-terminus of one of the heavy chains of a full-length antibody, and optionally to the N-terminus of the second heavy chain. An example of such an arrangement is P1AE1769.

[0300] Multispecific antibody binding to Pb-DOTAM and CEA In some embodiments, it may be preferable for the antibodies of the present invention to be multispecific, e.g., bispecific, antibodies that bind to both Pb-DOTAM and CEA. Thus, they contain an antigen-binding site for the Pb-DOTAM chelate and an antigen-binding site for CEA. In such embodiments, the antigen-binding site specific for the Pb-DOTAM chelate may be according to any of the embodiments described herein. This format may be any of the formats described herein.

[0301] Optionally, the antigen binding site that binds CEA may bind with a Kd value of 1 nM or less, 500 pM or less, 200 pM or less, or 100 pM or less for monovalent binding.

[0302] If desired, the antigen-binding site that binds to CEA may comprise at least one, two, three, four, five, or six CDRs selected from (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO: 11; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO: 12; (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO: 13; (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO: 14; (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO: 15; and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO: 16.

[0303] Optionally, the antigen-binding site that binds to CEA may comprise at least one, at least two, or all three VH CDR sequences selected from (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 11; (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 12; and (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 13. In one embodiment, the antibody comprises a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 13. In another embodiment, the antibody comprises a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 13 and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 16. In a further embodiment, the antibody comprises a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 13, a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 16, and a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 12. In a further embodiment, the antibody comprises (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 11; (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 12; and (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 13.

[0304] Optionally, the antigen-binding site that binds to CEA comprises at least one, at least two, or all three VL CDR sequences selected from (a) CDR-L1 comprising the amino acid sequence of SEQ ID NO: 14; (b) CDR-L2 comprising the amino acid sequence of SEQ ID NO: 15; and (c) CDR-L3 comprising the amino acid sequence of SEQ ID NO: 16. In one embodiment, the antibody comprises (a) CDR-L1 comprising the amino acid sequence of SEQ ID NO: 13; (b) CDR-L2 comprising the amino acid sequence of SEQ ID NO: 14; and (c) CDR-L3 comprising the amino acid sequence of SEQ ID NO: 15.

[0305] Optionally, the antigen-binding site that binds to CEA comprises: (a) a VH domain comprising at least one, at least two, or all three VH CDR sequences selected from (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO: 11, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO: 12, and (iii) CDR-H3 comprising an amino acid sequence selected from SEQ ID NO: 13; and (b) a VL domain comprising at least one, at least two, or all three VL CDRs selected from (i) CDR-L1 comprising the amino acid sequence of SEQ ID NO: 14, and (ii) CDR-L2 comprising the amino acid sequence of SEQ ID NO: 15, and (c) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 16.

[0306] In another embodiment, the antigen binding site that binds to CEA comprises (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO: 11; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO: 12; (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO: 13; (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO: 14; (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO: 15; and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO: 16.

[0307] In any of the above embodiments, the multispecific antibody may be humanized. In one embodiment, the anti-CEA antigen-binding site comprises the CDRs as in any of the above embodiments and further comprises an acceptor human framework, such as a human immunoglobulin framework or a human consensus framework.

[0308] In another embodiment, the antigen-binding site that binds to CEA comprises a heavy chain variable domain (VH) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 17. In certain embodiments, a VH sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions compared to the reference sequence, but the antigen-binding site comprising that sequence preferably retains the ability to bind to CEA with the affinity described above. In certain embodiments, a total of 1 to 10 amino acids are substituted, inserted, and / or deleted in SEQ ID NO: 17. In certain embodiments, the substitutions, insertions, or deletions are in regions outside the HVRs (i.e., FRs). Optionally, the antigen-binding site that binds to CEA comprises the VH sequence in SEQ ID NO: 17, including post-translational modifications of that sequence. In certain embodiments, the VH comprises one, two, or three CDRs selected from (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO: 11; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO: 12; and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO: 13.

[0309] In another embodiment, the antigen-binding site that binds to CEA comprises a light chain variable domain (VL) having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 18. In certain embodiments, a VL sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions compared to the reference sequence, but the antigen-binding site comprising that sequence preferably retains the ability to bind to CEA with the affinity described above. In certain embodiments, a total of 1 to 10 amino acids are substituted, inserted, and / or deleted in SEQ ID NO: 18. In certain embodiments, the substitutions, insertions, or deletions are in regions outside the HVR (i.e., the FR). Optionally, the antigen-binding site for CEA comprises the VL sequence in SEQ ID NO: 18, including post-translational modifications of that sequence. In certain embodiments, the VL comprises one, two, or three CDRs selected from (a) CDR-L1 comprising the amino acid sequence of SEQ ID NO: 14; (b) CDR-L2 comprising the amino acid sequence of SEQ ID NO: 15; and (c) CDR-L3 comprising the amino acid sequence of SEQ ID NO: 16.

[0310] In another embodiment, the antigen-binding site that binds to CEA comprises a VH according to any of the embodiments provided above and a VL according to any of the embodiments provided above. In one embodiment, the antibody comprises the VH and VL sequences of SEQ ID NO: 17 and SEQ ID NO: 18, respectively, including post-translational modifications of those sequences.

[0311] In some embodiments, the multispecific antibody can bind to the same CEA epitope as PRIT-0213 or PRIT-0214 provided herein.

[0312] Multispecific antibody binding to Pb-DOTAM and ERBB2 In some embodiments, it may be preferred that the antibodies of the present invention are multispecific, e.g., bispecific, antibodies that bind to both Pb-DOTAM and ERBB2. Thus, they comprise an antigen-binding site for the Pb-DOTAM chelate and an antigen-binding site for ERBB2. In such embodiments, the antigen-binding site specific for the Pb-DOTAM chelate may be according to any of the embodiments described herein. This format may be any of the formats described herein.

[0313] Optionally, an antigen binding site that binds to ERBB2 may bind with a Kd value of 1 nM or less, 500 pM or less, 200 pM or less, or 100 pM or less for monovalent binding.

[0314] If desired, the antigen-binding site that binds to ERBB2 may comprise at least one, two, three, four, five, or six CDRs selected from (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO: 28; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO: 29; (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO: 30; (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO: 31; (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO: 32; and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO: 33.

[0315] Optionally, the antigen-binding site that binds to ERBB2 may comprise at least one, at least two, or all three VH CDR sequences selected from (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:28; (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO:29; and (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:30. In one embodiment, the antibody comprises a CDR-H3 comprising the amino acid sequence of SEQ ID NO:30. In another embodiment, the antibody comprises a CDR-H3 comprising the amino acid sequence of SEQ ID NO:30 and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:33. In a further embodiment, the antibody comprises a CDR-H3 comprising the amino acid sequence of SEQ ID NO:30, a CDR-L3 comprising the amino acid sequence of SEQ ID NO:33, and a CDR-H2 comprising the amino acid sequence of SEQ ID NO:29. In a further embodiment, the antibody comprises (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:28; (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO:29; and (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:30.

[0316] Optionally, the antigen-binding site that binds to ERBB2 comprises at least one, at least two, or all three VL CDR sequences selected from: (a) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 31; (b) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 32; and (c) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 33. In one embodiment, the antibody comprises: (a) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 31; (b) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 32; and (c) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 33.

[0317] Optionally, the antigen-binding site that binds to ERBB2 comprises: (a) a VH domain comprising at least one, at least two, or all three VH CDR sequences selected from (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 28, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 29, and (iii) a CDR-H3 comprising an amino acid sequence selected from SEQ ID NO: 30; and (b) a VL domain comprising at least one, at least two, or all three VL CDRs selected from (i) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 31, and (ii) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 32, and (c) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 33.

[0318] In another aspect, the antigen binding site that binds to ERBB2 comprises (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO: 28; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO: 29; (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO: 30; (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO: 31; (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO: 32; and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO: 33.

[0319] In any of the above embodiments, the multispecific antibody may be humanized. In one embodiment, the anti-ERBB2 antigen-binding site comprises the CDRs as in any of the above embodiments and further comprises an acceptor human framework, e.g., a human immunoglobulin framework or a human consensus framework.

[0320] In another embodiment, an antigen-binding site that binds to ERBB2 comprises a heavy chain variable domain (VH) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 34. In certain embodiments, a VH sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions compared to the reference sequence, but an antigen-binding site comprising that sequence preferably retains the ability to bind to ERBB2 with the affinity described above. In certain embodiments, a total of 1 to 10 amino acids are substituted, inserted, and / or deleted in SEQ ID NO: 34. In certain embodiments, the substitutions, insertions, or deletions are in regions outside the HVRs (i.e., FRs). Optionally, the antigen binding site that binds to ERBB2 comprises the VH sequence in SEQ ID NO: 34, including post-translational modifications of that sequence. In certain embodiments, the VH comprises one, two, or three CDRs selected from: (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO: 28; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO: 29; and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO: 30.

[0321] In another embodiment, an antigen-binding site that binds to ERBB2 comprises a light chain variable domain (VL) having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 35. In certain embodiments, a VL sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions compared to the reference sequence, but the antigen-binding site comprising that sequence preferably retains the ability to bind to ERBB2 with the affinity described above. In certain embodiments, a total of 1 to 10 amino acids are substituted, inserted, and / or deleted in SEQ ID NO: 35. In certain embodiments, the substitutions, insertions, or deletions are in regions outside the HVRs (i.e., the FRs). Optionally, the antigen-binding site for CEA comprises the VL sequence in SEQ ID NO: 35, including post-translational modifications of that sequence. In certain embodiments, the VL comprises one, two, or three CDRs selected from: (a) CDR-L1 comprising the amino acid sequence of SEQ ID NO: 31; (b) CDR-L2 comprising the amino acid sequence of SEQ ID NO: 32; and (c) CDR-L3 comprising the amino acid sequence of SEQ ID NO: 33.

[0322] In another embodiment, the antigen binding site that binds to ERBB2 comprises a VH according to any of the embodiments provided above and a VL according to any of the embodiments provided above. In one embodiment, the antibody comprises the VH and VL sequences of SEQ ID NO: 34 and SEQ ID NO: 35, respectively, including post-translational modifications of those sequences.

[0323] In some embodiments, the multispecific antibody can bind to the same ERBB2 epitope as the P1AD9827 antibody provided herein.

[0324] Multispecific antibody binding to Pb-DOTAM and CD20 In some embodiments, it may be preferred that the antibodies of the present invention are multispecific, e.g., bispecific, antibodies that bind to both Pb-DOTAM and CD20. Thus, they comprise an antigen-binding site for the Pb-DOTAM chelate and an antigen-binding site for CD20. In such embodiments, the antigen-binding site specific for the Pb-DOTAM chelate may be according to any of the embodiments described herein. This format may be any of the formats described herein.

[0325] Optionally, the antigen-binding site that binds to CD20 may bind with a Kd value of 1 nM or less, 500 pM or less, 200 pM or less, or 100 pM or less for monovalent binding.

[0326] Optionally, the antigen-binding site that binds to CD20 may comprise at least one, two, three, four, five, or six CDRs selected from: (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO: 39; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO: 40; (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO: 41; (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO: 42; (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO: 43; and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO: 44.

[0327] Optionally, the antigen-binding site that binds to CD20 may comprise at least one, at least two, or all three VH CDR sequences selected from: (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:39; (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO:40; and (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:41. In one embodiment, the antibody comprises a CDR-H3 comprising the amino acid sequence of SEQ ID NO:41. In another embodiment, the antibody comprises a CDR-H3 comprising the amino acid sequence of SEQ ID NO:41 and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:44. In a further embodiment, the antibody comprises a CDR-H3 comprising the amino acid sequence of SEQ ID NO:41, a CDR-L3 comprising the amino acid sequence of SEQ ID NO:44, and a CDR-H2 comprising the amino acid sequence of SEQ ID NO:40. In a further embodiment, the antibody comprises (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO:39; (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO:40; and (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:41.

[0328] Optionally, the antigen-binding site that binds to CD20 comprises at least one, at least two, or all three VL CDR sequences selected from: (a) CDR-L1 comprising the amino acid sequence of SEQ ID NO: 42; (b) CDR-L2 comprising the amino acid sequence of SEQ ID NO: 43; and (c) CDR-L3 comprising the amino acid sequence of SEQ ID NO: 44. In one embodiment, the antibody comprises: (a) CDR-L1 comprising the amino acid sequence of SEQ ID NO: 42; (b) CDR-L2 comprising the amino acid sequence of SEQ ID NO: 43; and (c) CDR-L3 comprising the amino acid sequence of SEQ ID NO: 44.

[0329] Optionally, the antigen-binding site that binds to CD20 comprises: (a) a VH domain comprising at least one, at least two, or all three VH CDR sequences selected from (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 39, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 40, and (iii) a CDR-H3 comprising an amino acid sequence selected from SEQ ID NO: 41; and (b) a VL domain comprising at least one, at least two, or all three VL CDRs selected from (i) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 42, and (ii) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 43, and (c) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 44.

[0330] In another embodiment, the antigen-binding site that binds to CD20 comprises (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO: 39; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO: 40; (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO: 41; (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO: 42; (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO: 43; and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO: 44.

[0331] In any of the above embodiments, the multispecific antibody may be humanized. In one embodiment, the anti-CD20 antigen-binding site comprises the CDRs as in any of the above embodiments and further comprises an acceptor human framework, such as a human immunoglobulin framework or a human consensus framework.

[0332] In another embodiment, an antigen-binding site that binds to CD20 comprises a heavy chain variable domain (VH) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 45. In certain embodiments, a VH sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions compared to the reference sequence, but an antigen-binding site comprising that sequence preferably retains the ability to bind to CD20 with the affinity described above. In certain embodiments, a total of 1 to 10 amino acids are substituted, inserted, and / or deleted in SEQ ID NO: 45. In certain embodiments, the substitutions, insertions, or deletions are in regions outside the HVRs (i.e., FRs). Optionally, the antigen-binding site that binds to CD20 comprises the VH sequence in SEQ ID NO: 45, including post-translational modifications of that sequence. In a specific embodiment, the VH comprises one, two, or three CDRs selected from: (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO: 39; (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO: 40; and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO: 41.

[0333] In another embodiment, the antigen-binding site that binds to CD20 comprises a light chain variable domain (VL) having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 46. In certain embodiments, a VL sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions compared to the reference sequence, but the antigen-binding site comprising that sequence preferably retains the ability to bind to CD20 with the affinity described above. In certain embodiments, a total of 1 to 10 amino acids are substituted, inserted, and / or deleted in SEQ ID NO: 46. In certain embodiments, the substitutions, insertions, or deletions are in regions outside the HVRs (i.e., the FRs). Optionally, the antigen-binding site for CD20 comprises the VL sequence in SEQ ID NO: 46, including post-translational modifications of that sequence. In a specific embodiment, the VL comprises one, two, or three CDRs selected from: (a) CDR-L1 comprising the amino acid sequence of SEQ ID NO: 42; (b) CDR-L2 comprising the amino acid sequence of SEQ ID NO: 43; and (c) CDR-L3 comprising the amino acid sequence of SEQ ID NO: 44.

[0334] In another embodiment, the antigen binding site that binds to CD20 comprises a VH according to any of the embodiments provided above and a VL according to any of the embodiments provided above. In one embodiment, the antibody comprises the VH and VL sequences of SEQ ID NO: 45 and SEQ ID NO: 46, respectively, including post-translational modifications of those sequences.

[0335] In some embodiments, the multispecific antibody can bind to the same CD20 epitope as the P1AD9826 antibody provided herein.

[0336] Antibody variants In certain embodiments, amino acid sequence variants of the antibodies provided herein are contemplated. For example, it may be desirable to improve the binding affinity and / or other biological properties of the antibody. Amino acid sequence variants of antibodies can be prepared by introducing appropriate modifications into the nucleotide sequence encoding the antibody or by peptide synthesis. Such modifications include, for example, deletions from, and / or insertions into, and / or substitutions of residues within the amino acid sequence of the antibody. Any combination of deletions, insertions, and substitutions can be made to arrive at the final construct, provided that the final construct has the desired properties, for example, antigen binding.

[0337] Substitution, insertion, and deletion variants In certain embodiments, antibody variants with one or more amino acid substitutions are provided. Sites of interest for substitutional mutagenesis include HVRs (CDRs) and FRs. Conservative substitutions are shown in Table 1 under the heading of "preferred substitutions." More substantial changes are provided in Table 1 under the heading of "exemplary substitutions" and are further described below with reference to amino acid side chain classes. Amino acid substitutions can be introduced into the antibody of interest, and the products screened for desired activity, such as retained / improved antigen binding, reduced immunogenicity, or improved ADCC or CDC. TIFF0007582867000011.tif164170

[0338] Amino acids can be classified according to common side chain properties: (1) Hydrophobic: Norleucine, Met, Ala, Val, Leu, Ile; (2) Neutral hydrophilic: Cys, Ser, Thr, Asn, Gln; (3) Acidic: Asp, Glu; (4) basic: His, Lys, Arg; (5) Residues that influence chain orientation: Gly, Pro; (6) Aromatic: Trp, Tyr, Phe.

[0339] Non-conservative substitutions will involve exchanging a member of one of these classes for another class.

[0340] One type of substitutional variant involves substituting one or more hypervariable region residues of a parent antibody (e.g., a humanized or human antibody). Generally, the resulting variant selected for further testing will have a modification (e.g., an improvement) in certain biological properties (e.g., increased affinity, decreased immunogenicity) compared to the parent antibody and / or will substantially retain certain biological properties of the parent antibody. An exemplary substitutional variant is an affinity-matured antibody, which can be conveniently generated using, for example, phage display-based affinity maturation techniques such as those described herein. Briefly, one or more HVR residues are mutated, and the mutated antibodies are displayed on phage and screened for a particular biological activity (e.g., binding affinity).

[0341] Alterations (e.g., substitutions) can be made in HVRs, for example, to improve antibody affinity. Such alterations can be made in HVR "hotspots," i.e., residues encoded by codons that undergo frequent mutation during the somatic maturation process (see, e.g., Chowdfury, Methods Mol. Biol. 207:179-196 (2008)), and / or residues that contact the antigen with the resulting variant VH or VL being tested for binding affinity. Affinity maturation by constructing and then reselecting from a secondary library is described, for example, in Hoogenboom et al., Methods in Molecular Biology 178:1-37 (O'Brien et al. (eds.), Human Press, Totowa, NJ (2001)). In some affinity maturation embodiments, diversity is introduced into the variable genes selected for maturation by any of a variety of methods (e.g., error-prone PCR, chain shuffling, or oligonucleotide-directed mutagenesis). A secondary library is then generated. The library is then screened to identify any antibody variants with the desired affinity. Another method for introducing diversity involves the HVR designation approach, in which several HVR residues (e.g., 4-6 residues at a time) are randomized. HVR residues involved in antigen binding can be specifically identified using, for example, alanine scanning mutagenesis or modeling. CDR-H3 and CDR-L3 are often targeted in particular.

[0342] In certain embodiments, substitutions, insertions, or deletions may be made within one or more HVRs, as long as such changes do not substantially reduce the antibody's ability to bind to the antigen. For example, conservative changes (e.g., conservative substitutions provided herein) that do not substantially reduce binding affinity may be made in the HVRs. Such changes may, for example, be outside the antigen-contacting residues in the HVRs. In certain embodiments of the variant VH and VL sequences provided above, each HVR is unchanged or contains no more than one, two, or three amino acid substitutions.

[0343] A useful method for identifying antibody residues or regions that can be targeted for mutagenesis is called "alanine scanning mutagenesis," as described by Cunningham and Wells (1989) Science 244:1081-1085. In this method, a residue or group of target residues (e.g., charged residues such as arg, asp, his, lys, and glu) is identified and replaced with neutral or negatively charged amino acids (e.g., alanine or polyalanine) to determine whether the interaction between the antibody and antigen is affected. Further substitutions can be introduced at amino acid positions that demonstrate functional sensitivity to the initial substitution. Alternatively, or in addition, a crystal structure of an antigen-antibody complex can be used to identify contact points between the antibody and antigen. Such contact residues and neighboring residues can be targeted or removed as candidates for substitution. Variants can be screened to determine whether they contain the desired properties.

[0344] Amino acid sequence insertions include amino- and / or carboxyl-terminal fusions ranging in length from one residue to polypeptides containing 100 or more residues, as well as intrasequence insertions of single or multiple amino acid residues. An example of a terminal insertion is an antibody with an N-terminal methionyl residue. Other insertional variants of antibody molecules include the fusion to the N- or C-terminus of the antibody to an enzyme (e.g., for ADEPT) or a polypeptide that increases the serum half-life of the antibody.

[0345] Glycosylation variants In certain embodiments, the antibodies provided herein are altered to increase or decrease the extent to which the antibody is glycosylated. Addition or deletion of glycosylation sites to an antibody can be conveniently accomplished by altering the amino acid sequence such that one or more glycosylation sites are created or removed.

[0346] If the antibody contains an Fc region, the carbohydrate attached thereto can be altered. Natural antibodies produced by mammalian cells typically contain branched, biantennary oligosaccharides, generally attached by an N-linkage to Asn297 in the CH2 domain of the Fc region. See, e.g., Wright et al., TIBTECH 15:26-32 (1997). The oligosaccharides may contain various carbohydrates, such as mannose, N-acetylglucosamine (GlcNAc), galactose, and sialic acid, as well as fucose attached to GlcNAc in the "stem" of the biantennary oligosaccharide structure. In some embodiments, oligosaccharide modifications in the antibodies of the invention can be performed to generate antibody variants with improved certain properties.

[0347] In one embodiment, antibody variants are provided that have a glycosylation structure lacking fucose attached (directly or indirectly) to the Fc region. For example, the amount of fucose in such antibodies may be 1% to 80%, 1% to 65%, 5% to 65%, or 20% to 40%. The amount of fucose is determined by calculating the average amount of fucose in the glycosylation at Asn297 compared to all glycostructures (e.g., complex, hybrid, and high-mannose structures) attached to Asn297, as measured by MALDI-TOF mass spectrometry, e.g., as described in WO2008 / 077546. Asn297 refers to an asparagine residue located approximately at position 297 in the Fc region (EU numbering of Fc region residues); however, Asn297 may also be located approximately ±3 amino acids upstream or downstream of position 297, i.e., between positions 294 and 300, due to minor sequence variations in antibodies. Such fucosylation variants may have improved ADCC function. See, for example, U.S. Patent Application Publication Nos. 2003 / 0157108 (Presta, L.); 2004 / 0093621 (Kyowa Hakko Kogyo Co., Ltd.). Examples of publications relating to "defucosylated" or "fucose-deficient" antibody variants include US2003 / 0157108; WO2000 / 61739; WO2001 / 29246; US2003 / 0115614; US2002 / 0164328; US2004 / 0093621; US2004 / 0132140; US2004 / 0110704; US2004 / 0110282; US2004 / 01 09865; WO2003 / 085119; WO2003 / 084570; WO2005 / 035586; WO2005 / 035778; WO2005 / 053742; WO2002 / 031140; Okazaki et al., J. Mol. Biol. 336:1239-1249 (2004); Yamane-Ohnuki et al., Biotech. Bioeng. 87:614 (2004).Examples of cell lines capable of producing defucosylated antibodies include Lec13 CHO cells, which are deficient in protein fucosylation (Ripka et al., Arch. Biochem. Biophys. 249:533-545 (1986); U.S. Patent Application No. 2003 / 0157108A1, Presta, L; and WO2004 / 056312A1, Adams et al., especially Example 11), and knockout cell lines, such as alpha-1,6-fucosyltransferase gene, FUT8, knockout CHO cells (see, e.g., Yamane-Ohnuki et al., Biotech. Bioeng. 87:614 (2004); Kanda, Y. et al., Biotechnol. Bioeng., 94(4):680-688 (2006); and WO2003 / 085107).

[0348] Further provided are antibody variants having bisected oligosaccharides, for example, biantennary oligosaccharides attached to the Fc region of the antibody are bisected by GlcNAc. Such antibody variants may have reduced fucosylation and / or improved ADCC function. Examples of such antibody variants are described, for example, in WO 2003 / 011878 (Jean-Mairet et al.); U.S. Patent No. 6,602,684 (Umana et al.); and US 2005 / 0123546 (Umana et al.). Antibody variants having at least one galactose residue in the oligosaccharide attached to the Fc region are also provided. Such antibody variants may have improved CDC function. Such antibody variants are described, for example, in WO 1997 / 30087 (Patel et al.); WO 1998 / 58964 (Raju, S.); and WO 1999 / 22764 (Raju, S.).

[0349] It may be preferable to modify the antibody to reduce the degree of glycosylation. In some embodiments, the antibody may be aglycosylated or deglycosylated. The antibody may include a substitution at N297, for example, N297D / A.

[0350] Fc region variants In certain embodiments, Fc region variants can be generated by introducing one or more amino acid modifications into the Fc region of an antibody provided herein. The Fc region variants may comprise a human Fc region sequence (e.g., a human IgG1, IgG2, IgG3, or IgG4 Fc region) containing an amino acid modification (e.g., a substitution) at one or more amino acid positions.

[0351] In certain embodiments, the present invention contemplates antibody variants that have reduced effector function, e.g., reduced or ablated CDC, ADCC, and / or FcγR binding. In certain aspects, the present invention contemplates antibody variants that retain some, but not all, effector functions, making them desirable candidates for applications in which antibody half-life in vivo is important, but in which certain effector functions (e.g., complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC)) are unnecessary or deleterious.

[0352] In vitro and / or in vivo cytotoxicity assays can be performed to confirm reduced / depleted CDC and / or ADCC activity. For example, Fc receptor (FcR) binding assays can be performed to ensure that the antibody lacks FcγR binding (and thus likely lacks ADCC activity). The primary cells for mediating ADCC, NK cells, express only FcγRIII, whereas monocytes express FcγRI, FcγRII, and FcγRIII. FcR expression on hematopoietic cells is summarized in Table 3 on page 464 of Ravetch and Kinet, Annu. Rev. Immunol. 9:457-492 (1991). Non-limiting examples of in vitro assays to assess ADCC activity of a molecule of interest are described in U.S. Pat. No. 5,500,362 (see, e.g., Hellstrom, I. et al., Proc. Nat'l Acad. Sci. USA 83:7059-7063 (1986) and Hellstrom, I. et al., Proc. Nat'l Acad. Sci. USA 82:1499-1502 (1985)); U.S. Pat. No. 5,821,337 (see, Bruggemann, M. et al., J. Exp. Med. 166:1351-1361 (1987)). Alternatively, non-radioactive assay methods may be used (see, e.g., ACTI™ Non-Radioactive Cytotoxicity Assay for Flow Cytometry (CellTechnology, Inc. Mountain View, CA); and CytoTox 96® Non-Radioactive Cytotoxicity Assay (Promega, Madison, WI)). Useful effector cells for such assays include peripheral blood mononuclear cells (PBMCs) and natural killer (NK) cells. Alternatively, or additionally, ADCC activity of the molecule of interest can be assessed in vivo, e.g., in an animal model such as that disclosed in Clynes et al., Proc. Nat'l Acad. Sci. USA 95:652-656. A C1q binding assay may also be performed to confirm that the antibody is unable to bind C1q and therefore lacks CDC activity.See, for example, the C1q and C3c binding ELISAs described in WO2006 / 029879 and WO2005 / 100402. To assess complement activation, a CDC assay may be performed (see, for example, Gazzano-Santoro et al., J. Immunol. Methods 202:163 (1996); Cragg, MS et al., Blood 101:1045-1052 (2003); and Cragg, MS and MJ Glennie, Blood 103:2738-2743 (2004)). Determination of FcRn binding and in vivo clearance / half-life can also be performed using methods known in the art (see, e.g., Petkova, SB et al., Int'l. Immunol. 18(12):1759-1769 (2006); WO2013 / 120929A1).

[0353] Antibodies with reduced effector function include those with substitutions of one or more of Fc region residues 238, 265, 269, 270, 297, 327, and 329 (U.S. Patent No. 6,737,056), e.g., P329G. Such Fc variants include Fc variants with substitutions at two or more of amino acid positions 265, 269, 270, 297, and 327, including the so-called "DANA" Fc variant with substitutions of residues 265 and 297 to alanine (U.S. Patent No. 7,332,581).

[0354] In certain embodiments, the antibody variant comprises an Fc region having one or more amino acid substitutions that attenuate FcγR binding, e.g., substitutions at positions 234 and 235 of the Fc region (EU numbering of residues). In one embodiment, the substitutions are L234A and L235A (LALA). In certain embodiments, the antibody variant further comprises D265A and / or P329G in an Fc region derived from a human IgG1 Fc region. In one embodiment, the substitutions are L234A, L235A, and P329G (LALA-PG) in an Fc region derived from a human IgG1 Fc region (see, e.g., WO2012 / 130831). In another embodiment, the substitutions are L234A, L235A, and D265A (LALA-DA) in an Fc region derived from a human IgG1 Fc region.

[0355] In other embodiments, it may be possible to use IgG subtypes with reduced effector function, such as IgG4 or IgG2.

[0356] Certain antibody variants have been described with improved or diminished binding to FcRs (see, e.g., U.S. Pat. No. 6,737,056; WO 2004 / 056312; and Shields et al., J. Biol. Chem. 9(2):6591-6604 (2001)).

[0357] In some embodiments, alterations are made in the Fc region that result in altered (i.e., improved or attenuated, preferably attenuated) C1q binding and / or complement dependent cytotoxicity (CDC), e.g., as described in U.S. Pat. No. 6,194,551, WO 99 / 51642, and Idusogie et al., J. Immunol. 164:4178-4184 (2000).

[0358] In some embodiments, FcRn binding may be reduced, e.g., to have a shorter half-life. In other embodiments, FcRn binding may be normal. For example, in some embodiments, normal FcRn binding can be used in methods that include a clearing agent.

[0359] In certain embodiments, the antibody variant comprises an Fc region with one or more amino acid substitutions that reduce FcRn binding, e.g., substitutions at positions 253 and / or 310 and / or 435 (EU numbering of residues) of the Fc region. In certain embodiments, the antibody variant comprises an Fc region with amino acid substitutions at positions 253, 310, and 435. In one embodiment, the substitutions are I253A, H310A, and H435A in the Fc region derived from a human IgG1 Fc region. See, e.g., Grevys, A. et al., J. Immunol. 194 (2015) 5497-5508.

[0360] In certain aspects, the antibody variants comprise an Fc region having one or more amino acid substitutions that reduce FcRn binding, for example, substitutions at positions 310 and / or 433 and / or 436 (EU numbering of residues) of the Fc region. In certain aspects, the antibody variants comprise an Fc region having amino acid substitutions at positions 310, 433, and 436. In one aspect, the substitutions are H310A, H433A, and Y436A in the Fc region derived from a human IgG1 Fc region (see, e.g., WO2014 / 177460A1). For example, in some embodiments, normal FcRn binding can be used.

[0361] See also Duncan & Winter, Nature 322:738-40 (1988); U.S. Patent No. 5,648,260; U.S. Patent No. 5,624,821; and WO 94 / 29351 for other examples of Fc region variants.

[0362] The C-terminus of the heavy chain of the antibody reported herein may be a complete C-terminus with the amino acid residue PGK. The C-terminus of the heavy chain may also be a truncated C-terminus in which one or two C-terminal amino acid residues are removed. In one preferred embodiment, the C-terminus of the heavy chain is a truncated C-terminal PG.

[0363] In one aspect of all embodiments reported herein, an antibody comprising a heavy chain comprising a C-terminal CH3 domain as specified herein comprises a C-terminal glycine residue (G446, numbering according to the EU index of amino acid positions), which is still expressly encompassed with the term "full-length antibody" or "full-length heavy chain" as used herein.

[0364] antibody derivative In certain embodiments, the antibodies provided herein can be further modified to contain additional nonproteinaceous moieties that are known and readily available in the art. Suitable moieties for derivatization of antibodies include, but are not limited to, water-soluble polymers. Non-limiting examples of water-soluble polymers include, but are not limited to, polyethylene glycol (PEG), ethylene glycol / propylene glycol copolymers, carboxymethylcellulose, dextran, polyvinyl alcohol, polyvinylpyrrolidone, poly-1,3-dioxolane, poly-1,3,6-trioxane, ethylene / maleic anhydride copolymers, polyamino acids (homopolymers or random copolymers), and dextran or poly(n-vinylpyrrolidone) polyethylene glycol, propropylene glycol homopolymers, prolypropylene oxide / ethylene oxide copolymers, polyoxyethylated polyols (e.g., glycerol), polyvinyl alcohol, and mixtures thereof. Polyethylene glycol propionaldehyde may have manufacturing advantages due to its stability in water. The polymer may be of any molecular weight and may be branched or unbranched. The number of polymers attached to the antibody may vary, and if more than one polymer is attached, they may be the same or different molecules. In general, the number and / or type of polymers used for derivatization can be determined based on considerations such as, but not limited to, the specific properties or functions of the antibody to be improved, whether the antibody derivative will be used in therapy under specified conditions, etc.

[0365] In another embodiment, a conjugate of an antibody and a nonproteinaceous moiety that can be selectively heated by exposure to radiation is provided. In one embodiment, the nonproteinaceous moiety is a carbon nanotube (Kam et al., Proc. Natl. Acad. Sci. USA 102:11600-11605 (2005)). The radiation can be of any wavelength, including but not limited to, a wavelength that is not harmful to normal cells but heats the nonproteinaceous moiety to a temperature that kills cells proximate to the antibody-nonproteinaceous moiety.

[0366] Recombinant methods and compositions Antibodies can be produced using recombinant methods and compositions, such as those described in U.S. Patent No. 4,816,567. In one embodiment, an isolated nucleic acid encoding an antibody described herein is provided. Such a nucleic acid may encode an amino acid sequence comprising the VL of the antibody and / or an amino acid sequence comprising the VH of the antibody (e.g., the light chain and / or heavy chain of the antibody). In a further embodiment, one or more vectors (e.g., expression vectors) comprising such nucleic acids are provided. In a further embodiment, a host cell comprising such nucleic acids is provided. In one such embodiment, the host cell comprises (e.g., has been transformed into) (1) a vector comprising a nucleic acid encoding an amino acid sequence comprising the VL of the antibody and an amino acid sequence comprising the VH of the antibody, or (2) a first vector comprising a nucleic acid encoding an amino acid sequence comprising the VL of the antibody and a second vector comprising a nucleic acid encoding an amino acid sequence comprising the VH of the antibody.

[0367] In the case of multispecific antibodies, nucleic acids encoding each of the heavy and light chain components of a particular antibody format can be provided. A vector or set of vectors containing such nucleic acids is also provided.

[0368] In one embodiment, the host cell is a eukaryotic cell, such as a Chinese hamster ovary (CHO) cell or a lymphoid cell (e.g., a Y0, NS0, Sp20 cell). In one embodiment, a method of producing an antibody according to the invention is provided, comprising culturing a host cell containing nucleic acid encoding an antibody as provided above under conditions suitable for expression of the antibody, and, if desired, recovering the antibody from the host cell (or host cell culture medium).

[0369] For recombinant production of an antibody, nucleic acid encoding the antibody, e.g., as described above, is isolated and inserted into one or more vectors for further cloning and / or expression in host cells. Such nucleic acids can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes capable of binding specifically to genes encoding the antibody heavy and light chains).

[0370] Suitable host cells for cloning or expressing antibody-encoding vectors include the prokaryotic or eukaryotic cells described herein. For example, antibodies can be produced in bacteria, particularly if glycosylation and Fc effector functions are not required. For expression of antibody fragments and polypeptides in bacteria, see, e.g., U.S. Patent Nos. 5,648,237, 5,789,199, and 5,840,523 (see also Charlton, Methods in Molecular Biology, Vol. 248 (BKC Lo (ed.), Humana Press, Totowa, NJ, 2003, pp. 245-254), which describes the expression of antibody fragments in E. coli). After expression, the antibody can be isolated from the bacterial cell paste in a soluble fraction and further purified.

[0371] In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or yeast, including fungal and yeast strains in which the glycosylation pathway has been "humanized," resulting in the production of antibodies with partially or fully human glycosylation patterns, are suitable cloning or expression hosts for antibody-encoding vectors. See Gerngross, Nat. Biotech. 22:1409-1414 (2004), and Li et al., Nat. Biotech. 24:210-215 (2006).

[0372] Suitable host cells for the expression of glycosylated antibodies are also derived from multicellular organisms (invertebrates and vertebrates). Examples of invertebrate cells include plants and insect cells. In particular, several baculovirus strains have been identified that can be used with insect cells for transfection of Spodoptera frugiperda cells.

[0373] Plant cell cultures can also be used as hosts. See, e.g., U.S. Patent Nos. 5,959,177, 6,040,498, 6,420,548, 7,125,978, and 6,417,429 (which describe PLANTIBODIES™ technology for producing antibodies in transgenic plants).

[0374] Vertebrate cells may also be used as hosts. For example, mammalian cell lines adapted to grow in suspension may be useful. Other examples of useful mammalian host cell lines include the SV40-transformed monkey kidney CV1 cell line (COS-7); human embryonic kidney cell lines (e.g., 293 or 293 cells described in Graham et al., J. Gen Virol. 36:59 (1977)); baby hamster kidney cells (BHK); mouse Sertoli cells (e.g., TM4 cells described in Mather, Biol. Reprod. 23:243-251 (1980)); monkey kidney cells (CV1); African green monkey kidney cells (VERO-76); human cervical carcinoma cells (HELA); canine kidney cells (MDCK); buffalo rat liver cells (BRL3A); human lung cells (W138); human liver cells (HepG2); mouse mammary tumor (MMT060562); e.g., Mather et al., Annals Other useful mammalian host cell lines include TRI cells, described in NYAcad. Sci. 383:44-68 (1982); MRC5 cells; and FS4 cells. - Examples include Chinese hamster ovary (CHO) cells, including CHO cells (Urlaub et al., Proc. Natl. Acad. Sci. USA 77:4216 (1980)); and myeloma cell lines such as Y0, NS0, and Sp2 / 0. For a review of certain mammalian host cell lines suitable for antibody production, see, e.g., Yazaki and Wu, Methods in Molecular Biology, Vol. 248 (BKC Lo (eds.), Humana Press, Totowa, NJ), pp. 255-268 (2003).

[0375] Assay The antibodies provided herein can be identified, screened, or characterized for their physical / chemical properties and / or biological activity by a variety of assays known in the art.

[0376] Binding and other assays In one embodiment, the antibodies of the invention are tested for their antigen binding activity by known methods, such as, for example, ELISA, Western blot, etc.

[0377] In another aspect, a competition assay can be used to identify antibodies that compete with, for example, PRIT-0213 or PRIT-0214 for binding to Pb-DOTAM or CEA. In certain embodiments, such competing antibodies bind to the same epitope (e.g., a linear or conformational epitope) to which PRIT-0213 or PRIT-0214 binds. Detailed exemplary methods for mapping antibody-binding epitopes are provided in Morris (1996), "Epitope Mapping Protocols," Methods in Molecular Biology, vol. 66 (Humana Press, Totowa, NJ).

[0378] In an exemplary competitive assay, immobilized antigen is incubated in a solution containing a first labeled antibody that binds to the antigen (e.g., PRIT-0213 and PRIT-0214) and a second unlabeled antibody to be tested for its ability to compete with the first antibody for binding to the antigen. The second antibody may be present in the hybridoma supernatant. As a control, the immobilized antigen is incubated in a solution containing the first labeled antibody but not the second unlabeled antibody. After incubation under conditions that allow binding of the first antibody to the antigen, excess unbound antibody is removed and the amount of label bound to the immobilized antigen is measured. A substantial decrease in the amount of label bound to the immobilized antigen in the test sample compared to the control sample indicates that the second antibody competes with the first antibody for binding to the antigen. See Harlow and Lane (1988) Antibodies: A Laboratory Manual ch. 14 (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY).

[0379] antibody affinity In certain embodiments, the antibodies provided herein have a dissociation constant (Kd) of 1 nM or less, 500 pM or less, 200 pM or less, 100 pM or less, 50 pM or less, 20 pM or less, 10 pM or less, 5 pM or less, or 1 pM or less, or as otherwise described herein.

[0380] In one embodiment, Kd is measured by radiolabeled antigen binding assay (RIA). In one embodiment, the RIA is performed using a Fab version of the antibody of interest and its antigen. For example, the lytic binding affinity of the Fab for the antigen is determined by binding the Fab to the antigen at a minimum concentration of ( 125 I) After equilibration with labeled antigen, the bound antigen is measured using a plate coated with an anti-Fab antibody to capture the antigen (see, e.g., Chen et al., J. Mol. Biol. 293:865-881 (1999)). To establish the conditions for the assay, MICROTITER® multiwell plates (Thermo Scientific) are coated overnight with 5 μg / ml of capture anti-Fab antibody (Cappel Labs) in 50 mM sodium carbonate (pH 9.6), and then blocked with 2% (w / v) bovine serum albumin in PBS for 2-5 hours at room temperature (approximately 23°C). In non-adsorbent plates (Nunc #269620), 100 pM or 26 pM [ 125[I]-antigen is mixed with serial dilutions of the Fab of interest (e.g., consistent with the evaluation of the anti-VEGF antibody, Fab-12, in Presta et al., Cancer Res. 57:4593-4599 (1997)). The Fab of interest is then incubated overnight; however, incubation may be continued for a longer period (e.g., approximately 65 hours) to ensure equilibrium is reached. The mixture is then transferred to a capture plate for incubation at room temperature (e.g., for 1 hour). The solution is then removed, and the plate is washed eight times with 0.1% polysorbate 20 (TWEEN-20®) in PBS. When the plate has dried, 150 μL / well of scintillant (MICROSCINT-20™; Packard) is added, and the plate is counted for 10 minutes on a TOPCOUNT™ gamma counter (Packard). The concentration of each Fab that gives less than or equal to 20% of maximum binding is selected for use in the competitive binding assay.

[0381] According to another embodiment, Kd is measured using a BIACORE® surface plasmon resonance assay. For example, an assay using a BIACORE®-2000 or BIACORE®-3000 (BIAcore, Inc., Piscataway, NJ) is performed at 25°C using an immobilized antigen CM5 chip of approximately 10 response units (RU). In one embodiment, a carboxymethylated dextran biosensor chip (CM5, BIACORE, Inc.) is activated with N-ethyl-N'-(3-dimethylaminopropyl)-carbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (NHS) according to the supplier's instructions. To achieve approximately 10 response units (RU) of coupled protein, the antigen is diluted to 5 μg / ml (approximately 0.2 μM) using 10 mM sodium acetate, pH 4.8, before injection at a flow rate of 5 μl / min. After antigen injection, 1 M ethanolamine is injected to block unreacted groups. For kinetic measurements, two-fold serial dilutions of Fab (0.78 nM to 500 nM) are injected in PBS containing 0.05% polysorbate 20 (TWEEN-20™) surfactant (PBST) at a flow rate of approximately 25 μl / min at 25° C. By simultaneously fitting the association and dissociation sensorgrams, the binding rate (k) is calculated using a simple one-to-one Langmuir binding model (BIACORE® Evaluation Software version 3.2). on ) and dissociation rate (k off The equilibrium dissociation constant (Kd) is calculated by k off / k on See, for example, Chen et al., J. Mol. Biol. 293:865-881 (1999). The association rate is calculated as a ratio of 10 6 M -1 s -1above 100°C, the association rate can be determined by using a fluorescence quenching technique to measure the increase or decrease in fluorescence emission intensity (excitation = 295 nm; emission = 340 nxm, 16 nm bandpass) of 20 nM anti-antigen antibody (Fab form) in PBS, pH 7.2 at 25°C in the presence of increasing concentrations of antigen, as measured in a spectrophotometer, such as a spectrophotometer equipped with a flow stop (Aviv Instruments) or an 8000 series SLM-AMINCO™ spectrophotometer (ThermoSpectronic) containing a stirred cuvette.

[0382] In another embodiment, Kd is measured using a solution equilibrium titration (SET) assay. In this assay, a test antibody is typically applied at a fixed concentration and mixed with serial dilutions of the test antigen. After incubation to establish equilibrium, a portion of the free antibody is captured on an antigen-coated surface and detected with a labeled / tagged anti-species antibody, typically using electrochemiluminescence (e.g., as described in Haenel et al., Analytical Biochemistry 339 (2005) pp. 182-184).

[0383] For example, in one embodiment, a 384-well streptavidin plate (Nunc, Microcoat #11974998001) is incubated overnight at 4°C with 25 μl / well of antigen-biotin-isomer mixture in PBS buffer at a concentration of 20 ng / ml. For equilibration of antibody samples with free antigen, 0.01 nM to 1 nM antibody is titrated with the relevant antigen in dilution steps of 1:3, 1:2, or 1:1.7, starting with antigen concentrations of 2500 nM, 500 nM, or 100 nM. Samples are incubated overnight at 4°C in sealed REMP storage polypropylene microplates (Brooks). After overnight incubation, the streptavidin plate is washed three times with 90 μl of PBST per well. 15 μl of each sample from the equilibrated plate is transferred to the assay plate and incubated for 15 min at RT, followed by three washing steps with 90 μl of PBST buffer. Detection is carried out by adding 25 μl of goat anti-human IgG antibody-POD conjugate (Jackson, 109-036-088, 1:4000 in OSEP) followed by six washing steps with 90 μl of PBST buffer. 25 μl of TMB substrate (Roche Diagnostics GmbH, Cat. No. 11835033001) is added to each well. Measurements are taken at 370 / 492 nm on a Safire2 reader (Tecan).

[0384] In another embodiment, Kd is measured using a KinExA (Kinetic Exclusion A) assay. Typically, antigen is titrated into a fixed concentration of antibody binding sites, and the sample is allowed to equilibrate before passing through a flow cell where free antibody binding sites are captured on antigen-coated beads while the antigen-saturated antibody complex is washed away. The antibody captured on the beads is then detected with a labeled, e.g., fluorescently labeled, anti-species antibody (Bee et al., PloS One, 2012;7(4):e36261). For example, in one embodiment, KinExA experiments are performed at room temperature (RT) using PBS pH 7.4 as the running buffer. Samples are prepared in the running buffer ("sample buffer") supplemented with 1 mg / ml BSA. A flow rate of 0.25 ml / min is used. A fixed amount of antibody with a binding site concentration of 5 pM is titrated with antigen by two-fold serial dilutions starting at 100 pM (concentration range: 0.049 pM to 100 pM). One sample of antibody without antigen serves as 100% signal (i.e., no inhibition). The antigen-antibody complex is incubated at RT for at least 24 hours to reach equilibrium. The equilibrated mixture is then passed through a column of antigen-bound beads in the KinExA system in a volume of 5 ml, allowing unbound antibody to be captured by the beads without disturbing the solution equilibrium. The captured antibody is detected using an anti-human Fc fragment-specific secondary antibody conjugated to 250 ng / ml Dylight 650(C) in sample buffer. Each sample is measured twice for all equilibration experiments. KD is obtained from nonlinear regression analysis of the data using a one-site homogeneous binding model included in the KinExA software (version 4.0.11) using the "standard analysis" method.

[0385] Therapeutic methods and compositions As discussed above, the multispecific antibody according to the present invention is suitable for any treatment where it is desired to deliver a radionuclide to a target.Therefore, the present invention provides a targeted antibody, such as the multispecific or bispecific antibody described herein, for use in a treatment method.More specifically, the targeted antibody (e.g., multispecific or bispecific antibody) described herein is provided for use in a method of pretargeted radioimmunotherapy.In such an embodiment, the chelated Pb is preferably 212 It is Pb.

[0386] As mentioned above, the treatment may be for any condition treatable by cytotoxic activity targeted to diseased cells in a patient. The treatment is preferably for tumors or cancer. However, the applicability of the present invention is not limited to tumors and cancer. For example, the treatment may be for viral infection or infection by another pathogenic organism, such as a prokaryote. Optionally, targeting may be T cells for the treatment of T cell-induced autoimmune diseases or T cell-mediated hematological cancers. Thus, the conditions to be treated may include viral infections such as HIV, rabies, EBV, and Kaposi's sarcoma-associated herpesvirus, as well as autoimmune diseases such as multiple sclerosis and graft-versus-host disease.

[0387] As used herein, the term "cancer" includes lymphoma, lymphocytic leukemia, lung cancer, non-small cell lung (NSCL) cancer, bronchioloalveolar cell lung cancer, bone cancer, pancreatic cancer, skin cancer, head and neck cancer, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, gastric cancer, colon cancer, breast cancer, uterine cancer, fallot-piercing canal cancer, endometrial cancer, cervical cancer, vaginal cancer, vulvar cancer, Hodgkin's disease, esophageal cancer, small intestine cancer, cancer of the endocrine system, thyroid cancer, This includes both solid and hematological cancers such as thyroid cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, urethral cancer, penile cancer, prostate cancer, bladder cancer, cancer of the kidney or ureter, renal cell carcinoma, renal pelvis carcinoma, mesothelioma, hepatocellular carcinoma, bile duct cancer, neoplasms of the central nervous system (CNS), spinal tumors, brain stem glioma, glioblastoma multiforme, astrocytoma, schwannoma, ependymoma, medulloblastoma, meningioma, squamous cell carcinoma, pituitary adenoma and Ewing's sarcoma, including refractory forms of any of the above cancers, or a combination of one or more of the above cancers.

[0388] Methods for targeting radioisotopes to tissues or organs for therapy include: i) administering to a subject a multispecific or bispecific antibody described herein, wherein the antibody binds to a target antigen and localizes to the surface of a cell expressing the target antigen; and ii) subsequently administering to the individual a Pb radionuclide chelated with DOTAM or a functional variant thereof, wherein the Pb radionuclide binds to the cell surface-localized antibody. may include:

[0389] Optionally, a removing agent / blocking agent is administered between steps (i) and (ii). The removing agent / blocking agent can bind to the antigen binding site specific for Pb-DOTAM and block subsequent binding by the chelated radionuclide. The removing agent may comprise DOTAM or a functional variant thereof chelated with a metal ion and conjugated to a removing moiety.

[0390] Examples of suitable removal moieties may include moieties that increase the size and / or hydrodynamic radius of the molecule, inhibiting the molecule's ability to access tumors without interfering with its ability to bind to antibodies in the circulation. Exemplary moieties include hydrophilic polymers. The moiety may be, for example, a polymer or copolymer of dextran, dextrin, PEG, polysialic acid (PSA), hyaluronic acid, hydroxyethyl starch (HES), or poly(2-ethyl-2-oxazoline) (PEOZ). In other embodiments, the moiety may be an unstructured peptide or protein, such as an XTEN polypeptide (an unstructured hydrophilic protein polymer), homoamino acid polymer (HAP), proline-alanine-serine polymer (PAS), elastin-like peptide (ELP), or gelatin-like protein (GLK). Suitable molecular weights for the polymer may be, for example, at least 50 kDa, e.g., in the range of 50 kDa to 2000 kDa. For example, the molecular weight may be between 200 and 800 kDa, optionally greater than 300, 350, 400 or 450 kDa, optionally less than 700, 650, 600 or 550 kDa, optionally about 500 kDa.

[0391] In some embodiments, the clearing agent may be DOTAM or a functional variant thereof (chelated to a metal ion), for example, conjugated to dextran or a derivative thereof, as further described below.

[0392] In some embodiments, the weight ratio of antibody to clearing agent may range from 1:1, 2:1, 3:1, or 4:1 to 20:1, 15:1, 10:1, 8:1, 6:1, or 5:1, e.g., 1:1 to 20:1, 1:1 to 10:1, 2:1 to 8:1, or 2:1 to 6:1.

[0393] In some embodiments, the clearing agent may be administered several hours or days after treatment with the multispecific antibody. In some embodiments, it may be preferable to administer the clearing agent at least 2, 4, 6, 8, 10, 12, 16, 18, 22, or 24 hours, or at least 1, 2, 3, 4, 5, 6, or 7 days after the multispecific antibody. In some embodiments, it may be preferable to administer the clearing agent within 14 days, e.g., within 10, 9, 8, 7, 6, 5, 4, 3, or 2 days, after the antibody.

[0394] Optionally, the clearing agent is administered between 4-10 days, 4-7 days, 2-7 days, or 2-4 days after the multispecific antibody.

[0395] In some embodiments, the Pb radionuclide is administered minutes, hours, or days after the removal agent. In some embodiments, it may be preferable to administer the Pb radionuclide at least 30 minutes after the removal agent, and optionally within 48 hours, 24 hours, 8 hours, or 4 hours of administration of the removal agent. In some embodiments, the Pb radionuclide may be administered the day after administration of the removal agent.

[0396] In some embodiments, the antibodies described herein can be administered as part of a combination therapy, for example, they can be administered with one or more chemotherapeutic agents: the chemotherapeutic agents and antibodies can be administered simultaneously or sequentially in either order.

[0397] In some embodiments, the antibodies described herein may also or alternatively be administered with a radiosensitizer. The radiosensitizer and antibody may be administered simultaneously or sequentially in either order.

[0398] Pharmaceutical preparations Pharmaceutical formulations of the anti-Pb-DOTAM antibodies described herein, e.g., multispecific or bispecific antibodies, are prepared by combining such antibodies having the desired purity, in the form of a lyophilized formulation or aqueous solution, with one or more optional pharmaceutically acceptable carriers (Remington's Pharmaceutical Sciences, 16th ed., Osol, A. (ed.) (1980)). Pharmaceutically acceptable carriers are generally non-toxic to recipients at the dosages and concentrations employed, and include, but are not limited to, buffers such as phosphate, citric acid, and other organic acids; antioxidants such as ascorbic acid and methionine; preservatives (octadecyldimethylbenzylammonium chloride; hexamethonium chloride; benzalkonium chloride; phenol, butyl, or benzyl alcohol; parabens such as methyl or propylparaben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; Examples of suitable pharmaceutically acceptable carriers include peptides; proteins such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates, including glucose, mannose, or dextrin; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose, or sorbitol; salt-forming counterions such as sodium; metal complexes (e.g., Zn-protein complexes); and / or non-ionic surfactants such as polyethylene glycol (PEG). Exemplary pharmaceutically acceptable carriers herein further include interstitial drug dispersants, such as soluble neutral active hyaluronidase glycoproteins (sHASEGPs), e.g., human soluble PH-20 hyaluronidase glycoproteins, such as rHuPH20 (HYLENEX®, Baxter International, Inc.). Certain exemplary sHASEGPs, including rHuPH20, and methods of use are described in U.S. Patent Application Publication Nos. 2005 / 0260186 and 2006 / 0104968.In one embodiment, the sHASEGP is combined with one or more additional glycosaminoglycanases, such as chondroitinases.

[0399] Exemplary lyophilized antibody formulations are described in U.S. Patent No. 6,267,958. Aqueous antibody formulations include those described in U.S. Patent No. 6,171,586 and WO2006 / 044908, the latter formulations comprising a histidine-acetate buffer.

[0400] The formulations herein may also contain more than one active ingredient as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other. For example, it may be desirable to additionally provide a chemotherapeutic agent and / or a radiosensitizer, as discussed above. Such active ingredients are preferably present together in amounts that are effective for the intended purpose.

[0401] The active ingredient can be entrapped in microcapsules, for example, prepared by droplet formation technology or by interfacial polymerization, for example, in colloidal drug delivery systems (e.g., liposomes, albumin microspheres, microemulsions, nanoparticles and nanocapsules) or macroemulsions, hydroxymethylcellulose or gelatin microcapsules and poly-(methyl methacrylate) microcapsules, respectively. Such techniques are disclosed in Remington's Pharmaceutical Sciences, 16th edition, Osol, A. (ed.) (1980).

[0402] Sustained-release preparations can be prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, e.g., films, or microcapsules.

[0403] Preparations to be used for in vivo administration are generally sterile. Sterility is readily accomplished, for example, by filtration through sterile filtration membranes.

[0404] Methods and Compositions for Diagnostics and Detection The present invention further provides a targeted antibody, e.g., a multispecific antibody as described herein, for use in a diagnostic method performed on a subject. The diagnostic method may be, for example, a method of pretargeted radioimmunoimaging to diagnose a subject suspected of having a proliferative disease or an infectious disease. In such an embodiment, the chelated Pb is preferably 203 It is Pb.

[0405] Methods for targeting radioisotopes to tissues or organs for imaging include: i) administering to a subject a multispecific or bispecific antibody described herein, wherein the antibody binds to a target antigen and localizes to the surface of a cell expressing the target antigen; and ii) subsequently administering to the individual a Pb radionuclide chelated with DOTAM or a functional variant thereof, wherein the Pb radionuclide binds to the antibody localized on the surface of the cell. may include:

[0406] In another embodiment, the multispecific or bispecific antibodies described herein may be conjugated to a chelated Pb radionuclide at the time of administration.

[0407] Optionally, the method iii) Imaging tissues or organs in which Pb radionuclides chelated with DOTAM or its functional variants are localized or expected to be localized. It may further include:

[0408] In another embodiment, the methods of the present invention comprise the step of: i) a multispecific or bispecific antibody as described herein that binds to a target antigen and localizes to the surface of a cell that expresses the target antigen; and ii) A Pb radionuclide chelated with DOTAM or a functional variant thereof, wherein the Pb radionuclide is bound to an antibody localized on the surface of a cell. The method may include imaging a tissue or organ of interest in which the antibody has previously been administered to the individual.

[0409] Optionally, a clearing / blocking agent is administered between steps (i) and (ii). The clearing agent, the administration regimen for the clearing agent, and the weight ratio of antibody to clearing agent may be as described above.

[0410] The target antigen may be any target antigen discussed herein. In some embodiments, the target antigen may be a tumor-specific antigen as discussed above, and the imaging may be a method of imaging a tumor or multiple tumors. The individual may be known to have or suspected of having a tumor.

[0411] For example, the method may be used to treat lung cancer, non-small cell lung (NSCL) cancer, bronchioloalveolar cell lung cancer, bone cancer, pancreatic cancer, skin cancer, head and neck cancer, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, gastric cancer, colon cancer, breast cancer, uterine cancer, fallot-piercing canal cancer, endometrial cancer, cervical cancer, vaginal cancer, vulvar cancer, Hodgkin's disease, esophageal cancer, small intestine cancer, cancer of the endocrine system, thyroid cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, urethral cancer The method may also be a method of imaging tumors in an individual having or suspected of having penile cancer, prostate cancer, bladder cancer, cancer of the kidney or ureter, renal cell carcinoma, renal pelvis carcinoma, mesothelioma, hepatocellular carcinoma, bile duct cancer, neoplasms of the central nervous system (CNS), spinal tumors, brain stem glioma, glioblastoma multiforme, astrocytoma, schwannoma, ependymoma, medulloblastoma, meningioma, squamous cell carcinoma, pituitary adenoma, and Ewing's sarcoma (including refractory forms of any of the above cancers, or a combination of one or more of the above cancers).

[0412] Remover In a further aspect of the present invention, the inventors have developed novel clearing agents, which may be used in any of the diagnostic, imaging or therapeutic methods as described herein.

[0413] In one aspect, the present invention relates to a dextran-based clearing agent comprising dextran or a derivative thereof conjugated to M-DOTAM or a functional variant thereof.

[0414] In some embodiments, the clearing agent has the following formula: Dextran-(Linker-(M-DOTAM)) x [In the formula, Dextran is dextran or a derivative thereof; The linker is a connecting moiety; M-DOTAM is DOTAM or a functional variant thereof incorporating a metal ion; and x ≥ 1] It may also be a compound of the formula:

[0415] In some embodiments, the linking moiety is a urea group (—NH—C(O)—NH—), a substituted urea group (—NR x -C(O)-NR x - [wherein one or both R x group is not H), thiourea group (-NH-C(S)-NH-), substituted thiourea group (-NR x -C(S)-NR x - [wherein one or both R x group is not H), amide group (-C(O)-NH-), substituted amide group (-C(O)-NR x -[wherein, R x is not H), thioamide group (-C(S)-NH-), substituted amide group (-C(S)-NR x -[wherein, R xis not H), a triazole group, or a substituted triazole. In these embodiments, the linking moiety may optionally include one or more additional divalent functional groups, such as alkylene groups, arylene groups, heteroarylene groups, alkylene groups, and heteroaralkylene groups. The substituent R x is not particularly limited. In certain embodiments, R x When present, is selected from C1-C6 alkyl, C5-C12 aryl, C5-C12 heteroaryl, and halo groups.

[0416] In certain embodiments, the linking moiety may be or may include one or more divalent functional groups selected from a urea group, a thiourea group, an amide group, a thioamide group, or a triazole group.

[0417] In a preferred embodiment, the linking moiety comprises a divalent thiourea or divalent thioamide functional group.

[0418] In some embodiments, the linking moiety comprises a divalent thiourea functional group and an optionally substituted arylene group. In some embodiments, the linking moiety comprises a divalent thiourea functional group, an optionally substituted arylene group, and an optionally substituted alkylene group. In certain embodiments, the linking moiety comprises a divalent thiourea functional group covalently bonded to an optionally substituted arylene group through one of its nitrogen atoms. In further embodiments, the linking moiety comprises a divalent thiourea functional group covalently bonded to an optionally substituted arylene group through one of its nitrogen atoms, and the optionally substituted arylene group is covalently bonded to an optionally substituted alkylene group. In preferred embodiments, the arylene group is unsubstituted. In certain embodiments, the arylene group is a phenylene group. In preferred embodiments, the alkylene group is unsubstituted. In certain embodiments, the alkylene group is a C1-C6 alkyene group. In particularly preferred embodiments, the alkylene group is selected from methylene and ethylene. When present in a linking moiety, the arylene and alkylene groups can be unsubstituted. In certain embodiments, the linking moiety consists of a divalent thiourea functional group covalently bonded via one of its nitrogen atoms to an arylene group, which is covalently bonded to an alkylene group.

[0419] In some embodiments, the linking moiety comprises a divalent thioamide functional group and an optionally substituted arylene group. In some embodiments, the linking moiety comprises a divalent thioamide functional group, an optionally substituted arylene group, and an optionally substituted alkylene group. In certain embodiments, the linking moiety comprises a divalent thioamide functional group covalently bonded to an optionally substituted arylene group through one of its nitrogen atoms. In further embodiments, the linking moiety comprises a divalent thioaide functional group covalently bonded to an optionally substituted arylene group through one of its nitrogen atoms, and the optionally substituted arylene group is covalently bonded to an optionally substituted alkylene group. In preferred embodiments, the arylene group is unsubstituted. In certain embodiments, the arylene group is a phenylene group. In preferred embodiments, the alkylene group is unsubstituted. In certain embodiments, the alkylene group is a C1-C6 alkylene group. In particularly preferred embodiments, the alkylene group is selected from methylene and ethylene. When present in a linking moiety, the arylene and alkylene groups can be unsubstituted. In certain embodiments, the linking moiety consists of a divalent thioamide functional group covalently bonded via one of its nitrogen atoms to an arylene group, which is covalently bonded to an alkylene group.

[0420] In some embodiments, the linking moiety has the following formula: TIFF0007582867000012.tif38170 [wherein y is 1 to 6 (preferably 1 or 2), * represents the point of attachment to dextran or a derivative thereof, ** represents the point of attachment to a ring atom of DOTAM or its functional variants] It may be or include a group of the formula:

[0421] In some embodiments, the linking moiety can be formed from the conjugation of an amine (preferably a primary amine) with an isocyanate or an isothiocyanate. Such conjugation forms a divalent urea functional group and a divalent thiourea functional group, respectively. In such embodiments, when an isocyanate is one of the reactants, the linking moiety may be considered to include a divalent urea functional group or a divalent amide functional group, as appropriate. In such embodiments, when an isothiocyanate is one of the reactants, the linking moiety may be considered to include a divalent thiourea functional group or a divalent thioamide functional group, as appropriate.

[0422] Preferably, when x is greater than 1, each dextran has an average number of M-DOTAM or functional variants thereof per molecule that is greater than 1. For example, x can be 2 or more, 5 or more, 10 or more, 15 or more, 20 or more, 25 or more, 30 or more, 35 or more, 40 or more, or preferably 50 or more. The inventors have found that improved removal can be achieved using dextran labeled with multiple M-DOTAM groups.

[0423] DOTAM or its functional variants contain only one linker and can prevent cross-linking of dextran.

[0424] Dextran derivatives that may be useful in the removal agent include aminodextran, in which the dextran is substituted with one or more amines. Particularly useful are aminodextran, in which one or more hydroxyl groups of the dextran are substituted with amino-substituted carboxymethylamide groups. Such compounds can be produced by modifying dextran with carboxymethyl groups (e.g., by reacting with chloroacetic acid) and then further reacting with an optionally substituted diamine (preferably an α,ω-alkylenediamine, e.g., an alkyldiamine such as ethylenediamine).

[0425] The amino groups provide attachment points for the linker. At least 30%, preferably at least 40%, more preferably at least 50% of the available amino groups can be substituted with DOTAM or a functional variant thereof.

[0426] Preferably, the "dextran" in the above formula is an aminodextran, which corresponds to a dextran substituted with one or more carboxymethyl groups which are themselves substituted with ethylenediamine.

[0427] Dextran has the formula -CH2C(=O)NH(CH2) f NHR F [In the formula, R F represents hydrogen or a linker to DOTAM, and f is 1 to 6, most preferably 2. For example, the group may be substituted with one or more groups of the formula: TIFF0007582867000013.tif29170 [where the dashed line indicates the point of attachment to the oxygen on the dextran] may have

[0428] Aminodextran may have a backbone of predominantly α(1,6)-linked glucopyranosyl repeating units, which may have branches of other glucopyranosyl units linked by, for example, α(1,2), α(1,3), or α(1,4) glycosidic bonds. At least some of the hydroxyl groups may be amino-substituted carboxymethylamide groups (particularly those of the formula -CHC(=O)NHCHCHNHR), as discussed above. F In other words, the aminodextran is substituted with a group of the formula: TIFF0007582867000014.tif110170[R G are H, an amino-substituted carboxymethylamide group (-CHC(=O)NHCHCHNHR F etc.), or primarily via α(1,6) linkages to further glucopyranosyl units, with dashed lines indicating attachment to adjacent units] It may also include units of:

[0429] The remover has the following formula: TIFF0007582867000015.tif71170[In the formula, ** represents a point of attachment to DOTAM or a functional variant thereof, and y is as defined above.

[0430] Dextran derivatives may include dextran or aminodextran modified with one or more groups selected from amino acids or sugars other than glucose. For example, dextran may be modified (e.g., capped) with one or more glutamic acid or polyglutamic acid units, including Glu, (Glu)2, (Glu)3, or (Glu)4. Additionally or alternatively, dextran may be modified (e.g., capped) with sugars other than glucose, such as N-acetylgalactosamine (GalNAc), or polysaccharides formed from such sugars, such as tri-GalNAc.

[0431] In some embodiments, the molecular weight of the dextran component may be at least 50 kDa, e.g., between 50 kDa and 2000 kDa. For example, the molecular weight may be between 200 and 800 kDa, optionally greater than 300, 350, 400, or 450 kDa, optionally less than 700, 650, 600, or 550 kDa, optionally about 500 kDa.

[0432] The number of amino groups as a percentage of the number of glucose units of the dextran or dextran derivative ("saturation" of glucose units by amino groups) may be at least 0.5%, at least 1%, at least 2%, at least 5%, at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or preferably 100%. In some embodiments, it may be preferred that the saturation of the dextran by amino groups is at least or about 1% or 10%, e.g., 1%-10%.

[0433] The number of DOTAM groups as a percentage of the number of amino units in the dextran derivative ("saturation" of the aminodextran moiety with DOTAM) may be at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or preferably 100%. In some embodiments, saturation of the available amino groups in the dextran derivative with DOTAM may be preferred to be at least or about 40% or 50%, e.g., 40-60%.

[0434] One potential difficulty with the use of clearing agents is the possibility that they may enter the tumor, bind to tumor-associated antigens, and negatively affect subsequent binding of the radioligand.

[0435] The inventors have further found that when using a dextran-based clearing agent that i) has a high average molecular weight and ii) is subject to a molecular weight cutoff so that fragments below a certain size are removed, good clearance from the blood can be achieved along with low clearing agent penetration into tumors. The cutoff can be applied to the dextran or dextran derivative before the conjugation step; and / or to the clearing agent after conjugation; and / or to the clearing agent after complexation with a metal.

[0436] Thus, clearing agents useful in the present invention are dextran-based clearing agents comprising dextran or a derivative thereof (e.g., as defined above, preferably aminodextran) conjugated to a metal chelate, wherein i) the average molecular weight of the dextran or derivative thereof is preferably 200-800 kDa, optionally greater than 300, 350, 400 or 450 kDa, optionally less than 700, 650, 600 or 550 kDa, optionally about 500 kDa, and ii) dextran, dextran derivative or clearing agent below a molecular weight cut-off is removed, and The cutoff may be a dextran-based clearing agent having a cutoff of 50 kDa or more, 100 kDa or more, or 200 kDa or more, optionally in the range of 50 kDa to 250 kDa or 50 kDa to 200 kDa, optionally 100 kDa to 200 kDa, optionally about 100 kDa or 150 kDa or 200 kDa (for the avoidance of doubt, when the inventors state that the cutoff is 50 kDa or more, this means that the cutoff may be 50 kDa or any value above 50 kDa, but it is still dextran, dextran derivatives or clearing agents below the cutoff that will be cleared).

[0437] The amount of species having a molecular weight below the cutoff may be, for example, as a weight percentage of the scavenging agent, 5 wt% or less, 4 wt% or less, 3 wt% or less, 2 wt% or less, 1 wt% or less, 0.5 wt% or less, 0.4 wt% or less, 0.3 wt% or less, 0.2 wt% or less, 0.1% wt% or less, or 0.01 wt% or less. Preferably, the scavenging agent is essentially free of species having a molecular weight below the cutoff.

[0438] The molecular weight cut-off can be achieved by filtration, for example, diafiltration, ultrafiltration, tangential flow filtration or cross-flow filtration. Preferably, at least two filtration steps are carried out, and if necessary, at least three filtration steps are carried out. By "average molecular weight," we mean the weight-average molecular weight determined by SEC-MALS analysis.

[0439] It will be understood that when incorporated into DOTAM or its functional variants, the metals will exist as metal ions and the oxidation state will vary depending on the particular element. Thus, the knowledgeable reader will recognize, for example, lead, Pb, or 206 It will be understood that the term Pb is intended to encompass the ionic forms of the element, particularly Pb(II).

[0440] The metal present in the removal agent may be a stable (non-radioactive) isotope of lead, or a stable or essentially stable isotope of another metal ion, provided that the metal ion-DOTAM complex is recognized with high affinity by the antibody. For example, another suitable metal is Zn (Zn 2+ ), Ca(Ca 2+ )or 209 Bi (Bi 2+ ), the latter of which is radioactive but is considered substantially stable due to its very long half-life.

[0441] In a further aspect, the present invention relates to a method for preparing a removal agent comprising conjugating dextran or a dextran derivative to DOTAM or a functional variant or derivative thereof, and comprising chelating DOTAM with Pb or another metal ion as described above [e.g., Pb(II)] before and / or after conjugation of DOTAM or a functional variant thereof to dextran.

[0442] In a further aspect, the present invention provides a method for preparing a removal agent, comprising the steps of: forming a conjugate by conjugating DOTAM or a functional variant or derivative thereof to dextran or a dextran derivative. Includes; Prior to conjugation, the dextran or dextran derivative may be subjected to a filtration step to remove species below a molecular weight cutoff / threshold, for example in the range of 50 kDa or more, 100 kDa or more or 200 kDa or more, optionally 50 kDa to 250 kDa or 50 kDa to 200 kDa, optionally 100 kDa to 200 kDa, for example species below 100 kDa, 150 kDa or 200 kDa; or The present invention relates to a method for preparing a removal agent, the method further comprising subjecting the conjugate to a filtration step to remove species below a molecular weight cutoff / threshold in the range of, for example, 50 kDa or more, 100 kDa or more or 200 kDa or more, optionally 50 kDa to 250 kDa or 50 kDa to 200 kDa, optionally 100 kDa to 200 kDa, for example species below 100 kDa, 150 kDa or 200 kDa.

[0443] As described above, the inventors have found that it is beneficial to apply a molecular weight cutoff to remove fragments below a certain size. The filtration method may be, for example, diafiltration. The knowledgeable reader will understand that the word "remove" in "remove species below the molecular weight cutoff / threshold" is synonymous with "reduce the number" and that some residual low molecular weight species may remain depending on the specific filtration method used. The amount of species having a molecular weight below the cutoff may be, for example, 5 wt% or less, 4 wt% or less, 3 wt% or less, 2 wt% or less, 1 wt% or less, 0.5 wt% or less, 0.4 wt% or less, 0.3 wt% or less, 0.2 wt% or less, 0.1% wt% or less, or 0.01 wt% or less, as a weight percentage of the removal agent. Preferably, the removal agent is essentially free of species having a molecular weight below the cutoff / threshold after filtration.

[0444] A functional variant or derivative of DOTAM may be as defined above and may contain at least one R 1 The group serves as a linker moiety. For example, a suitable (linker-(M-DOTAM)) group can be formed by reacting a compound of the following formula with the aminodextran described above: TIFF0007582867000016.tif61170

[0445] The synthesis of this compound is described in Chappell et al., Nuclear Medicine and Biology, Vol. 27, pp. 93-100, 2000, and DOTAM derivatives are commercially available from Macrocyclics, Inc. (Plano, Texas).

[0446] DOTAM or its functional variants may be added in excess so that each dextran derivative has, on average, more than one DOTAM. The average number of DOTAM or its functional variants on each dextran may be greater than 1, e.g., 2 or more, 3 or more, 4 or more, 5 or more, 10 or more, 15 or more, 20 or more, 25 or more, 30 or more, 35 or more, 40 or more, 50 or more, 100 or more, or preferably 40 or more. The inventors have found that improved removal can be achieved using dextran conjugated to multiple M-DOTAM groups.

[0447] Preferably, the dextran has an average molecular weight of between 200 and 800 kDa, optionally greater than 300, 350, 400 or 450 kDa, optionally less than 700, 650, 600 or 550 kDa, optionally about 500 kDa.

[0448] The method for preparing the remover may also include a chelation step, which includes chelating DOTAM or a functional variant thereof with a metal ion. The metal ion may be a non-radioactive isotope, for example, a non-radioactive isotope of Pb, Ca, Zn, or 209 It may also be a substantially stable isotope such as Bi.

[0449] The chelation step is carried out before conjugation of DOTAM or its functional variant to dextran and / or after conjugation of DOTAM or its functional variant to dextran, optionally before the filtration step. Chelation of metal ions by DOTAM or its functional variant may be necessary to ensure proper binding of the bispecific antibody to the clearing agent, e.g., to ensure that DOTAM or its functional variant adopts the correct conformation for encountering the antibody.

[0450] If the method includes a chelation step, the method preferably also includes a subsequent step of removing unbound metal. This can be achieved by adding an additional chelating agent, which can then be separated from the DOTAM or its functional variant bound to the dextran during the filtration step. The additional chelating agent is preferably different from DOTAM or its functional variant. Preferably, the additional chelating agent has a lower molecular weight than the dextran-chelating agent conjugate to facilitate size-based separation. For example, the additional chelating agent may be a polyaminocarboxylic acid or its salt, such as ethylenediaminotetraacetic acid (EDTA).

[0451] Preferably, the method for preparing the chelating agent comprises: i) forming a conjugate by conjugating DOTAM or a functional variant or derivative thereof to dextran or a dextran derivative; ii) optionally removing low molecular weight species from the product of step (i); iii) chelating the conjugate with a metal ion, e.g., an ion of Pb, Bi, Zn, or Ca; iv) adding additional chelating agent to chelate unbound metal ions; and v) performing a filtration step to remove species below a molecular weight cutoff / threshold; Includes:

[0452] DOTAM-chelated Pb radionuclides A Pb radionuclide chelated with DOTAM or its functional variant can be used in any of the diagnostic, imaging, or therapeutic methods described herein. When used in such methods, it will be understood that the Pb radionuclide chelated with DOTAM or its functional variant is included in a composition. In one particular embodiment, the composition comprises a Pb radionuclide chelated with DOTAM or its functional variant and a DOTAM or its functional variant that is not chelated with a Pb radionuclide. Thus, in another aspect, the present invention relates to such compositions and / or such compositions for use in any of the imaging or therapeutic methods described herein. The DOTAM-chelated Pb radionuclide referred to in such methods may be in the form of a composition described herein.

[0453] The DOTAM or functional variant thereof not chelated with a Pb radionuclide may be unchelated DOTAM or functional variant thereof. When used in vivo, the unchelated DOTAM or functional variant thereof can form a complex with metal ions, such as calcium ions, from the environment. Such calcium ions chelated with DOTAM or its functional variant are pharmacologically inactive and can potentially block the pharmacologically active Pb radionuclide chelated with DOTAM or its variant from the target in the tumor, thereby reducing the efficacy of treatment and / or the standardized uptake values ​​for imaging and diagnosis.

[0454] By quenching unchelated DOTAM or its functional variant under defined conditions, the inventors can increase control of the in vivo formulation of the chelated Pb radionuclide and / or avoid or reduce potential competition between pharmaceutically active and inactive chelates. Thus, in some embodiments, the DOTAM or its functional variant that is unchelated with a Pb radionuclide is a DOTAM or its functional variant that is chelated with a non-radioactive metal ion.

[0455] In some embodiments, the chelated Pb radionuclide is 212 In some embodiments, the chelated Pb radionuclide is 203 It is Pb.

[0456] It will be understood that when incorporated into DOTAM or its functional variants, the Pb radionuclide will exist as a metal ion, with the oxidation state varying depending on the particular element. Thus, the knowledgeable reader will understand that, e.g., Pb, or 206 It will be understood that the term Pb is intended to encompass the ionic forms of the element, particularly Pb(II).

[0457] The non-radioactive metal present in the composition may be a stable (non-radioactive) isotope of lead, or a stable or essentially stable isotope of another metal ion. For example, other suitable metals are Gd (Gd2+), Cu (Cu2+), Zn (Zn2+), Ca (Ca2+), or 209 It may be Bi (Bi2+), the latter of which is radioactive but is believed to be substantially stable due to its very long half-life. In some embodiments, the metal is Ca or Cu, and in some embodiments, the metal is Ca.

[0458] A functional variant or derivative of DOTAM may be as defined above.

[0459] In a further aspect, the present invention provides a method for preparing a composition comprising a Pb radionuclide chelated with DOTAM or a functional variant thereof, comprising the steps of: i) providing a Pb radionuclide; ii) chelating the Pb radionuclide with DOTAM or a functional variant thereof; iii) Chelating unchelated DOTAM or a functional variant thereof with a non-radioactive metal ion. The present invention relates to a method comprising:

[0460] The unchelated DOTAM or functional variant thereof in step iii) is DOTAM or functional variant thereof that has not been chelated with a Pb radionuclide in step ii).

[0461] The non-radioactive metal ion may be a Pb, Ca, Zn, Gd, or Cu ion. In some embodiments, the metal ion is a Ca or Cu ion. In some embodiments, the metal ion is a Ca ion, particularly Ca.

[0462] In some embodiments, the unchelated DOTAM or functional variant thereof remaining after step ii) is at least 90 mol%, at least 95 mol%, at least 99 mol% of the DOTAM or functional variant thereof added to the Pb radionuclide. In one particular embodiment, the unchelated DOTAM or functional variant thereof remaining after step ii) is at least 99 mol%.

[0463] In some embodiments, the amount of unchelated DOTAM or functional variant thereof remaining after step iii) is less than 5 mol%, less than 2 mol%, less than 1 mol%, less than 0.1 mol%, or less than 0.01 mol% of the DOTAM or functional variant thereof added to the Pb radionuclide. In one particular embodiment, the amount of unchelated DOTAM or functional variant thereof remaining after step iii) is less than 1 mol%, less than 0.1 mol%, or less than 0.01 mol%.

[0464] The Pb radionuclide provided in step a) can be generated by placing in a generator a radioactive material that decays the desired Pb radionuclide and that binds to the solid material. For example, 212 Such radioactive material in the production of Pb may be radium-224. The desired radionuclide is then extracted from the generator into an aqueous solution that may contain radioactive and chemical impurities. The aqueous solution containing the desired Pb radionuclide and impurities is purified by liquid chromatography on a column. The liquid chromatography on a column may be extraction or partition chromatography. Extraction or partition chromatography is based on the distribution of the components to be separated between an organic phase, or extract, and an aqueous phase; the extract is bound to an inert support and forms the stationary phase, while the aqueous phase is the mobile phase.

[0465] Extraction chromatography may use a stationary phase comprising an ether crown, in particular dicyclohexano-1,8-crown-6 or dibenzo-1,8-crown-6, in which the cyclohexyl or benzyl group is substituted with one or more C[to C] alkyl groups, with linear or branched chains, as the extractant, in solution in a water-immiscible organic diluent, typically a long hydrocarbon chain alcohol, i.e., C chain or longer.

[0466] In particular, a stationary phase containing 4,4'(5')-di-er-butylcyclohexano-1,8-crown-6 as an extract, preferably diluted in octan-1-ol, may be used. Such a stationary phase is typically obtained from a radium-224 generator. 212 Selectively survives >99% in aqueous solutions containing 1.5-2.5 mol / L of strong acid, corresponding to the type of solution used to extract Pb. 212 The advantage is that Pb is present. This type of stationary phase is available, for example, in bottles as well as packaged in ready-to-use columns or cartridges for chromatography from the company TRISKEM International under the trade name "Pb Resin."

[0467] Alternatively, a solution containing the desired radionuclide and impurities can be purified using ion exchange chromatography, for example, cation exchange chromatography.

[0468] 212 Methods for producing and purifying Pb are described in WO2013174949.

[0469] array Certain specific sequences described herein are provided in the table below. TIFF0007582867000017.tif224170TIFF0007582867000018.tif255170TIFF0007582867000019.tif252170TIFF0007582867000020.tif255170 TIFF0007582867000021.tif255170TIFF0007582867000022.tif254170TIFF0007582867000023.tif255170TIFF0007582867000024.tif221170

[0470] The disclosures of all patent and scientific literature cited herein are expressly incorporated by reference in their entirety.

[0471] The present invention will now be further described with reference to specific examples, it being understood that various other embodiments may be practiced in light of the general description provided above. [Example]

[0472] Example 1: Immunization Description Immunization of rabbits A 1:1 mix of two enantiomeric Pb-DOTAM-alkyl-PEG4-KLH fractions (MS2-DOTAM KLH fraction 1 and MS2-DOTAM KLH fraction 2) was used to immunize New Zealand White rabbits or transgenic rabbits containing human immunoglobulin loci, as reported in WO2000 / 46251, WO2002 / 12437, WO2005 / 007696, WO2006 / 047367, US2007 / 0033661, and WO2008 / 027986. Each rabbit was immunized intradermally with 500 μg of the immunogen mix emulsified in complete Freund's adjuvant on day 0, followed by alternating intramuscular and subcutaneous immunizations with 500 μg each on days 7, 14, 28, and 56. Thereafter, rabbits received monthly subcutaneous immunizations of 500 μg, and small blood samples were taken 7 days after immunization for determination of serum titers. Larger blood samples (10% of estimated total blood volume) were taken in the third and ninth months of immunization (days 5-7 post-immunization) to isolate peripheral mononuclear cells, which were used as a source of antigen-specific B cells in the B cell cloning process (Example 2).

[0473] Serum titer determination (ELISA) Each of the two enantiomeric Pb-DOTAM fractions (PJRD05.133F1 or PJRD05.133F2) was immobilized onto a 96-well NUNC Maxisorp plate at 1 μg / ml in PBS, 100 μl / well, followed by blocking the plate with 2% Crotein C in PBS at 200 μl / well; application of serial dilutions of duplicate antisera in 0.5% Crotein C in PBS at 100 μl / well; and detection with HRP-conjugated donkey anti-rabbit IgG antibody (Jackson Immunoresearch / Dianova 711-036-152; 1 / 16000) and streptavidin-HRP, each diluted in 0.5% Crotein C in PBS at 100 μl / well. Plates were incubated at 37°C for 1 hour for all steps. Between all steps, plates were washed three times with 0.05% Tween 20 in PBS. Signal was developed by adding 100 ul / well of BM Blue POD substrate soluble form (Roche); it was stopped by adding 100 ul / well of 1 M HCl. Absorbance was read at 450 nm with 690 nm as reference. Titer was defined as the dilution of antiserum that gave half-maximal signal.

[0474] Example 2: B cell cloning from rabbits Isolation of rabbit peripheral blood mononuclear cells (PBMCs) Blood samples were collected from immunized rabbits. EDTA-containing whole blood was diluted two-fold with 1x PBS (PAA, Pasching, Austria) and then subjected to density centrifugation using a mammalian lymphocyte (Cedarlane Laboratories, Burlington, Ontario, Canada) according to the manufacturer's specifications. PBMCs were washed twice with 1x PBS.

[0475] EL-4 B5 medium RPMI 1640 (Pan Biotech, Aidenbach, Germany) supplemented with 10% FCS (Hyclone, Logan, UT, USA), 2 mM glutamine, 1% penicillin / streptomycin solution (PAA, Pasching, Austria), 2 mM sodium pyruvate, 10 mM HEPES (PAN Biotech, Aidenbach, Germany) and 0,05 mM b-mercaptoethanol (Gibco, Paisley, Scotland) was used.

[0476] Plate coating Sterile cell culture 6-well plates were coated overnight at 4°C with 2 μg / ml KLH in carbonate buffer (0.1 M sodium bicarbonate, 34 mM disodium hydrogencarbonate, pH 9.55). Plates were washed three times with sterile PBS before use. Sterile streptavidin-coated 6-well plates (Microcoat, Bernried, Germany) were coated with a 1 + 1 enantiomeric mixture of biotinylated TCMC-Pb-dPEC3-biotin isomers A (1 μg / ml) and B (1 μg / ml) in PBS for 3 hours at room temperature. Prior to the panning step, these 6-well plates were washed three times with sterile PBS.

[0477] Macrophage / monocyte depletion PBMCs were seeded into sterile KLH-coated 6-well plates to deplete macrophages and monocytes due to nonspecific adhesion and remove KLH-binding cells. Each well was filled with 4 ml of medium and a maximum of 6 x 10e6 PBMCs from immunized rabbits and allowed to bind for 1 hour at 37°C and 5% CO2. Cells in the supernatant (peripheral blood lymphocytes (PBLs)) were used for the antigen panning step.

[0478] B cell enrichment in Pb-containing TCMC enantiomers Up to 6 x 10e6 PBLs per 4 ml of medium were seeded onto 6-well plates coated with a mixture of enantiomers of TCMC-Pb-dPEC3-biotin isomers A and B and allowed to attach for 1 hour at 37°C and 5% CO2. Nonadherent cells were removed by carefully washing the wells 1-3 times with 1x PBS. Remaining adherent cells were detached with trypsin for 10 minutes at 37°C and 5% CO2. Trypsinization was stopped with EL-4 B5 medium. Cells were kept on ice until immunofluorescence staining.

[0479] Immunofluorescence staining and flow cytometry Anti-IgG FITC (AbD Serotec, Düsseldorf, Germany) was used for single-cell sorting. For surface staining, cells from the depletion and enrichment steps were incubated with anti-IgG FITC antibody in PBS for 45 minutes at 4°C in the dark. After staining, PBMCs were washed twice with ice-cold PBS. Finally, PBMCs were resuspended in ice-cold PBS and immediately subjected to FACS analysis. Propidium iodide (BD Pharmingen, San Diego, CA, USA) was added at a concentration of 5 μg / ml prior to FACS analysis to distinguish between dead and live cells.

[0480] A Becton Dickinson FACSAria (BD Biosciences, USA) equipped with a computer and FACSDiva software was used for single cell sorting.

[0481] B cell culture Rabbit B cell cultures were prepared according to the method described by Lightwood et al. (J Immunol Methods, 2006, 316:133-143). Briefly, single sorted rabbit B cells were incubated in a 96-well plate with 200 μl / well of EL-4 B5 medium containing Pansorbin cells (1:100,000) (Calbiochem (Merck), Darmstadt, Germany), 5% rabbit thymocyte supernatant (MicroCoat, Bernried, Germany), and gamma-irradiated mouse EL-4 B5 thymoma cells (5 × 10e5 cells / well) in an incubator for 7 days at 37°C. The B cell culture supernatant was removed for screening, and the remaining cells were immediately harvested and frozen at -80°C in 100 μl RLT buffer (Qiagen, Hilden, Germany).

[0482] Example 3: Expression of rabbit antibodies PCR amplification of V-domains Total RNA was prepared from B cell lysates (resuspended in RLT buffer - Qiagen - Cat. No. 79216) using the NucleoSpin 8 / 96 RNA Kit (Macherey & Nagel; 740709.4, 740698) according to the manufacturer's protocol. RNA was eluted in 60 μl of RNase-free water. 6 μl of RNA was used to generate cDNA by reverse transcriptase reaction using Superscript III First-Strand Synthesis SuperMix (Invitrogen 18080-400) and oligo dT primer according to the manufacturer's instructions. All steps were performed on a Hamilton ML Star System. Four microliters of cDNA was used to amplify immunoglobulin heavy and light chain variable regions (VH and VL) using AccuPrime Supermix (Invitrogen 12344-040) in a final volume of 50 μl, with primers rbHC.up and rbHC.do for the heavy chain and rbLC.up and rbLC.do for the light chain (Table 3). All forward primers were specific for the signal peptide (for VH and VL, respectively), while the reverse primers were specific for the constant region (for VH and VL, respectively). PCR conditions for RbVH+RbVL were as follows: a hot start at 94°C for 5 minutes; 35 cycles of 94°C for 20 seconds, 70°C for 20 seconds, 68°C for 45 seconds, and a final extension at 68°C for 7 minutes. TIFF0007582867000025.tif67170

[0483] Eight μl of the 50 μl PCR solution was loaded onto a 48 E-gel 2% (Invitrogen G8008-02). Positive PCR reactions were cleaned up using the NucleoSpin Extract II kit (Macherey & Nagel 740609250) according to the manufacturer's protocol and eluted in 50 μl elution buffer. All cleanup steps were performed on a Hamilton ML Starlet System.

[0484] Recombinant expression of rabbit monoclonal bivalent antibodies For recombinant expression of rabbit monoclonal bivalent antibodies, PCR products encoding VH or VL were cloned as cDNA into expression vectors using the overhang cloning method (R.S. Haun et al., Biotechniques (1992) 13, 515-518; M.Z. Li et al., Nature Methods (2007) 4, 251-256). The expression vectors contained an expression cassette consisting of a 5' CMV promoter containing intron A and a 3' BGH polyadenylation sequence. In addition to the expression cassette, the plasmids contained a pUC18-derived origin of replication for plasmid amplification in Escherichia coli (E. coli) and a beta-lactamase gene conferring ampicillin resistance. Three variants of the basic plasmid were used: one plasmid containing rabbit IgG constant regions designed to accept the VH region, while two additional plasmids contained rabbit or human kappa LC constant regions to accept the VL region. Linearized expression plasmids encoding the kappa or gamma constant regions and VL / VH inserts were amplified by PCR using overlapping primers. The purified PCR products were incubated with T4 DNA polymerase, which generated single-stranded overhangs. The reaction was stopped by adding dCTP. In the next step, the plasmids and inserts were combined and incubated with recA, which induces site-specific recombination. The recombinant plasmids were transformed into E. coli. The following day, grown colonies were picked and tested for the correct recombinant plasmids by plasmid preparation, restriction analysis, and DNA sequencing. For antibody expression, the isolated HC and LC plasmids were transiently cotransfected into 2 ml (96-well plates) of FreeStyle HEK293-F cells (Invitrogen R790-07) using 239-Free transfection reagent (Novagen) according to the procedure suggested by the reagent supplier. After one week, the supernatant was collected and sent for purification.

[0485] Example 4: Selection of rabbit monoclonal antibodies The table below shows the properties of various monoclonal bivalent rabbit antibodies. PRIT-0128 was selected as a lead candidate due to its comparable binding to chelated Pb and Bi, reduced binding to other chelated metals, and high affinity (<100 pM).

[0486] SET (solubility equilibrium titration) assays were performed as described below.

[0487] Assay plate preparation: 384-well streptavidin plates (Nunc, Microcoat #11974998001) were incubated overnight at 4° C. with 25 μl / well of DOTAM-biotin-isomer mix in PBS buffer at a concentration of 20 ng / ml.

[0488] Equilibration of anti-DOTAM antibody samples with free DOTAM-metal chelates (Pb, Bi, Ca, Cu, Zn, Mg, Fe): 0.01 nM to 1 nM antibody was titrated with the relevant DOTAM-metal chelate in 1:3, 1:2, or 1:1.7 dilution steps starting from 2500 nM, 500 nM, or 100 nM DOTAM-metal chelate. Samples were incubated overnight at 4°C in sealed REMP Storage polypropylene microplates (Brooks).

[0489] After overnight incubation, the streptavidin plate was washed 3x with 90 μl of PBST per well. 15 μl of each sample from the equilibration plate was transferred to the assay plate and incubated for 15 min at RT, followed by 3x 90 μl washing steps with PBST buffer. Detection was performed by adding 25 μl of goat anti-human IgG antibody-POD conjugate (Jackson, 109-036-088, 1:4000 in OSEP) followed by 6x 90 μl washing steps with PBST buffer. 25 μl of TMB substrate (Roche Diagnostics GmbH, catalog number: 11835033001) was added to each well. Measurements were performed at 370 / 492 nm on a Safire2 reader (Tecan).

[0490] material: 1. DOTAM-Biotin-Isomeric Mix: A mixture of the following components, concentration = 20ng / ml: - Pb-Dotam-Bn-Biotin / TCMC-Pb-dPEG3-Biotin, Isomer A - Pb-Dotam-Bn-Biotin / TCMC-Pb-dPEG3-Biotin, isomer B - Pb-Dotam-Alkyl-Biotin Isomer A - Pb-Dotam-Alkyl-Biotin Isomer B 2.PBS: DPBS, PAN, P04-36500 3.BSA:Roche, 10735086001 4. Tween 20: Polysorbate 20 (USB, #20605, 500ml) 5.PBST:10×, Roche, #11666789001 / 0,1%Tween 20 6. OSEP: PBS (10x, Roche, #11666789001) / 0.5% BSA (bovine serum albumin fraction V, fatty acid-free, Roche, #10735086001) / 0.05% Tween 20 TIFF0007582867000026.tif84170

[0491] Example 5: Molecular Biology Recombinant DNA Techniques DNA was manipulated using standard methods as described in Sambrook, J. et al., Molecular cloning: A laboratory manual; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989. Molecular biological reagents were used according to the manufacturer's instructions.

[0492] Gene and Oligonucleotide Synthesis The desired gene segments were prepared by chemical synthesis at Geneart GmbH (Regensburg, Germany). The synthesized gene fragments were cloned into E. coli plasmids for propagation / amplification. The DNA sequences of the subcloned gene fragments were verified by DNA sequencing. Alternatively, short synthetic DNA fragments were assembled by annealing chemically synthesized oligonucleotides or by PCR. The respective oligonucleotides were prepared by metabion GmbH (Planegg-Martinsried, Germany).

[0493] Protein determination The protein concentration of the purified polypeptide was determined by determining the optical density (OD) at 280 nm using the molar extinction coefficient calculated based on the amino acid sequence of the polypeptide.

[0494] Generation of plasmids for recombinant expression of antibody heavy or light chains The desired proteins were expressed by transient transfection of human embryonic kidney cells (HEK293). For expression of the desired gene / protein (e.g., a full-length antibody heavy chain, a full-length antibody light chain, or a full-length antibody heavy chain containing an additional domain (e.g., an immunoglobulin heavy or light chain variable domain at its C-terminus)), a transcription unit containing the following functional elements was used: - the immediate early enhancer and promoter from human cytomegalovirus (P-CMV) including intron A, - human heavy chain immunoglobulin 5'-untranslated region (5'UTR), - mouse immunoglobulin heavy chain signal sequence (SS), - the gene / protein to be expressed, and - Bovine growth hormone polyadenylation sequence (BGH pA).

[0495] In addition to the expression unit / cassette containing the desired gene to be expressed, the basic / standard mammalian expression plasmid contained an origin of replication from the vector pUC18, which allows replication of this plasmid in E. coli, and a beta-lactamase gene, which confers ampicillin resistance in E. coli.

[0496] a) Expression plasmid for antibody heavy chain A complete and functional antibody heavy chain was assembled by fusing DNA fragments encoding each sequence element (V-heavy or V-light), separated by a G4S × 4 linker, to the C-terminus of the CH3 domain of a human IgG molecule, followed by a C-terminal fusion gene containing an additional antibody V-heavy or V-light domain (VH-CH1-hinge-CH2-CH3-linker-VH or VH-CH1-hinge-CH2-CH3-linker-VL). Recombinant antibody molecules, each containing one VH and one VL domain C-terminal to the two CH3 domains, were expressed using knob-into-hole technology.

[0497] The expression plasmid for transient expression of an antibody heavy chain and a C-terminal VH or VL domain in HEK293 cells contained, in addition to the antibody heavy chain fragment and C-terminal VH or VL domain expression cassette, an origin of replication derived from the vector pUC18, which allows replication of this plasmid in E. coli, and a beta-lactamase gene, which confers ampicillin resistance in E. coli. The transcription unit for the antibody heavy chain fragment and C-terminal VH or VL domain fusion gene contains the following functional elements: - the immediate early enhancer and promoter from human cytomegalovirus (P-CMV) including intron A, - human heavy chain immunoglobulin 5'-untranslated region (5'UTR), - mouse immunoglobulin heavy chain signal sequence, - an antibody heavy chain (VH-CH1-hinge-CH2-CH3-linker-VH or VH-CH1-hinge-CH2-CH3-linker-VL) encoding nucleic acid, and - Bovine growth hormone polyadenylation sequence (BGH pA).

[0498] Expression plasmids encoding all heavy chain polypeptides / proteins mentioned in Table 2 were constructed according to the methods outlined previously.

[0499] b) Expression plasmid for antibody light chain By fusing DNA fragments encoding each sequence element, an antibody light chain-encoding gene containing a complete and...

Claims

1. A removal agent for removing a multispecific or bispecific antibody comprising at least one antigen binding site specific for a Pb-DOTAM chelate and at least one antigen binding site specific for a target antigen, comprising a dextran or aminodextran conjugated to a chelator selected from DOTAM and a functional variant of DOTAM, wherein the chelator complexes with a metal ion and the functional variant of DOTAM has the following formula: [In the formula, R N is H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, C 3-7 Cycloalkyl-C 1-4 Alkyl, C 2-7 Heterocycloalkyl, C 2-7 Heterocycloalkyl-C 1-4 Alkyl, phenyl, phenyl-C 1-4 Alkyl, C 1-7 Heteroaryl, and C 1-7 Heteroaryl-C 1-4 alkyl; 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, and C 2-6 Alkynyl is one, two, three, or four independently selected R W group; 3-7 Cycloalkyl, C 3-7 Cycloalkyl-C 1-4 Alkyl, C 2-7 Heterocycloalkyl, C 2-7 Heterocycloalkyl-C 1-4 Alkyl, phenyl, phenyl-C 1-4 -Alkyl, C 1-7 Heteroaryl, and C 1-7 Heteroaryl-C 1-4 -alkyl is one, two, three, or four independently selected R X each optionally substituted with a group; L 1 is independently C 1-6 Alkylene, C 1-6 Alkenylene, or C 1-6 alkynylene, each of which is one, two or three independently selected R 1 may be substituted with a group; L 2 is C 2-4 R is a linear alkylene, and is independently selected 1 may be substituted with a group; 1-4 Alkyl and / or C 1-4 optionally substituted with 1, 2, 3, or 4 groups independently selected from haloalkyl; R 1 D 1 -D 2 -D 3 , halogen, cyano, nitro, hydroxyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Alkylthio, C 1-6 Alkylsulfinyl, C 1-6 Alkyl sulfonyl, amino, C 1-6 Alkylamino, di-C 1-6 Alkylamino, C 1-4 Alkylcarbonyl, Carboxy, C 1-6 Alkoxycarbonyl, C 1-6 Alkylcarbonylamino, di-C 1-6 Alkylcarbonylamino, C 1-6 Alkoxycarbonylamino, C 1-6 Alkoxycarbonyl-(C 1-6 Alkyl)amino, carbamyl, C 1-6 Alkylcarbamyl, and di-C 1-6 independently selected from alkylcarbamyl; D 1 are respectively C 6-10 Aryl-C 1-4 Alkyl, C 1-9 Heteroaryl-C 1-4 Alkyl, C 3-10 Cycloalkyl-C 1-4 Alkyl, C 2-9 Heterocycloalkyl-C 1-4 Alkyl, C 1-8 Alkylene, C 1-8 Alkenylene, and C 1-8 alkynylene; 1-8 Alkylene, C 1-8 Alkenylene, and C 1-8 Alkynylene is one, two, three or four independently selected R 4 group; 6-10 Aryl-C 1-4 Alkyl, C 1-9 Heteroaryl-C 1-4 Alkyl, C 3-10 Cycloalkyl-C 1-4 Alkyl, C 2-9 Heterocycloalkyl-C 1-4 Alkyl is one, two, three, or four independently selected R 5 each optionally substituted with a group; D 2 Each of 1-20 is a straight chain alkylene, 1-20 The 1 to 6 non-adjacent methylene groups of the linear alkylene are independently selected from -D 4 - moieties, provided that the C 1-20 At least one methylene unit in the linear alkylene chain is optionally -D 4 - moiety; provided that said C 1-20 The straight chain alkylene is halogen, cyano, nitro, hydroxyl, C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 1-4 Haloalkoxy, Amino, C 1-4 Alkylamino, di-C 1-4 Alkylamino, C 1-4 Alkylcarbonyl, Carboxy, C 1-4 Alkoxycarbonyl, C 1-4 Alkylcarbonylamino, di-C 1-4 Alkylcarbonylamino, C 1-4 Alkoxycarbonylamino, C 1-4 Alkoxycarbonyl-(C 1-4 Alkyl)amino, carbamyl, C 1-4 Alkylcarbamyl, and di-C 1-4 may be substituted with one or more groups independently selected from alkylcarbamyl; D 3 are H, halogen, cyano, nitro, hydroxyl, and C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-14 Cycloalkyl, C 3-14 Cycloalkyl-C 1-4 Alkyl, C 2-14 Heterocycloalkyl, C 2-14 Heterocycloalkyl-C 1-4 Alkyl, C 6-14 Aryl, C 6-14 Aryl-C 1-4 Alkyl, C 1-13 Heteroaryl, C 1-13 Heteroaryl-C 1-4 alkyl; 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl is one, two, three, or four independently selected R 6 group; 3-14 Cycloalkyl, C 3-14 Cycloalkyl-C 1-4 Alkyl, C 2-14 Heterocycloalkyl, C 2-14 Heterocycloalkyl-C 1-4 Alkyl, C 6-14 Aryl, C 6-14 Aryl-C 1-4 Alkyl, C 1-13 Heteroaryl, C 1-13 Heteroaryl-C 1-4 Alkyl is one, two, three or four independently selected R 7 each optionally substituted with a group; D 4 are respectively -O-, -S-, and -NR a C(=O)-, -NR a C(=S)-,-NR b C(=O)NR c --, --NR b C(=S)NR c -, -S(=O)-, -S(=O) 2 -, -S(=O)NR a -, -C(=O)-, -C(=S)-, -C(=O)O-, -OC(=O)NR a -, -OC(=S)NR a --, --NR a --, --NR b S(=O)NR c - and NR b S (=O) 2 N.R. O - independently selected from; R 4 and R 6 are halogen, cyano, nitro, hydroxyl, and C 1-4 Alkoxy, C 1-4 Haloalkoxy, C 1-4 Alkylthio, C 1-4 Alkylsulfinyl, C 1-4 Alkyl sulfonyl, amino, C 1-4 Alkylamino, di-C 1-4 Alkylamino, C 1-4 Alkylcarbonyl, Carboxy, C 1-4 Alkoxycarbonyl, C 1-4 Alkylcarbonylamino, di-C 1-4 Alkylcarbonylamino, C 1-4 Alkoxycarbonylamino, C 1-4 Alkoxycarbonyl-(C 1-4 Alkyl)amino, carbamyl, C 1-4 Alkylcarbamyl, and di-C 1-4 independently selected from alkylcarbamyl; R 5 are halogen, cyano, cyanate, isothiocyanate, nitro, hydroxyl, and C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Alkoxy, C 1-4 Haloalkoxy, C 1-4 Alkylthio, C 1-4 Alkylsulfinyl, C 1-4 Alkyl sulfonyl, amino, C 1-4 Alkylamino, di-C 1-4 Alkylamino, C 1-4 Alkylcarbonyl, Carboxy, C 1-4 Alkoxycarbonyl, C 1-4 Alkylcarbonylamino, di-C 1-4 Alkylcarbonylamino, C 1-4 Alkoxycarbonylamino, C 1-4 Alkoxycarbonyl-(C 1-4 Alkyl)amino, carbamyl, C 1-4 Alkylcarbamyl, and di-C 1-4 independently selected from alkylcarbamyl; R 7 are halogen, cyano, nitro, hydroxyl, and C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, C 3-7 Cycloalkyl-C 1-4 Alkyl, C 2-7 Heterocycloalkyl, C 2-7 Heterocycloalkyl-C 1-4 Alkyl, phenyl, phenyl-C 1-4 Alkyl, C 1-7 Heteroaryl, C 1-7 Heteroaryl-C 1-4 Alkyl, -OR O , -SR O , -S(=O)R P , -S(=O) 2 R P , -S(=O)NR s R t , -C(=O)R P , -C(=O)OR P , -C(=O)NR s R t , -OC(=O)R P , -OC(=O)NR s R t , -NR s R t , -NR q C(=O)R r , -NR q C(=O)OR r , -NR q C(=O)NR r , -NR q S (=O) 2 R r and -NR P S (=O) 2 N.R. s R t Independently selected from the group consisting of 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 The alkynyl may each be substituted with 1, 2, 3, or 4 independently selected R′ groups; 3-7 Cycloalkyl, C 3-7 Cycloalkyl-C 1-4 Alkyl, C 2-7 Heterocycloalkyl, C 2-7 Heterocycloalkyl-C 1-4 Alkyl, phenyl, phenyl-C 1-4 Alkyl, C 1-7 Heteroaryl, C 1-7 Heteroaryl-C 1-4 The alkyl is optionally substituted with 1, 2, 3, or 4 independently selected R″ groups; R a , R b , and R c are H and C, respectively. 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, C 3-7 Cycloalkyl-C 1-4 Alkyl, C 2-7 Heterocycloalkyl, C 2-7 Heterocycloalkyl-C 1-4 Alkyl, phenyl, phenyl-C 1-4 Alkyl, C 1-7 Heteroaryl, C 1-7 Heteroaryl-C 1-4 alkyl; 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl is one, two, three, or four independently selected R W group; 3-7 Cycloalkyl, C 3-7 Cycloalkyl-C 1-4 Alkyl, C 2-7 Heterocycloalkyl, C 2-7 Heterocycloalkyl-C 1-4 Alkyl, phenyl, phenyl-C 1-4 Alkyl, C 1-7 Heteroaryl, C 1-7 Heteroaryl-C 1-4 Alkyl is one, two, three, or four independently selected R X each optionally substituted with a group; R O , R p , R q , R r , R s and R t are H and C, respectively. 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, C 3-7 Cycloalkyl-C 1-4 Alkyl, C 2-7 Heterocycloalkyl, C 2-7 Heterocycloalkyl-C 1-4 Alkyl, phenyl, phenyl-C 1-4 Alkyl, C 1-7 Heteroaryl, C 1-7 Heteroaryl-C 1-4 alkyl; 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl is one, two, three, or four independently selected R y group; 3-7 Cycloalkyl, C 3-7 Cycloalkyl-C 1-4 Alkyl, C 2-7 Heterocycloalkyl, C 2-7 Heterocycloalkyl-C 1-4 Alkyl, phenyl, phenyl-C 1-4 Alkyl, C 1-7 Heteroaryl, C 1-7 Heteroaryl-C 1-4 Alkyl is one, two, three, or four independently selected R z each optionally substituted with a group; R', R w and R y are hydroxyl, cyano, nitro, and C 1-4 Alkoxy, C 1-4 Haloalkoxy, Amino, C 1-4 Alkylamino, and di-C 1-4 independently selected from alkylamino; R'', R x , and R z are hydroxyl, halogen, cyano, nitro, and C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 1-4 Haloalkoxy, Amino, C 1-4 Alkylamino, and di-C 1-4 independently selected from alkylamino; provided that the valence does not exceed the valence of each atom of the optionally substituted moiety. or a pharma- ceutically acceptable salt thereof.

2. R N are H and C, respectively. 1-6 Alkyl, or C 1-6 haloalkyl; L 1 are C 1-4 alkylene; L 2 are C 2 The removal agent of claim 1 which is an alkylene.

3. The dextran or aminodextran conjugated to a chelating agent has the following formula: Dextran-(Linker-(M-DOTAM)) x [In the formula, The dextran is dextran or an aminodextran thereof; The linker is a linking moiety; M-DOTAM is DOTAM or a functional variant thereof incorporating a metal ion; and x≧1. The remover according to claim 1 or 2, which is a compound represented by the formula:

4. 4. The removal agent of claim 3, wherein x is 20 or more, 25 or more, 30 or more, 35 or more, 40 or more, or 50 or more.

5. The linking moiety has the following formula: [In the formula, y is 1 to 6, * represents the attachment point to dextran, ** represents the point of attachment to a ring atom of DOTAM or said functional variant thereof. The remover according to claim 3 or 4, wherein the divalent group is

6. 6. The removal agent according to any one of claims 1 to 5, wherein the aminodextran is substituted with one or more groups selected from amino acids and sugars other than glucose.

7. 7. The remover according to any one of claims 1 to 6, wherein the number of DOTAM groups as a percentage of the number of glucose units of dextran or aminodextran is at least 1%, at least 1.5%, at least 2%, at least 2.5%, at least 3%, at least 5%.

8. The removal agent according to any one of claims 1 to 7, wherein the average molecular weight of the dextran is 200 to 800 kDa.

9. 9. The removal agent of claim 8, wherein dextran components or removal agents below a molecular weight cutoff have been removed, the molecular weight cutoff being 50 kDa or more, 100 kDa or more, or 200 kDa or more.

10. 10. The remover according to any one of claims 1 to 9, wherein the metal ion is a stable or essentially stable metal ion selected from Pb, Bi or Ca ions.

11. 3. A method for producing the removing agent according to claim 1 or 2, comprising chelating DOTAM with a metal ion before and / or after conjugation of DOTAM to dextran.

12. Prior to conjugation, the dextran or aminodextran is subjected to a filtration step to remove species below a molecular weight cutoff / threshold of 50 kDa or more, 100 kDa or more, or 200 kDa or more; and / or 12. The method of claim 11, comprising subjecting the conjugate to a filtration step to remove species below a molecular weight cutoff / threshold of 50 kDa or more, 100 kDa or more, or 200 kDa or more.

13. i) administering to a subject a multispecific or bispecific antibody comprising at least one antigen binding site specific for a Pb-DOTAM chelate and at least one antigen binding site specific for a target antigen, where after administration, the antibody binds to the target antigen and localizes to the surface of a cell expressing the target antigen; ii) administering a clearing agent according to any one of claims 1 to 10, capable of binding to an antibody at the binding site for the Pb-DOTAM chelate and increasing the clearance of the antibody that is not localized at the surface of the cell and / or blocking its antigen binding site; iii) then administering a complex comprising DOTAM chelated with a Pb radioisotope, said complex binding to the antibody localized on the surface of the cell. The removal agent according to any one of claims 1 to 10 for use in a method of pretargeted radiation imaging comprising:

14. The method further comprising: iv) imaging tissues or organs in which the chelated radionuclide has localized. The remover of claim 13 further comprising:

15. i) administering to a subject a multispecific or bispecific antibody comprising at least one antigen binding site specific for a Pb-DOTAM chelate and at least one antigen binding site specific for a target antigen, where after administration, the antibody binds to the target antigen and localizes to the surface of a cell expressing the target antigen; ii) administering a clearing agent according to any one of claims 1 to 10, capable of binding to an antibody at the binding site for the Pb-DOTAM chelate and increasing the clearance of the antibody that is not localized at the surface of the cell and / or blocking its antigen binding site; iii) then administering a complex comprising DOTAM chelated with a Pb radioisotope, said complex binding to the antibody localized on the surface of the cell. The removal agent according to any one of claims 1 to 10 for use in a method of pretargeted radioimmunotherapy comprising:

16. An antigen-binding site specific for the Pb-DOTAM chelate, a) a heavy chain CDR1 comprising the amino acid sequence GFSLSTYSMS (SEQ ID NO:1); b) a heavy chain CDR2 comprising the amino acid sequence FIGSRGDTYYASWAKG (SEQ ID NO:2); c) a heavy chain CDR3 comprising the amino acid sequence ERDPYGGGAYPPHL (SEQ ID NO:3); d) a light chain CDR1 comprising the amino acid sequence QSSHSVYSDNDLA (SEQ ID NO:4); e) a light chain CDR2 comprising the amino acid sequence QASKLAS (SEQ ID NO:5); and f) a light chain CDR3 comprising the amino acid sequence LGGYDDESDTYG (SEQ ID NO: 6) The remover according to any one of claims 13 to 15, comprising:

17. The remover according to any one of claims 13 to 16, wherein the antigen-binding site specific for the Pb-DOTAM chelate is human, chimeric or humanized.

18. i) the antigen-binding site specific for the Pb-DOTAM chelate comprises a heavy chain variable domain comprising an amino acid sequence selected from the group consisting of SEQ ID NO:7 and SEQ ID NO:9, or a variant thereof comprising an amino acid sequence having at least 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to SEQ ID NO:7 or SEQ ID NO:9; and / or ii) The remover according to claim 16, wherein the antigen-binding site specific for the Pb-DOTAM chelate comprises a light chain variable domain comprising an amino acid sequence selected from the group consisting of SEQ ID NO:8 and SEQ ID NO:10, or a variant thereof comprising an amino acid sequence having at least 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity to SEQ ID NO:8 or SEQ ID NO:

10.

19. i) an antigen-binding site specific for the Pb-DOTAM chelate comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:7 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO:8; or ii) the antigen-binding site specific for the Pb-DOTAM chelate comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:9 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO:10; A remover according to any one of claims 16 to 18.

20. The removal agent according to any one of claims 13 to 19, wherein the target antigen is a tumor-specific antigen.

21. The removal agent of claim 20, wherein the tumor-specific antigen is selected from the group consisting of CEA, HER2 and CD20.

22. The removal agent according to any one of claims 13 to 21, wherein the multispecific or bispecific antibody comprises an Fc region.

23. The removal agent of claim 22, wherein the Fc region has been engineered to reduce effector function.

24. The clearing agent of claim 23, wherein the Fc region has been engineered to reduce effector function by substitution of one or more of residues 234, 235, 238, 265, 269, 270, 297, 327 and / or 329.

25. Multispecific or bispecific antibodies i) a full-length antibody comprising an antigen-binding site for a first antigen, and ii) comprising at least a second heavy chain variable domain and a second light chain variable domain which together form an antigen-binding site for a second antigen, wherein either the first or second antigen is a Pb-DOTAM chelate and the other is a target antigen; 25. The remover according to any one of claims 22 to 24.

26. The removal agent of claim 25, wherein the multispecific or bispecific antibody comprises a full-length antibody comprising an antigen-binding site for a first antigen, wherein the N- or C-terminus of one of the heavy chains is linked to a first polypeptide via a polypeptide linker, and the first polypeptide associates with a second polypeptide to form a Fab or cross-Fab comprising a binding site for the second antigen.

27. A multispecific or bispecific antibody is one in which the first and second polypeptides together form an antigen-binding site for a second antigen. i) a first polypeptide consisting of a VH domain and a CH1 domain associated with a second polypeptide consisting of a VL and a CL domain; or ii) a first polypeptide consisting of a VL domain and a CH1 domain associated with a second polypeptide consisting of a VH and a CL domain; or iii) a first polypeptide consisting of a VH domain and a CL domain associated with a second polypeptide consisting of a VL domain and a CH1 domain; 27. The remover of claim 26, comprising:

28. The removal agent of claim 27, wherein the multispecific or bispecific antibody comprises a full-length antibody comprising an antigen-binding site for a first antigen, and the C-terminus of one of the heavy chains is linked via a polypeptide linker to a first polypeptide consisting of a VL domain and a CH1 domain, which is associated with a second polypeptide consisting of a VH and a CL domain.

Citation Information

Patent Citations

  • MRI with contrast agent with time-modulated contrast enhancement

    JP2008538972A

  • Multispecific antibody having affinity for human a33 antigen and dota metal complex and use thereof

    JP2018505681A

  • Chelator-functionalized nanoparticles

    US20090087381A1